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 The Group A Streptococcus (GAS, Streptococcus pyogenes) is a Gram-positive 
human pathogen that must adapt to unique host environments in order to survive. Links 
between sugar metabolism and virulence have been demonstrated in GAS, where mutants 
in the phosphoenolpyruvate-dependent phosphotransferase system (PTS) exhibited 
Streptolysin S (SLS)-mediated hemolysis during exponential growth. This early onset 
hemolysis correlated with an increased lesion size and severity in a murine soft tissue 
infection model when compared with parental M1T1 MGAS5005. To identify the PTS 
components responsible for this phenotype, we insertionally inactivated the 14 annotated 
PTS EIIC-encoding genes in the GAS MGAS5005 genome to functionally characterize each 
EIIC. It was found that a few EIIs had a limited influence on PTS sugar metabolism, whereas 
others were promiscuous. The mannose-specific EII locus exhibited the most influence on 
PTS sugar metabolism. Importantly, the mannose-specific EII also acted to prevent the early 
onset of SLS-mediated hemolysis. These roles were not identical in two different M1T1 
GAS strains, highlighting the versatility of the PTS to adapt to strain-specific needs. This 
is further illustrated by the fructose-specific EII, which is important for survival in whole 
human blood for MGAS5005, but not 5448. The mannose-specific EII can transport glucose 
in other pathogens, but the route of glucose utilization is unknown in GAS. MGAS5005 
mutants were generated in a non-PTS glucose transporter (GlcU) and a glucokinase 
(NagC) of an annotated non-PTS glucose metabolic pathway. Since ∆ptsI, ∆nagC, and 
∆glcU all grow to some extent in glucose, it is evident that glucose can be metabolized 
both by PTS and non-PTS routes. . However, the route of glucose utilization affects overall 
pathogenesis, as ∆nagC survives like WT in whole human blood, whereas ptsI is unable to 
survive. Subcutaneous infection of mice with ∆nagC did not exhibit increased lesion size, 
although these lesions are more severe than MGAS5005 due to the early onset of hemolysis. 
Overall this suggests that the routes of glucose metabolism greatly influence SLS-mediated 
hemolysis. These results highlight that PTS carbohydrate metabolism plays an important role 
for GAS pathogenesis in both the skin and whole human blood, through the actions of EIIs.
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Chapter 1: Literature Review
Historical perspective
 In 1842, Ignaz Semmelweis demonstrated that you could reduce the mortality 
rate in hospital birthing wards by having the doctors wash their hands and cleaning the 
sheets between patients. This prevented the spread of puerperal fever, or more commonly 
known as childbed fever, which was the cause of the high mortality rate. Pasteur would 
later validate his work at a seminar in 1879 at the French Academy of Sciences, when he 
stated that the epidemic seen in hospital wards was the result of a chain-forming microbe 
that was being spread by the hospital staff from sick to healthy patients (Ferretti, 2016). 
Despite this notion, Semmelweis’ work was generally ridiculed, and he died in an asylum 
from a blood infection 2 weeks after he was admitted (Ferretti, 2016). Pasteur was the 
first to isolate streptococcus from women with puerperal fever. However, the first mention 
of streptococcus was in 1874, when Theodor Billroth described the microbe found in 
wound infections (Ferretti, 2016). Streptococcus (twisted berry) pyogenes (pus-forming) 
officially got its name in 1884, when Friedrich ulius osenbach isolated this bacterium 
from suppurative lesions (Ferretti, 2016, Evans, 1936).  In the 1920s, George and Gladys 
Dick showed that scarlet fever was associated with a sore throat caused by hemolytic 
streptococci that produced a secreted toxin that they referred to as Dick toxin (Ferretti, 
2016). These important events set the foundation for research in streptococcal diseases that 
have plagued the world for centuries. 
Cl ssific tio 	of	 A
 Streptococcus pyogenes is a Gram-positive human pathogen that forms chains 
during growth. GAS exhibits beta-hemolysis (complete lysis of red blood cells) when 
streaked on 5% sheep blood agar plates. It currently has no other known reservoirs outside 
of humans, is catalase negative, and does not form spores. Colonies are opaque and tend to 
be mucoid, especially in strains that express increased amounts of capsule (Martin, 2000). 
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GAS is also a facultative anaerobe, so it is still able to grow in the presence of oxygen. 
However, it does not contain a complete TCA cycle, so GAS relies mainly on glycolysis 
for the fermentation of sugars, usually leading to the production of lactic acid. GAS can be 
grown in the presence of many sugars; however, it is auxotrophic for multiple amino acids 
(Slade et al., 1951). 
 In 19 , ebecca Lancefield was able to divide streptococcal species through 
surface antigens, splitting them into Groups from A to X, with the Group A Streptococcus 
isolated strains from human diseases (Ferretti, 016). She later developed the Lancefield 
M-typing system, a serological antigen-antibody reaction system to identify distinct M 
types. M protein is a surface protein on GAS that has multiple functions, most notably in 
resistance to phagocytosis (Ferretti, 016, Lancefield, 196 ). To differentiate the M type of 
a strain, antisera from rabbits against different M types was incubated with the extraction of 
the M protein from a strain and monitored for the formation of precipitate (Facklam, 1999). 
Serum opacity factor typing can also be used, as some M-types produce opacity factor 
(OF, apoproteinase), which increases the opacity of mammalian serum (Facklam, 1999). T 
typing further classifies similar M types. T antigen is also detected by agglutination assays, 
and is often used in conjunction with M typing (Beall et al., 1998). The serotype most 
prominently found in invasive and noninvasive infections in North America is M1T1. 
Clinical perspective
 GAS normally colonizes the nasopharyngeal mucosa or the skin of humans, as it 
is a strictly human pathogen. This leads to the development of pharyngitis and impetigo, 
which can be treated with antibiotics, and are generally self limiting. However, there are 
many strains that are invasive and can access sterile sites via the bloodstream, leading to 
more severe outcomes such as necrotizing fasciitis, scarlet fever, STSS and septicemia. 
Complications can also occur post infection with the development of streptococcal reactive 
arthritis, rheumatic fever, and glomerulonephritis. GAS infections have also been linked to 
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obsessive compulsive disorder (OCD), tourettes, endophthalmitis, and more controversially, 
pediatric autoimmune neuropsychiatric disorders associated with strepotcoccal infections 
(PANDAS) (Fig 1.1). Without a licensed vaccine against GAS, these infections lead to 
more than 500,000 deaths every year making it the 9th leading infectious cause of human 
mortality worldwide (Cunningham, 2008). The following section will look at some of the 
symptoms mentioned above in more detail.   
 Pharyngitis (Non Invasive). Pharyngitis develops when GAS colonies the throat, 
often noted by white spots visible to the eye. GAS is the cause of pharyngitis in 20-40% 
of children between 5-15 years old, most commonly in the winter or spring in the US. 
Pharyngitis is often accompanied with fever, pain while swallowing, and tender lymph 
nodes, but vomiting, abdominal pain, and edema of the tonsils can also occur. Symptoms 
3
Figure 1.1 Examples of clinical manifestations of GAS infections. GAS infections are 
typically split into three disease categories.  Each are shown here, with examples of typical 
clinical outcomes listed as examples below. Examples of neuropsychiatric disorders linked 
to GAS infections are also shown.  Black lines depict areas of the human body that are 























usually resolve within a week, although GAS is still present in the throat if antibiotics are 
not administered. Complications such as peritonsillar abscess, sinusitis, otitis media, and 
bacteremia can also occur from pharyngitis. Throat swabs are primarily used to diagnose 
GAS infections, and once confirmed, patients are given either penicillin (preferred) or 
cephalosporin (penicillin allergic patients) (Wessels, 2016). 
 Impetigo (Non Invasive).  Infections of the skin usually result in impetigo, which 
is an infection of the outer keratin layer. These infections form crusty patches usually on 
the lower extremities and the face and occur in mostly tropical areas associated with poorer 
living conditions and declining personal hygiene practices. Like with pharyngitis, these 
infections are localized and are treated with penicillin. Complications can also occur, most 
notably acute glomerulonephritis (Stevens, 2016).
 Necrotizing Fasciitis (Invasive). Invasive infections in the U.S. have become 
increasingly abundant after 1980, such as necrotizing fasciitis (NF), where GAS is able 
to penetrate into deeper tissues and destroy underlying layers. This spreads very quickly, 
( 4-  hours) from the site of infection, with extensive tissue necrosis and inflammation 
becoming more and more apparent (Stevens, 2016b). Mortality rates are between 70-80%, 
and many times removal of the infected tissue or amputation is the only course of treatment 
(Stevens, 2016b).
 Streptococcal Toxic Shock Syndrome (Invasive). Streptococcal toxic shock 
syndrome (STSS) is when a GAS infection leads to systematic organ failure, typically 
through bacteremia as GAS moves from the site of infection to sterile sites. Many GAS toxins 
act as superantigens for T-cells, which leads to massive cytokine induction. STSS begins 
with fever, chills, nausea and vomiting. Pain begins to increase, along with disorientation, 
tachycardia, and tachypnea  (Stevens, 2016b). In last phase of STSS, hypotension and 
organ failure begin. Because many patients only come into the hospital at this point, death 
usually occurs 24-48 hours post-admission  (Stevens, 2016b). Once a patient is admitted 
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and confirmed to have STSS, they are treated with broad-spectrum antibiotics, put on 
ventilator, given intravenous immune globulin (IVIG), among other drastic measures 
(Stevens, 2016b). STSS rarely develops from pharyngeal infections (Stevens, 2016b).
 Scarlet Fever (Invasive).  Scarlet Fever can occur in combination with pharyngitis, 
where a red rash that feels like sandpaper begins to develop on the trunk of the body 
and spreads to the arms and legs. According to the CDC, scarlet fever symptoms include 
fever, headaches, swollen glands, nausea, vomiting, abdominal pain, and a strawberry 
tongue.  Although still not well understood, these infections are treatable and usual resolve 
quickly (CDC). Streptococcal pyrogenic exotoxins are thought to play a primary role in the 
development of scarlet fever (Wessels, 2016). Although rare, GAS skin infections can also 
lead to the development of scarlet fever (Wessels, 2016).
 Glomerulonephritis (Post-Infection).  Acute poststreptococcal glomerulonephritis 
(APSGN) is an infection that occurs after GAS infection where nephritogenic immune 
complexes form in circulation or when the antigen and antibody collide in the glomeruli. 
These stimulate the activity of immune cells, leading to an inappropriate inflammatory 
response ( odriguez-Iturbe, 016). Treatment, outside of the treatment of the GAS infection, 
includes limiting salt and fluid intake ( odriguez-Iturbe, 016). Diuretics generally have 
mixed results, as some are beneficial, but most lead to additional complications ( odriguez-
Iturbe, 2016). APSGN can also lead to chronic kidney disease, impaired renal function, 
and persisting arterial stiffness ( odriguez-Iturbe, 016). The mortality rate for APSGN 
is around 0  however, prognosis for children is usually very good ( odriguez-Iturbe, 
2016).
 Acute Rheumatic Fever,  ARF (Post-Infection).  A F is a post-infection 
complication that develops in children ages 5-15 as a result of a GAS pharyngeal infection 
only. The ma or criteria for diagnosis of A F after a confirmed GAS infection are carditis, 
polyarthritis, chorea, subcutaneous nodules, and erythema marginatum, with only 2 of these 
6
re uired for a positive diagnosis. A F occurs when antibodies produced by B-cells against 
GAS, M protein, or GlcNAc bind to valve endothelium in the heart. Damaged endothelium 
recruit activated T cells that produce cytokines and infiltrate the heart valve, where they 
elicit a -interferon TH1 response. Autoimmune activity of T cells breaks down the heart 
valve, causing an increased immune response and impairing heart function. epeated 
infections lead to scarring of the heart valve in patients, making them more susceptible to 
repeated bouts of A F (Cunningham, 016).
 PANDAS (Post-Infection).  A more controversial post-infection complication is 
the development of Pediatric Autoimmune Neuropsychiatric Disorders Associated with 
Streptocccal infections (PANDAS). The criteria for a PANDAS diagnosis is (1) OCD/tic, 
(2) Prepubertal symptom onset, (3) Acute onset of symptom, (4) Close timing of S. pyogenes 
infection and symptom onset, and (5) presence of neurologic abnormalities (Swedo et al., 
1998). The controversy for this condition stems from the difficulty in reliably linking the 
cause of neuropsychiatric disorders to GAS infections. Different techniques may be used to 
test for GAS infections. Additionally, tics/OCD are the manifestation of complex processes 
and are hard to strictly associate to one trigger. Depending on the study, there is reported 
to be either an association, or no association between these two clinical manifestations 
(Murphy et al., 2012, Bernstein et al., 2010, Kurlan et al., 008, Leckman et al., 2011). 
However, antibody cross-reactivity between GAS and the brain occurs in some patients 
with Syndenham s chorea (SC) (Orefici et al., 2016). These antibodies stimulate excess 
dopamine signaling in the brain, leading to the development of symptoms. PANDAS 
patients had similar antibodies against dopamine receptors as SC patients (Cox et al., 2013). 
Associative evidence exists from animal models showing that the presence and absence 
of these antibodies help mediate SC and PANDAS.  Whether these mechanisms actually 




 A significant number of GAS infections occur around the world each year, leading 
to both mortality and economic loss as a result of treatment expenses. The 2010 Global 
Burden of Disease study estimated that 140,495,000 cases of impetigo occurred worldwide 
each year (Hay et al., 2014). Pharyngitis cases are harder to estimate, as there are high rates 
of throat colonization of GAS in school-aged children combined with misclassification of 
pharyngitis causes (Sanyahumbi et al, 2016). More severe clinical manifestations of GAS 
infections lead to more problematic infections, and afflict millions of people worldwide. 
Although estimates of acute rheumatic fever and glomerulonephritis vary widely based on 
the region of the world, the 2010 Global Burden of Disease study estimated over 34 million 
cases of rheumatic heart disease leading to over 345,000 deaths a year (Sanyahumbi et al, 
2016). 
Invasive cases in United States 
 The Active Bacterial Core surveillance (ABCs) set up by the CDC Emerging 
Infection Program network monitors the occurrence of invasive bacterial infections in 
10 sites across the country to map disease trends (CDC, 1997-2014). From 1997-2014, 
invasive GAS (iGAS) infections in the elderly (>50 years old) have increased (Fig. 1.2A). 
The number of cases observed between the ages of 5-17 is relatively low. This would 
suggest that the elderly may be more susceptible to more invasive forms of GAS infections. 
Overall, the estimated number of national cases has increased, although the number of 
resulting deaths has stayed the same (Fig. 1.2B). Compared to two other commonly 
invasive streptococci [Group B Streptoccocus (GBS) and S. pneumonaie], the number of 
deaths has remained the same, indicating that therapeutic interventions are not improving 
to effectively treat invasive infections (Fig. 1.2C). Additionally, the number of overall 
cases of invasive disease has decreased for S. pneumonaie, but this has not been the case 
for GAS (Fig. 1.2C). With the estimated % of cases resulting in death remaining around 
8
10-15% for GAS over the last 17 years, increased understanding of the pathogenesis of 
iGAS strains is essential to improve therapeutic interventions (Fig. 1.2D).
Vaccine production
 Currently, a licensed vaccine does not exist for GAS, with vaccine development 
hindered by the fact that a US federal ban existed from 1969 to 2006 that prevented testing 
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GAS GBS S. pneumoniae
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C. D.
Figure 1.2 Trends of invasive streptococcal infections as determined by the CDC ABC 
program (https://www.cdc.gov/abcs/reports-findings/surv-reports.html).  (A) Invasive 
GAS infections from 1997-2014 were graphed according to age group and the number of 
cases observed in each surveillance area. (B) Based on the data from the observed areas, 
the CDC estimated the number of invasive GAS infections that occur nationwide over 
the 17-year period. The black line represents the number of cases, whereas the red line 
depicts the estimated number of deaths. (C) The estimated number of cases and deaths for 
GAS (black) was compared to two other streptococcal species: (1) GBS (blue) and (2) S. 
pneumoniae (red). Solid lines illustrate the number of cases estimated, and the dotted lines 
represent the number of deaths estimated. (D) The CDC also estimated the % of deaths 
that resulted from invasive streptococcal infections. The same color scheme as observed 
in (C) was used.
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children were thought to develop A F as a result of the vaccine, although this has been 
disputed by the trial authors (Dale et. al., 2016). A 26-valent M protein based vaccine has 
completed phase I and II clinical trials, and has been shown to provide protective immunity 
for 79% of serotypes found in the United States (Dale et. al., 2016). This vaccine has been 
shown to provide immunity without generating cross-reactive antibodies, a historically 
well-documented problem with the immune response to GAS infections in general (Hu 
et al., 2002, Dale et. al., 2016). Based on increasing epidemiological studies, a 30-valent 
M protein vaccine was developed, which accounted for 98  of the serotypes identified in 
North America, and for 78% of invasive disease in Europe (Dale et. al., 2016). Although 
other targets have been used as the basis for development of a vaccine, such as fibronectin-
binding protein (Kawabata et al., 2001), serum opacity factor (Courtney et. al., 2003, 
Schulze et. al., 2006), and SpeB (Kapur et al., 1994), these have not yet moved beyond 
animal studies (Dale et. al., 2016). The development of vaccines has improved and shows 
promise, but there is still not an available vaccine for human use. Therefore, ongoing 
studies to find more beneficial therapeutic targets are essential. 
ise	of	t e	 	clo e
 The rise of the M1T1 clone of GAS can be attributed to the acquisition of new 
genes that allow it to infect humans with greater persistence. M1T1 infections rose in the 
late 1980s, and have now frequently been isolated from invasive (iGAS) and noninvasive 
infections. Two prophages, encoding a superantigen (speA ) and a streptococcal nuclease 
(sd ), have been identified in M1T1 strains that diversify these clones from other M1 
strains. The speA  reintroduction into M1T1 is thought to coincide with its global rise, 
as for 60 years before, M1 isolates did not have SpeA2. Sda1 degrades DNA neutrophil 
extracellular traps (NETs), which allow GAS to escape and invade host tissues. The SpeB 
cysteine protease degrades many GAS virulence factors important for virulence, thereby 
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decreasing virulence potential. However, invasive strains have much lower SpeB as the 
result of a spontaneous mutation in covS. The Cov S two-component system regulates 
around 15% of the genome, including many virulence genes. This increase in virulence 
gene expression, and the lower expression of speB, gives rise to more severe infections 
and the increased ability of M1T1s to survive in humans (Aziz & Kotb, 2008) M1T1 
MGAS5005 (cov-) is a model strain isolated from the cerebrospinal fluid of a patient in 
Ontario in 1996 (Sumby et al., 2005). This strain is used in this dissertation to study the 
dynamics of iGAS pathogenesis along with M1T1 5448, a cov+ isolate from a patient with 
necrotizing fasciitis in Ontario in 1994 (NCBI). 
A ti iotic	tre tme t
 The Group A Streptococcus is still extremely sensitive to penicillin, and therefore 
remains the preferred drug for treatment. Confirmed GAS pharyngitis cases should be treated 
with a 10-day course of oral penicillin V, or amoxicillin, or a single dose of Benzathine 
penicillin injected intramuscularly. Those that have penicillin allergies are recommended 
to be given a 5-10 day course of  cephalexin, cefadroxil, clindamycin, azithromycin, or 
clarithromycin orally. Although antibiotic resistance has been observed for many of the 
alternative antibiotics, no known cases of penicillin resistant GAS have been documented 
to date (CDC, https://www.cdc.gov/groupastrep/diseases-hcp/index.html). 
u rs	prese t	i 	t e	 um 	 od
 Many sugars line the surface of cells and proteins, are present in tissues and biofluids 
of humans, and are consumed on a daily basis. Pathogens can utilize and often rely on these 
sugars to survive and grow in the host. ust as tissue types vary in different parts of the body, the 
availability of carbohydrates and metabolites vary as well. If a pathogen is able to use this as 
environmental cues, it could be used to determine where in the body it is located, and execute 
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the appropriate virulence program. Although we are still far-removed from those types of 
conclusions, it suggests that there is a host niche metabolic signature that pathogens can sense. 
  The phosphoenolpyruvate-phosphotransferase system (PTS) is a major carbon 
transport system in many bacteria that is responsible for the transport of specific sugars. 
These sugars are abundantly present and detected in many host tissues and biofluids (Table 
1.1, 1.3), with 75% of GAS PTS sugars have been detected in human blood (Table 1.1) and 
58% (7/12) of PTS sugars detected in saliva (Table 1.1) (Wishart et. al, 2013, Wishart et. al, 
2009, Wishart et. al, 2007). The sugar content of saliva may be 67% given that maltose has 
been detected by other groups on mucins (Shelburne et al., 2008b). Surprisingly, galactose 
and ascorbic acid are present in the most number of biofluids (Table 1.1), although glucose 
is the most abundantly found. As expected, glucose is found in the highest concentration in 
both blood and saliva (Table 1.2). Mannose, fructose, mannitol, ascorbic acid, and galactose 
are also found in blood at a concentration about 1000-fold less than glucose, which indicates 
that, although very scarce, these sugars may potentially be available for GAS (Table 
1.2). Sucrose is also detected in blood, but at minute concentrations (Table 1.2). Saliva 























































Blood X X X X X X X X X
Breast Milk X X X X X
Cellular cytoplasm X X X
Cerebrospinal Fluid X X X X X X
Feces X X X X X X X X X
Saliva X X X X X X X
Urine X X X X X X X X X X
Table 1.1. Presence of PTS sugars in Human Biofluids
Blue indicates biofluid potentially encountered during throat infection
ed indicates biofluid encountered during blood sepsis
Source data from HMDB ( ishart et. al, 2013, Wishart et. al, 2009, Wishart et. al, 2007)
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followed 3-fold less galactose (Table 1.2). PTS carbohydrates in the cerebrospinal fluid 
are important, since MGSA5005 was isolated from the CSF. Concentrations of glucose are 
reported to be similar to blood, with fructose and ascorbic acid at a concentration of 1000-
fold less (Table 1.2)(Wishart et. al, 2013, Wishart et. al, 2009, Wishart et. al, 2007). 
 When we extend our outlook to PTS sugars that have been detected in any human 
tissue, it is evident that they are present in almost every part of the body (Table 1.3); 
however, very few tissues have the exact same PTS sugars present in the same combination 
and likely not at the same concentration (Table 1.3). The situation gets considerably more 
complex when one considers other metabolites that are present in these environments as 
well. Considering that CSF contains 440 metabolites, Urine contains 4060, Serum contains 
4561, Saliva contains 1233, and Feces contains 695 (Wishart et. al, 2013, Wishart et. al, 
2009, Wishart et. al, 00 ), the uni ueness of the types of PTS sugars present in biofluids 
does not even begin to describe the complexity that potentially exists in the metabolome 
of these host environments. Therefore, a metabolic signature is more than possible, which 
could potentially allow pathogens to exploit this to successfully survive in the host. 
Sugar Blood CSF Saliva
Glucose 4781.13 ± 425.33 (10) 3356.67 ± 1866.88 (3) 287.73 ± 284.83 (6)
Fructose 39.5 ± 12.02 (2) 200 ± 56.57 (2) -
Mannose 51.5 ± 17.68 (2) 44 ± 28.28 (2) -
Sucrose 1.8 (1) - 38 ± 19.80 (2)
Mannitol 34 (1) 4.875 ± 0.50 (4) -
Cellobiose - - -
Ascorbic Acid 49.6 ± 25.58 (6) 134.56 ± 39.51 (5) 3.11 ± 4.24 (3)
Lactose - - -
Galactose 63.65 ± 34.86 (2) 166 (1) 83.46 (1)
Maltose - - -
Salicin - - -
Trehalose - - -
Table 1.2 Concentrations (mM) of PTS sugars identified in the Human Biofluids
 *mean ± SD (number of studies)
 * - (no values reported)
  source data from HMDB (Wishart et. al, 2013, Wishart et. al, 2009, Wishart et. al, 
2007)
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Table 1.3 Presence of PTS sugars in Tissues
*Blue indicates tissue potentially encountered during throat infection
ed indicates tissue potentially encountered during blood sepsis
*Gold indicates tissue potentially encountered during skin infections
























































Adipose Tissue X X X
Adrenal Cortex X X
Adrenal Gland X
Adrenal Medulla X X X
Beta Cell X
Bladder X X X X X
Brain X X X X
Brain Plaques X
Epidermis X X X X X
Erythrocyte X
Eye Lens X X
Fetus X




Intestine X X X X X X
Kidney X X X X X




Muscle X X X X X X
Myelin X X X X
Nerve Cells X X
Neuron X X X
Pancreas X X
Placenta X X X X
Platelet X X X X X
Prostate X X X X X X
Skin X X
Sperm X




A 	c r o 	met olism
Glycolysis
 GAS relies heavily on glycolysis for the fermentation of incoming sugars. The 
pathway, outlined in Figure 1.3, is made up of almost entirely essential proteins, again 
highlighting its importance (Le Breton et al., 2015). The pathway begins when a glucokinase 
(Spy_1311) uses ATP to phosphorylate glucose to generate glucose-6-phosphate (G-6-P), 
which is then converted to fructose-6-phosphate (F-6-P) by  phosphoglucose isomerase 
(Pgi). Phosphofructokinase (Pfk) then uses another ATP to phosphorylate F-6-P to create 
fructose-1,6-bisphosphate (FBP) that is then broken down into Dihydrooxyacetone 
phosphate (DHAP) and glyceraldehyde- -phosphate (GAP) by fructose-bisphosphate 
aldolase (Fba). Glyceraldehyde- -phosphate dehydrogenase (GAPDH) coverts GAP 
into 1- -bisphoglycerate, generating nicotinamide adenine dinucleotide (NADH). 
This is then converted by phosphoglycerate kinase (Pgk) to 3-phosphoglycerate, which 
generates 1 ATP. Next, Phosphoglycerate mutase (PgmA) converts 3-phosphoglycerate to 
2-phosphoglycerate with is then converted by enolase into phosphoenolpyruvate (PEP). 
The conversion of PEP to pyruvate generates an ATP, but this conversion can also be used 
Figure 1.3 Glycolysis in GAS. Glycolytic intermediates are shown. Enzymes that carry out 
each reaction is shown above the arrows. ed arrows depict reactions where the enzyme 
was shown to be essential in GAS (Le Breton, et. al, 2015) and occur in the direction 
indicated, whereas green arrows were not. Orange curved arrows represent irreversible 




















to phosphorylate Enzyme I (EI) to start PTS uptake of sugars. The enzymes of glycolysis 
are usually activated by divalent cations to allow for binding of the negatively charged 
phosphorylated sugars (Pancholi et. al., 016). In all, this pathway produces  NADHs and 
2 ATPs. Since GAS is a lactic acid bacterium, pyruvate is generally converted to lactate/
lactic acid by L-lactate dehydrogenase (Ldh).
Entner-Doudoroff
 The Entner-Doudoroff pathway (ED), which was discovered in in Pseudomonas 
s cc rop il  in 1952, is an alternate to glycolysis that uses a different set of intermediates 
(Conway, 199 ). ather than cleaving fructose-1,6-bisphosphate by Fba to yield 
GAP and dihydroxyacetone phosphate, the ED pathway cleaves  2-dehydro-3-deoxy-
phosphogluconate (KDPG) by the KDPG aldolase (Eda) to create GAP and pyruvate 
(Conway, 1992). The only two enzymes from this pathway that are present in GAS are Eda 
and the 2-dehydroxy-3-deoxygluconokinase, the latter of which creates KDPG (Pancholi 
et. al., 016). However, the enzymes re uired for glucose entry into the ED pathway are 
not annotated or have not been identified, therefore this pathway is largely incomplete. 
It is possible that GAS may scavenge 2-dehydroxy-3-deoxy-D-gluconate and use this 
incomplete pathway as another source of pyruvate, but this has not been extensively 
explored. Therefore, this significance of this pathway in GAS in currently unknown 
(Pancholi et. al., 2016).
Pentose phosphate pathway
 The pentose phosphate pathway (PPP) is an alternate pathway to glycolysis that 
metabolizes glucose-6-phosphate through an oxidative and non-oxidative branch that 
generates fructose-6-phosphate and glyceraldehyde-3-phosphate that can be fed back into 
glycolysis (Stincone et al., 2015). This pathway provides the cell with many precursors 
for the biosynthesis of nucleotides, amino acids, and vitamin B6 (Stincone et al., 2015). 
Like other pathways in GAS, except glycolysis, not all reactions in this pathway are 
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predicted to be intact. GAS contains a 6-phosphogluconate dehydrogenase, transaldolase, 
transketolase, and a ibulose-5-P-4-epimerase, allowing GAS to produce fructose-6-
phosphate and glyceraldehyde- -phosphate from 6-phosphogluconate. However, the steps 
to convert glucose-6-phosphate into 6-phosphogluconate are absent and the role of PPP in 
GAS physiology remains to be seen.  
TCA cycle
 The tricarboxylic acid (TCA) cycle is an 8 protein metabolic pathway that is 
responsible for the degradation of Acetyl-CoA to generate 12 ATPs. GAS does not 
posses an intact TCA cycle, but the enzymes to generate Acetyl-CoA (AcoA/B–pyruvate 
dehydrogenase E1, AcoC-a-ketoacid dehydrogenase E , and AcoL-dihydrolipoamide 
dehydrogenase) are present (Pancholi et. al., 016). The functional significance of this is 
unknown, as no role for Acetyl-CoA generation has been attributed in GAS physiology 
(Pancholi et. al, 2016). The absence of a TCA cycle does mean that Streptococcus pyogenes 
relies heavily on glycolysis for the fermentation of incoming sugars to generate ATP. 
The phosphoenolpyruvate-dependent phosphotransferase system (PTS)
 The PTS is a carbohydrate transport system present in most bacteria that couples 
the translocation of an incoming sugar with its subsequent phosphorylation (Deutscher et 
al., 006). The PTS is made up of two types of proteins, general and sugar specific. The 
general proteins Enzyme I (EI, ptsI) and HPr are cytosolic and are common to all the EIIs 
present in a bacterium. The sugar-specific proteins are Enzyme II complexes (EII) that are 
made up of two cytosolic components (EIIA and EIIB), as well as one or two membrane 
transporters (EIIC and EIID). To date, EIIDs are only found in the mannose-family EIIs 
(Deutscher et al., 2006).  
 EI is autophosphorylated at the expense of phosphoenolpyruvate (PEP), which 
will then phosphorylate HPr on its Histidine-15 residue. Subse uently Hpr-His-15 
phosphorylates EIIA, which phosphorylates EIIB, followed by phosphorylation of the 
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incoming sugar that is transported by EIIC/D (Deutscher et al., 2006) (Fig 1.4). The 
phosphorelay also allows for the PTS to participate in signal transduction, as EIIBs can 
phosphorylate PTS-regulatory domains found within several transcriptional regulators in 
the absence of its inducing source (Fig 1.4). In addition, HPr can be phosphorylated on its 
Serine-15 residue in the presence of a preferred carbon source, and in conjunction with 
the carbon catabolite protein A (CcpA), can limit the expression of alternative metabolic 
pathways (carbon catabolite repression, CC ) (Fig 1.4). These two processes allow for the 
PTS to potentially influence the expression of a wide variety of genes.
 Four EII Families. The four main families of EIICs are (1) Glucose-Fructose-
Lactose, ( ) Ascorbate-Galactitol, ( ) Mannose, and (4) Dihydroxyacetone. The Glucose-
Fructose-Lactose family is thought to be the original and largest family, with each 
Figure 1.4 The PTS. Enzymes involved with PTS-mediated sugar transport and 
regulation are depicted. Blue arrows depict the phosphotransfer of a phosphate (red P) 
to each phosphocarrier protein or incoming sugar in the relay. Black arrows indicate the 
networks in the CcpA-mediated CC  pathway. The green arrows depict the modification 
of PTS-regulatory domain (P D)-containing regulators as a way to affect global gene 
expression. 
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EIIC having 10 transmembrane (TM) domains (Saier, 2015). The EIIA, EIIB, and EIIC 
components in this family are not thought to coevolve. The Ascorbate-Galactitol family 
is made up of mostly fusion proteins, with each EIIC component containing 11 or 12 TM 
domains (Saier, 2015) . Not much is known about the Dihydroxyacetone family, other than 
that it appears the newest of all the EII families (Saier, 2015). The Mannose EII family is 
the only one that has an EIID component and, while other EIIB are phosphorylated on a 
cysteine residue, mannose family EIIB is phosphorylated on a histidine residue. In addition 
to transporting the most substrates of the EII families, it is also the most structurally unique 
(Saier, 015). The significance of the mannose-specific EII, and the extensive role it plays in 
the physiology and virulence of many human pathogens will be discussed in later sections 
of this dissertation.
 Predicted TM domains for MGAS5005 EIICs. Using the transmembrane (TM) 
prediction program Protter (http://wlab.ethz.ch/protter/start/), we predicted the number of 
TM domains in each EII present in the GAS genome to roughly predict which families are 
represented. We found three (Spy_0520; Spy_0782; Spy_1480) that belong to the mannose 
family, as these all have an EIID associated with their respective EIIC (Table 1.4). Six 
predicted EIIs appear to fall in the Ascorbate-Galactitol EII family (Spy_0475; Spy_0662; 
Spy_1542; Spy_1692), as these are fusion proteins (Table 1.4). However, the ma ority are 
annotated for sugars in the Glucose-Lactose-Fructose family, yet do not have the predicted 
number of TM domains characteristic of this family. Therefore, assigning families for 
each EII is problematic using just transmembrane domains and subunit compositions. 
Still, the predicted transmembrane domains reveal that EIIs tend to have between 10-12 
transmembrane domains to facilitate sugar translocation (Table 1.4). 
 Comprehensive EII metabolic studies. Two studies in Gram-positive bacteria have 
looked deeply into characterizing each EII to assign sugar specificities. These studies 
highlight some key points into what may be observed in GAS. 
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*includes both EIIC and EIID
** If a fusion protein, subunits that are fused 
     together with the EIIC are listed
Table 1.4 Plotter prediction of the number of transmembrane domains present in 
each EIIC/D.
 In S. pneumoniae, 1 EIIs have been identified in the pan-genome (Bidossi et al., 
2012). 26 strains of S. pneumoniae were compared, and surprisingly, each had different 
number of EIIs (between 15-20). This indicates that not only are there metabolic differences 
between species, but within strains. Additionally, the ability of each strain to ferment each 
tested sugar also varies. For the most part, EII annotations matched the experimentally 
verified substrates (Bidossi et al., 01 ). However, this is partly due to the fact that most 
mutants were only assessed for their ability to grow in the carbohydrate for which they 
were annotated, missing pleiotropic effects. As seen with many streptococci, the mannose-
specific EII have the broadest range of substrates of all the EIIs (Bidossi et al., 2012). 
 t p lococcus	 ureus has the most (29) encoded transporters (Vitko et al., 2016) 
compared to t p lococcus	epidermidis (16 transporters), t p lococcus	 emol ticus 
(20 transporters), and t p lococcus	s prop ticus (21 transporters). It also has the most 
unique number of transporters of the compared species with 10 (Vitko et al., 2016). S. aureus 
has 1  PTS-specific sugars, and 15 EIIs currently annotated in its genome. Annotations for 
these EIIs are very broad and appear to be annotated based on the family of EII and not a 
specific sugar, as in GAS MGAS5005 ( itko et al., 2016). Deletion of an EII leads to very 
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limited affects on growth, as most EII mutants only affect growth of S. aureus in one or 
two sugars. Because the annotations are broad, no comparison can be made on the accuracy 
of annotation versus function. However, this illustrates the need to experimentally verify 
sugar-specificities in strains when an EII s role is of interest.
Glucose metabolism
 Glucose metabolism in GAS has not been studied in any detail; however, an in 
depth analysis of glucose metabolism has been done in S. aureus. Glucose transport in 
this pathogen is highly redundant, where a substantial decrease in growth and uptake of 
glucose was only observed when four transporter proteins (3 PTS, 1 non-PTS: GlcU) 
were mutagenized (Vitko et al., 2016). Even this quadruple mutant had residual glucose 
metabolism, indicating the potential for an unidentified transporter. This additional 
transporter is not a PTS EII, as a ∆glk∆pts A mutant (a strain that cannot transport 
glucose through the PTS or be phosphorylated by the glucokinase (GlK), does not grow 
on glucose, indicating that glucose in S. aureus is only metabolized via the PTS or by the 
glucokinase pathway (Vitko et al., 2016). This appears to be the case for GAS as well 
and is the focus of studies described in Chapter 7. Glucose transport and metabolism are 
highly redundant, as no single EII has ever been shown to be solely responsible for glucose 
transport. In addition, many bacteria posses alternate pathways to metabolize glucose 
separate from glycolysis, highlighting the extreme importance of glucose metabolism for 
pathogenic bacteria. 
Mixed acid fermentation 
 Mixed acid fermentation occurs when ethanol, acetate, and formate are generated as 
the end products of fermentation. Pyruvate-formate lyase (Pfl) converts pyruvate to formate 
and Acetyl-CoA. Acetyl-CoA can then be converted into ethanol by alcohol dehydrogenase 
(AdhE), or into acetate by the enzyme acetate kinase. Phosphoenolpyruvate carboxylase 
can also convert PEP into oxaloacetate (Forster et.al., 2014). GAS possesses genes that 
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are annotated to encode pyruvate-formate lyase (Spy_1569), alcohol dehydrogenase 
(Spy_0039), acetate kinase (Spy_0094), and PEP carboxylase (Spy_0505). Although little 
is known about the functions of these proteins, and if their annotations are appropriate, this 
suggests that GAS can generate alternative end products to lactic acid when a carbohydrate 
is metabolized and that pH alone is likely not the only readout for positive carbohydrate 
metabolism by a GAS strain. 
C r o 	c t olite	repressio 	 CC  
 Carbon catabolite repression is a condition induced in the presence of a preferred 
carbon source, usually glucose, where bacteria have developed several mechanisms to 
prevent either the expression or the activity of alternate carbon source metabolic enzymes 
to prevent the metabolism of less favorable carbon sources. In this section, two mechanisms 
of CC  will be explored. 
i) Carbon Control Protein A (CcpA)-dependent CCR. 
  In GAS, this is the major form of catabolite repression. It occurs when the metabolism 
of a preferred carbon source produces high amounts of fructose-1,6-bisphosphate, which 
stimulates the kinase activity of the Hpr  kinase phosphorylase that in turn phosphorylates 
Hpr on its serine-46 residue. Hpr(Ser-P) acts as a cofactor to CcpA, allowing CcpA to bind 
catabolite response elements (cre) to regulate expression of the target gene (Deutscher et al., 
199 ). However, the presence of a cre site does not guarantee that CcpA is able to bind, as 
was shown for the m  and rcA C operons in S. suis (Willenborg et al., 2014). When 
FBP levels are lower and phosphate levels increase, Hpr  acts as a phosphorylase and 
cleaves the phosphate off of the serine-46 residue, allowing for HPr to be phosphorylated 
on its histidine-15 residue to facilitate PTS uptake activity of alternate carbon sources; 
leading to the relief of CC  (Deutscher et al., 199 ).  HPr(Ser-P) has also been shown to 
elicit CC  on its own by binding to sugar permeases in certain bacteria (Saier et al., 1996), 
and is also required for growth on a wide range of sugars (Zeng & Burne, 2010). 
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 In reality, this model is fairly simplistic, and the discovery of a fourth form of HPr 
has further complicated matters. HPr(Ser-P) is thought to greatly inhibit the phosphorylation 
of the histidine-15. However, HPr(Ser-P)(His-P) can build up in rapidly growing bacteria 
( oy et. al., 2008). This does not occur in all bacteria, as those that are able to control 
intracellular pH do not have high levels of HPr(Ser-P)(His-P) (Bacilli and Enterococci) 
whereas those that do not regulate their intracellular pH have higher levels ( oy et. 
al., 008). HPr(Ser-P)(His-P) is generated due to the high concentration of HPr(Ser-P) 
present in rapidly growing cells, which is able to be phosphorylated by EI at an acidic pH 
(Casabon et. al., 006). Although EI normally phosphorylates HPr, its preferred substrate, 
this doesn t occur as strongly at a lower pH, where HPr(Ser-P) phosphorylation by EI is 
enhanced (Casabon et. al., 006). It is unclear at the moment if HPr(Ser-P)(His-P) is able to 
interact with CcpA, but this can potentially add another wrinkle into CcpA-dependent CC  
regulation. Interrogation of the role of HPr and HPr  is problematic, as both of the genes 
that encode these proteins (ptsH and ptsK respectively), are critical for in vitro growth in 
GAS (Le Breton et al., 2015). 
 CcpA affects gene expression by binding to cre sites in the promoter region of 
many genes. The traditional consensus sequence in cillus	su tilis is TGWAANCGNT, 
where W represents an A or a T, and N represents any base. A variable cre site (crevar) was 
identified in C.	 ceto ut licum, which has the distinct feature of variable spacer regions 
(0-40 nt) that allow for increased variability in CcpA regulation (Yang et al., 2017). The 
consensus sequence for crevar is Nx TGTAAA-Yx –TTTA CAMx, where N and M represent 
bases that complement each other, Y represents any base, and X represent the number of 
bases. YX represents the variable spacer region present in crevar. Genes that contain crevar 
generally encode proteins for substrate transport, metabolism, redox balancing, sporulation, 
or solvent production categories (Yang et. al., 2017). Another variable cre 	is also present 
(TTTTCAAAAAATTTTC) and is usually found in genes associated with stationary phase 
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and are located mostly inside open reading frames (Willenborg et al., 2014). With three 
types of cre sites, CcpA-dependent CC  is complex, and regulation of gene expression 
may have many layers to ensure efficient use of the nutrients available. 
ii) EII-mediated CCR.  
 CC  can also occur by EIIAGlc in Gram-negative bacteria. In E.coli, EIIAGlc that is 
unphosphorylated can bind to other sugar permeases, namely the maltose, melibiose, and 
raffinose, lactose, galactose, and L-arabinose transporters (Chen et. al., 2013, Deutscher 
et. al., 2006). In the case of maltose, EIIAGlc that is unphosphoryalted will prevent the 
outward facing conformation of the maltose transporter which is required for maltose 
translocation, as well as inhibiting ATP hydrolysis (Chen et. al., 2013). EIIAGlc also prevent 
glycerol metabolism by preventing glycerol kinase (GlpK) from phosphorylating glycerol 
to generate glycerol-3-phosphate  (Deutscher et. al., 2006). This is predicted to occur in 
GAS as well, although through EI rather than EIIAGlc. Since this mode of CC  only occurs 
when the unphosphoryalted EIIAGlc binds to each transporter, cells are able to prioritize the 
metabolism of one sugar over others apart from CcpA-dependent CC . This is because an 
unphosphoryalted EIIAGlc will only occur when glucose is being transported by its cognate 
EIIC (Deutscher et. al., 2006). Binding of EIIAGlc to other membrane transporters has never 
been seen with Gram-positive bacteria. 
 This does not exclude the ability of EIIs to elicit CC . In oral streptococci, ManL 
(EIIABman) is a well-characterized CcpA-independent CC  mechanism. In S. mutans, ManL 
helps change the expression profile when the external media goes from glucose-rich to 
glucose-poor (Moye et. al., 2014). In S. gordonii, this is done by regulating the expression 
of several other EIIs, namely the fructose-specific EIIs (fruA and levD) (Tong et al., 2011). 
In these cases, dephosphoryaltion of ManL due to sugar transport through ManM (EIIC) 
and ManN(EIID) elicits ManL-dependent CC  (Tong et. al., 011). However, ManL-
dependent CC  is limited to glucose and mannose in S. mutans, which is not the case in S. 
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gordonii  (Tong et al., 011). The mannose-specific EII in S. pneumoniae affects growth 
on many different non-preferred sugars and is thought to be the result of the transport of 
multiple sugars that stimulates the expression of other PTS operons specific for that sugar 
(Fleming  Camilli, 016). In support of this, a ∆m  mutant failed to stimulate 
expression of the lactose-specific metabolic operon (Fleming  Camilli, 016). However, 
m  has a higher affinity for glucose compared to lactose, and via inducer exclusion, 
can suppress the expression of the lactose-specific metabolic operon in the presence of 
glucose (Fleming & Camilli, 2016). Inducer exclusion is a common phenomenon observed 
in bacteria, where transport of a preferred carbon source, usually glucose, prevents the 
transport of another less preferred carbon source. 
CcpA core regulon in GAS 
 The core CcpA regulon was recently compiled by Deb oy et. al (2016), compiling 
a list of differentially regulated genes in ∆ccpA mutants in MGAS2221 (M1), MGAS10870 
(M ), and MGAS6180 (M 8) using NA-se  (Deb oy et al., 2016). Overall, 310-386 
genes were identified as CcpA-regulated in each strain, with a core group of 1  genes 
(Deb oy et al., 2016). As expected, many transport and metabolism genes fell in the core 
CcpA regulon, including nine EIIs anticipated since PTS transport systems are generally 
specific for alternate carbohydrates (Deb oy et al., 016). However, in S. suis the CcpA 
regulon only includes four EIIs (Willenborg et al., 2014). Although the largest number of 
genes affected by the deletion of ccpA involves carbohydrate metabolism, many also are 
involved in amino acid, nucleotide, and lipid metabolism (Deb oy et al., 2016). In almost 
all cases, CcpA acts as a repressor to the core regulon genes identified, again illustrating the 
importance of CcpA to CC  in GAS.
 Interestingly, only two virulence gene loci were identified in the core regulon. The 
first is endoS, encoding a secreted endoglycosidase (Deb oy et al., 2016) that is responsible 
for the processing of glycoproteins. The second is the 9-gene sag operon required for 
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Streptolysin S or SLS production (Deb oy et al., 2016), which is known to be catabolite 
repressed. However, the mechanism by which CcpA influences SLS expression appears 
to be indirect, as binding of CcpA to the sag promoter was only shown in vitro (Kinkel 
& McIver, 2008) but not in vivo (Kietzman & Caparon, 2010). The inclusion of the sag 
operon in the CcpA core regulon corroborates several observations that ∆ccpA	exhibits 
early onset of hemolysis (Kinkel & McIver, 2008, Shelburne et al., 2008a). CcpA has 
been linked to virulence in other pathogens as well. CcpA is required for the colonization 
of the nasopharynx and the lung. In S. mutans, it governs acid formation and tolerance. 
In Clostridium	 perfri e s  it regulates (either directly or indirectly) the expression of 
enterotoxin. In C.	difficile, CcpA regulates toxin production (Antunes et al., 2011).  In 
S. aureus and S. gordonii, CcpA contributes to methicillin and penicillin resistance 
respectively (Gorke  Stulke, 008). This illustrates that efficient metabolism of preferred 
carbohydrates is intimately tied with virulence. 
i s	 et ee 	met olism	 d	 irule ce	i 	 r m positi e	p t o e s	
 PTS carbohydrate metabolism is vital to the pathogenesis of many human pathogens. 
In this section, a few examples are highlighted in closely-related Gram-positive pathogens. 
In S. aureus, severely hampering the ability to utilize glucose leads to a dramatic reduction 
in lesion size and lower bacterial burden in a subcutaneous murine infection model (Vitko 
et al., 016). The mannose-specific EII appears repeatedly as being important for virulence 
of other pathogens. In cto cillus	pl t rum, impairment of m  expression led to 
peroxide sensitivity (Stevens et al., 2010). In S. mutans, ManL helps biofilm formation and 
competence (Abranches et al., 006). ManLMN also affect virulence gene expression. In L. 
monocytogenes, dephosphorylated ManL depresses the activity of the virulence regulator 
PrfA, which in turn activates the expression of the virulence genes l  and acta (Ake et 
al., 2011). Similarly, ManN (EIIDman) prevents suislysin expression, which leads to the 
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absence of hemolysis (Lun et al., 2004). One of the more interesting roles that the mannose-
specific EII plays in virulence relates to bacteriocins. Many bacteria use bacteriocins when 
competing with other populations. The mannose-specific EII is known to be a target for 
class IIa bacterocins (Kjos et al., 2011), which are small peptides produced by lactic acid 
bacteria that inhibit growth. It also is a target for mutacins, as a ∆m  mutant in S. 
salivarius had reduced sensitivity to I-T9 and - B (Nicolas et. al. , 2010). The mannose-
specific EII may play such a significant role, because it is constitutively expressed in vivo 
(Watanabe et. al., 2013) and in vitro (Shelburne et al., 2008b, Fleming & Camilli, 2016). 
 The influence of metabolism is not ust limited to the mannose-specific EII or 
mannose metabolism, as fructose metabolism also seems to play a large role in virulence. 
In S. gordonii, FruA (fructose-specific EII) senses high levels of fructose, switching cells 
from a sessile to planktonic phenotype, thereby aiding the formation of biofilms (Loo et al., 
2003). In S. iniae, fruA is found only in five virulent strains that were studied, but was absent 
in five non-virulent strains (Pridgeon et al., 2013). fruA also is important for the ability of 
GAS to adjust to different blood-related stresses, which will be discussed in the next section. 
Deletion of the cellobiose-PTS reduces the virulence of K. pneumoniae, is attenuated in 
a S. pneumonaie/sepsis model and reduces survival in the nasopharynx, blood, ears, and 
lungs of mice (Wu et. al., 2012, McAllister et al., 2012). Sucrose metabolism perturbations 
lead to attenuation of S. pneumoniae in the nasopharynx (Iyer & Camilli, 2007). Maltose 
utilization promotes intestinal colonization by commensal and enterohemorraghic E. coli 
(Le Bouguenec et. al., 2010). Preventing mannitol utilization hinders the ability of S. 
aureus to survive exposure to host antimicrobial fatty acids (Kenny et al., 01 ). NA-se  
from murine tissues following i.p. infection with Group G streptococci found the mannose, 
glucose, mannitol, cellobiose, sucrose, galactitol, b-glucoside, N-acetylglucosamine, 
and the N-acetylgalactoseamine PTS EIIs were upregulated over the course of 8 hours 
(Watanabe et. al., 2013). This highlights the importance of sugar metabolism in the overall 
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pathogenic process. 
A 	 ersus	t e	 ost 
 S. pyogenes contains an arsenal of weapons to not only combat the host immune 
response, but also to coordinate expression of the appropriate virulence factors in order to 
survive during infection. Here, selected genes specifically involved in virulence that also 
have a connection with carbon metabolism are highlighted. 
CovRS
 Cov S is a two-component system in GAS, whose loss has been linked to the 
hypervirulent phenotype seen in many invasive strains. In the two strains used in this study, 
MGAS5005 is a spontaneous covS mutant whereas 5448 is wild type for covRS. Cov S 
specifically responds to Mg2+ and LL- , but loses this ability as spontaneous mutations can 
occur when exposed to neutrophils. As a result, the repression of many virulence factors 
is lost, increasing the virulence potential of these strains (Federle et al., 1999, Heath et al., 
1999, Bernish  van de i n, 1999). One visible result of the loss of covS is a hypermucoid 
phenotype resulting from an increase in sA expression (Levin  essels, 1998). The 
Cov S regulon also includes many metabolic genes, including those involved in mannose, 
maltose, and b-glucoside metabolism (Graham et al., 2002). As a result, a covS mutant may 
exhibit different metabolic capability over the course of infection that allows it to have a 
greater virulence potential. 
SpeB
 SpeB is a cysteine protease responsible for the degradation of many GAS and host 
proteins. It is translated as a 40 kDa immature protein, which is autocleaved to form a 28 kDa 
active protein (Hynes et. al., 2016). Expression of speB is significantly induced after  days 
post infection in a subcutaneous murine infection model (Loughman  Caparon, 006b). 
SpeB activity is also highest at a pH of 6.5 and low chloride concentration (Loughman  
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Caparon, 2006a). speB is also catabolite repressed, as CcpA binds to the speB promoter 
(Kietzman & Caparon, 2010), although expression in GAS is affected by the PTS in a 
strain-specific manner. In GAS MGAS5005 and 5448AP, speB was lower in ∆ptsI mutant 
strains as compared to their parental strains. However, this was not the case for a covS+ 
parental strain, where ∆ptsI had the same level of expression of speB as compared to 5448 
(Gera, 2014). 
Mga
 Mga is a stand-alone regulator that controls the transcription of many virulence 
and metabolic genes in GAS, and is most active in late exponential to late-log phase 
(McIver, 2009).  The Mga regulon encompasses genes that are both directly (core) and 
indirectly affected by Mga activity (Hondorp  McIver, 00 ). The core Mga regulon is 
directly regulated by Mga and includes genes for adhesion and internalization such as M 
protein (emm) and fibronectin-binding surface adhesion (f ), immune evasion such as 
C5a peptidase (scpA) and secreted inhibitor of complement (sic) and its own expression 
(Hondorp  McIver, 00 ). Many sugar utilization genes are indirectly regulated by Mga, 
including the mannose fructose-specific EII (ptsA C ) and the fructose-specific EII 
(fru A); however, the Mga regulon can vary depending on the serotype (Valdes, 2016). 
 PTS-regulatory domains (P Ds) are phosphorylated by either EI Hpr or EIIBs in 
the appropriate conditions. Mga is a P D-containing virulence regulator (PC ) that is 
able to alter its activity based on the phosphorylation status of PTS enzymes. EIIBs can 
phosphorylate P Ds in the absence of the inducing sugar, as the phosphate will reside on 
the EIIB rather than being passed onto a translocated sugar. Hpr-His P can phosphorylate 
P Ds as well, which is prevented in the presence of a preferred carbon source as Hpr 
will be phosphorylated on its Serine residue in this situation. P Ds are present in many 
bacteria, specifically on antiterminators and activators, but have only been found on 
virulence regulators in Gram-positive bacteria (Stulke et al., 1998). 
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 Mga in GAS has two P Ds. P D1 has two conserved histidines that were shown 
to be phosphorylated by EI Hpr (Hondorp et al., 01 ). Phosphorylation of P D1 is 
thought to inhibit Mga activity, as in vitro transcription of emm is higher when EI Hpr is 
not phosphorylated (Hondorp et al., 01 ). EIIBs are thought to phosphorylate P D  in 
the absence of the inducing sugar (Hondorp et al., 2013). As a result, mutations in the PTS 
alter Mga activity. A ∆ptsI mutant in the M4 GA40634, which cannot phosphorylate Mga 
on either P D, has lower expression of the core regulon genes arp and sof (Hondorp et al., 
01 ), indicating a reduction in Mga activity. Additionally, an MGAS5005 ∆ptsI mutant 
had lower expression of sic. However, there appears to be strain specificity, as 5448AP.∆ptsI 
has no effect on the expression of emm or sic, whereas 5448.∆ptsI has increased expression 
of both genes (Gera, 2014). 
 Interestingly, not only is Mga activity affected by the PTS, but the Mga regulon 
itself can change depending on the nutrient conditions of the environment. The Mga regulon 
determined for GAS grown in THY differs significantly from the regulon when GAS was 
grown in low glucose C-media ( aldes, 016).This includes the Streptolysin S (SLS) 
operon, which is Mga-regulated (most likely indirectly) in low glucose, but not in high 
glucose ( aldes, 016). This appears to correlate with differences in P D phosphorylation. 
Overall, this suggests that the PTS may signal virulence pathways through Mga to impact 
both virulence and sugar metabolism, an important concept that will be touched upon 
throughout this dissertation.  
Sugar metabolism genes essential for virulence
 Many PTS genes have also been demonstrated to be important for GAS pathogenesis. 
Maltose/maltodextrin metabolism was shown to be necessary for GAS colonization and 
disease burden in the mouse oropharynx (Shelburne et al., 2008b). Fructose-metabolic 
genes have been found to be required for survival against neutrophil killing, a process that 
is explored more in Chapter 6 of this dissertation (Valdes et al., 2016). Several metabolism 
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genes were identified in a whole genome mutagenesis screen for GAS survival in whole 
human blood, including the fructose-specific EII, the mannose-specific EII, and a sucrose-
6-phosphate hydrolase (scrB)(Le Breton et al., 2013).  In a gene expression analysis of 
pathways critical for GAS survival in whole human blood, many carbohydrate metabolism 
genes appeared such as the mannose-specific EII (Graham et al., 2005).  Furthermore, the 
expression levels varied over the course of 90 minutes, highlighting how GAS is able to 
adapt to quickly changing nutrient content (Graham et al., 2005). Studies on blood related 
stresses have identified PTS genes as well. The GAS regulon in the presence of heme 
stress, a condition that is likely to occur with the lysis of BCs, identified the fructose-
specific EII and the lactose-specific EII as induced, while the mannose fructose-specific 
EII was repressed (Sachla et al., 2014). 
 Elimination of the PTS phosphorelay by deletion of the first enzyme in the pathway 
(EI) in GAS led to the early expression of the toxin Streptolysin S, (see below) rather 
than being expressed in late-log growth phase like its parental wild type strain (Gera et 
al., 2014). This also resulted in larger more necrotic lesions at the site of infection in a 
subcutaneous murine skin infection model (Gera et al., 2014). This suggests that the PTS 
mediates SLS activity in vivo. 
Streptolysin S
 SLS is a potent Class I bacterocin that lyses many host cells (Molloy et al., 2011, 
Nizet et al., 000). SLS-like toxins exist across many bacterial species, and are hardly 
uni ue to GAS. Although not all are bioactive like SLS, SLS-like clusters have been found 
in irmicutes 	 piroc etes  and Acti o cteri   (Molloy et al., 2011). Many important 
pathogens such as Listeria monocytogenes and S. aureus also have regions of homology to 
the sag operon, although many of them have not been as extensively studied  (Molloy et al., 
011).  Hemolysis associated with streptococcal infections was observed in the late 1800s, 
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but SLS was not identified until the late 19 0s (Todd, 19 8). 
 SLS is encoded by a 9-gene operon that is responsible for extracellular release of 
mature SLS (Fig. 1.5). The operon consists of s A , each encoding  a protein responsible 
for a different step in SLS biosynthesis and transport. s A encodes an immature SLS 
peptide that is further processed post-transcriptionally by SagBCD to create the SLS to 
be exported (Molloy et al., 2011). SagD forms a complex with SagBC to carry out the 
reaction, where SagC produces thiazoline and CH3-oxazoline rings by removing water 
from the SLS-precursor peptide backbone (Molloy et al., 2011). SagB then catalyzes a 
dehydrogenase reaction to remove the hydrogen to create an aromatic thiazole and CH3-
oxazole heterocycles (Molloy et al., 011). The mature SLS is now structurally rigid, 
which allows for better binding to its targets (Molloy et al., 011). SagGHI are thought 
to create an ABC transporter to export SLS, where SagG is the ATP-binding protein, and 
SagHI create the membrane channel. SagE is thought to be the immunity protein, but also 
hypothesized to cleave the leader se uence from SLS to make a bioactive SLS that is 
exported (Molloy et al., 011). Little is known about the role SagF plays, other than that it 
is membrane associated (Molloy et al., 2011).  
 Many functions have been proposed for SLS, with the underlying theme being to 
help GAS survive in the host. The vast majority (99%) of GAS isolates have been shown 
to produce SLS (Molloy et. al, 011), and ∆s A mutants in many GAS strains were 
shown to be attenuated in different infection models (Datta et. al., 005). SLS has been 
associated with soft tissue injuries (Datta et. al., 2005), evasion of the immune system 
Figure 1.5 The sag operon in GAS. The gene names (below arrows), and encoded protein 
functions (above arrows, color coded) are shown respective to each gene in the sag operon. 
Arrows are color coded according to the encoded protein function, and are drawn to scale. 
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through programmed cell death (Datta et. al., 2005, Goldmann et. al, 2009), translocation 
across the epithelial barrier (Sumitomo et. al, 011), and in uorum-sensing (Lyon et al., 
001). The hallmark of SLS activity has been observed with the lysing of BCs, which 
has been thought to occur to promote GAS to gain access to iron (heme) (Sachla et. al., 
014). This is supported by the fact that SLS expression is also stimulated by the presence 
of serum (unpublished).    
 Until recently, not much was known about the mechanism by which SLS lysed 
target cells, other than the process appeared to be osmotic. Higashi et. al. (2016) discovered 
that SLS actually interacts with membrane ion channels, where Cl- ions are rapidly influxed 
into BCs, which causes a massive influx of water and results in cell lysis. They showed 
that SLS interacts with a particular ion channel called Anion exchanger 1 (AE1 or band ), 
which is almost exclusively and most abundantly found on BCs (Higashi et. al, 2016). 
Anion channels on other host cells are now hypothesized to be targets for SLS, although no 
evidence has been presented that would confirm this assertion as of yet. 
 Triggers for SLS activity have long been a sub ect of study. hen SLS was first 
discovered, it was found that potassium ions stabilize SLS, and that nucleic acids serve 
as a sufficient stimulant for SLS production (Bernheimer et. al, 1948). In addition, it was 
observed that SLS activity was also stimulated by maltose, trehalose, inulin, raffinose, 
mannose, and glucosamine to different extents (Bernheimer et. al, 1948). Most interestingly, 
it was noted that SLS activity was diminished in the presence of glucose and heme stress, 
the first suggestion that SLS is catabolite repressed (Bernheimer et. al, 1948, Sachla et. al., 
2014).
Chapter 2: Overview 
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 The Group A Streptococcus (GAS, Streptococcus pyogenes) is a Gram-positive 
human pathogen that must adapt to unique host environments in order to survive. Invasive 
GAS (iGAS) is able to infiltrate into sterile sites in a human, re uiring a mechanism to 
integrate different environmental cues to coordinate an appropriate virulence expression 
program for each host niche. Although iGAS may not be as common as superficial infections 
that infect the throat and skin, they do lead to the development of more serious clinical 
symptoms such as necrotizing fasciitis and streptococcus toxic shock syndrome (STSS). 
Unlike superficial infections that are usually treated with antibiotics and are generally self-
limiting, invasive infections are much more complicated to treat due to antibiotic access 
and effectiveness (Cunningham, 2000). Without a licensed vaccine, GAS continues to be a 
public health problem whose healthcare costs can reach millions of dollars per year (Pfoh 
et. al.,2008) and it ranks as the 9th leading infectious cause of human mortality (Carapetis 
et al., 2005). 
 One mechanism that bacteria employ to coordinate environmental nutrient 
availability with gene expression is through sugar metabolism and transport.  Sugars and 
carbohydrate metabolic pathways have long been implicated in the virulence processes 
of many human pathogens (López-Garrido et al., 2015, Foster et al., 00 , Petzold et al., 
006, Lowe et al., 2009, Ngamskulrungroj et al., 2009, Tournu et al., 01 ). Links between 
sugar metabolism and virulence have been demonstrated in GAS, where mutants in the 
phosphoenolpyruvate-dependent phosphotransferase system (PTS) exhibited premature 
Streptolysin S (SLS)-mediated hemolysis during exponential growth. This early onset 
hemolysis correlated with an increased lesion size and severity in a murine soft tissue 
infection model when compared with parental M1T1 MGAS5005 (Gera et al., 2014), a 
representative strain from the most commonly found GAS serotype in North American. 
 To identify the PTS components responsible for this phenotype, we insertionally 
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inactivated the 14 annotated PTS sugar transporter-encoding genes (Enzyme IIC 
components, EIICs) in the GAS MGAS5005 genome and sub ected this library to 
metabolic and hemolysis assays to functionally characterize each EIIC. It was found that a 
few EIIs had a very limited influence on PTS sugar metabolism, whereas others were fairly 
promiscuous. ery few EIIs affected the metabolism of a sole carbon source, illustrating 
the inherent redundancy within the PTS for the transport and utilization of carbohydrates.  
EIIs contribute to the early hemolytic phenotype seen in MGAS5005.∆ptsI, which suggests 
that the regulation of SLS-mediated hemolysis may re uire many inputs. However, early 
hemolysis did not affect survival in whole human blood, as only two EIIs were found to be 
important for survival in this environment. 
 One of the main EIICs that contributed heavily to both GAS metabolism and 
hemolysis is the mannose-specific EII. The mannose-specific EII locus, encoded by 
manLMN, was expressed as a mannose-inducible operon that exhibited the most influence 
on PTS sugar metabolism, including mannose. Each individual subunit of the mannose-
specific EII also affects the metabolism of PTS carbohydrates to different extents, with the 
EIID having the least influence. Importantly, components of the mannose-specific EII also 
acted to prevent the early onset of SLS-mediated hemolysis. Interestingly, these roles were 
not identical in two different M1T1 GAS strains, highlighting the possible versatility of the 
PTS to adapt to strain-specific needs. The mannose-specific EIICD mutant (∆manMN) also 
exhibits more severe lesions in a subcutaneous murine infection model, although the lesion 
size is similar to that in MGAS5005. 
 Strain specificity also appeared when we functionally characterized the fructose-
specific EII operon (fruA) in another M1T1 5448. Components of the predicted fructose 
metabolic operon (fruRBA), made up of the fructose-specific EII (fruA), a fructose-1-
phosphate kinase (fruB), and the operon regulator (fruR) were implicated as essential for 
survival against neutrophil killing (Valdes et al., 016). However, fruA was not one of 
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them, and was not important for survival in whole human blood. Interestingly, these 
ex vivo virulence-related phenotypes were not the same for a ∆fruA strain created in 
MGAS5005, highlighting again the divergent roles of the same protein in two different 
strains of the same serotype. In this study, we characterized the metabolic influence of 
FruA in 5448 and compared it to MGAS5005 to identify other points of variation. e also 
characterized under which conditions this metabolic operon is expressed in an effort to 
determine the cause behind its importance in GAS immune evasion (Valdes et al., 2016). 
 Although we managed to characterize two EIIs that are important for overall 
GAS pathogenesis and metabolism, we could not find an EII that fully explained the 
early hemolytic phenotype seen in MGAS5005.∆ptsI. However, we did determine 
that hemolysis occurs only in low nutrient conditions, strengthened by the fact that 
MGAS5005.∆ccpA, a mutant unable to initiate carbon catabolite repression (CCR), 
also exhibited early hemolysis. e hypothesized that perturbations in efficient glucose 
metabolism may be the cause for the misregulation of SLS-mediated hemolysis. The 
route of glucose utilization is unknown in GAS, therefore we made mutants in a non-
PTS glucose transporter (glcU) and a glucokinase (nagC) of an annotated non-PTS 
glucose metabolic pathway. It is evident that glucose can be metabolized both by the PTS 
and non-PTS routes, as ∆ptsI, ∆nagC, and ∆glcU all grow to some extent in glucose. 
However, the route of glucose utilization affects overall pathogenesis, as forcing glucose 
to go through the PTS (∆nagC) allows for survival of MGAS5005 in whole human 
blood, whereas absence of PTS (∆ptsI) transport is detrimental to overall survival in 
whole human blood. In addition, components of the non-PTS glucose metabolic pathway 
influence the utilization of PTS carbohydrates, as ∆glcU does not grow similarly to T 
in mannose, and ∆nagC has affected growth in many PTS sugars presented as the sole 
carbon source.  Interestingly, all three mutants display the early onset of SLS-mediated 
hemolysis, although to largely different levels. Similar to ∆ptsI, ∆nagC also displayed
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more severe lesions as compared to MGAS5005 in a murine skin infection model. 
However, unlike what was observed with ∆ptsI, these lesions were not significantly 
larger than those of wild type. Dissemination of all three strains was unaffected, as 
similar CFUs were obtained from the spleen 48 hours post infection (hpi). All of these 
data suggest that carbohydrate metabolism plays an extensive role in GAS pathogenesis.
Chapter 3: Materials and Methods
Bacterial strains and media
Media
 GAS was grown in either Todd-Hewitt broth with 0.2% yeast extract (THY), 
Chemically defined medium (CDM, Alpha Biosciences), or C-media. Composition of all 
three medias are presented in Appendix. Freshly prepared sodium bicarbonate (59.51 mM) 
and L-cysteine (11.68 mM) were added to CDM before use. The carbon source for CDM 
or C-media was added at either 1  (all other PTS sugars) or 0.5  (glucose) prior to GAS 
inoculation. On occasion, various concentrations of glucose was used.  Luria-Broth (LB) 
was used to grow E.coli strains. anamycin ( m) was used at 50 mg ml-1 for E.coli and at 
300 mg ml-1 for GAS. Spectinomycin (Sp) was used at 100 mg ml-1 for both E.coli and GAS. 
M1T1 strains
 Bacterial strains used in this study are listed in Table 3.1. 
E. coli strains 
 Bacterial strains used in this study are listed in Table 3.1. 
Generation of the annotated EII mutant library in MGAS5005 
 Mutagenic temperature sensitive pC S integrative plasmids were used to create 
the annotated EII mutant library as previously described (Le Breton  McIver, 01 , Le 
Breton et al., 01 ).  Briefly, 500 bp region of homology to each EIIC was inserted into 
SmaI-cut pC S to create a mutagenic plasmid (Table 3.2). The mutagenic plasmid was 
then transformed into electrocompetant MGAS5005 and plated at 0oC for  days with 5  
CO2. The resulting transformants were then transferred to THY Spec
100 plates at 0oC (5  
CO2) for 1 day, passaged in THY Spec
100 broth for 1 day at oC (5  CO ), then plated on 
THY Spec100 for 1 day. 
 Proper insertion of the mutagenic plasmid, which was checked for accuracy by 
BamH1 digestion and se uencing, was validated by PC  using specific validation primers
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and the plasmid primers 1 01, 1 11, pvuII , and pvuIIF (Table 3.2). escue strains were 
generated for each mutant by passaging confirmed mutants twice in THY broth for 1 day 
each at 30oC, then plated on THY at oC (5  CO2). escues were confirmed by checking 
for spectinomycin sensitivity. 
Generation of mannose EII subunit mutants in the M1T1s MGAS5005 and 5448  
 Using the pSinS (repA deleted) mutagenic plasmid approach, stable insertional 
mutants were created in some of the mannose EII subunits (Le Breton et al., 015). Briefly, 
mutagenic pSinS plasmids were created by cloning 500bp of a region of homology 
to an EII subunit into a SmaI-cut pSinS. BamH1 digestion and se uencing was used to 
determine insert orientation and accuracy. The mutagenic plasmids were then transformed 
into electrocompetent 5448 or MGAS5005 cells containing pHlp  (which provides the 
repAts gene to pSinS), and plated on THY  Sp100 m300 at 30oC (5  CO2) for  days. 
Transformants were then passaged in THY  Sp100 m300 for 1 day, pelleted, resuspended 
and incubated in saline for  hours in a oC water bath, and plated on THY Sp100 at oC 
(5  CO2). Mutants showed spectinomycin resistance and kanamycin sensitivity, and were 
confirmed via PC  using specific mutant confirmation primers and either 1 01 or 1 11 
(Table 3.2). 
eneration of fructose metabolic operon mutants and sloR 
 Allelic exchange to create nonpolar mutants of fruR, fruB, and fruA was employed. 
Briefly, the open reading frame of each gene was replaced with a cat cassette as previously 
described ( ose, 1988). The primers oA Spy066(0- ).( , ,5,6) (Table 3.2) were used to 
amplify the region up and downstream of the CDS with overlaps of the cat cassette, and 
ligated by PC -splicing by overlap extension (SOE). The cat cassette was amplified using 
oCatFwd and oCat ev (Table 3.2). This PC  product was digested by SmaI and cloned 
into SmaI digested pC S, creating each mutagenic plasmid (Table 3.4). The mutagenic 
plasmids were integrated into the GAS genome by double-crossover homologous 
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recombination and passaged to select for both the mutant and revertant strains. Mutants 
were selected for by looking for colonies that were Cm  but SpS, indicating the successful 
exchange of the cat cassette for the selected gene as well as loss of the mutagenic plasmid. 
evertant strains were selected as having sensitivity for both antibiotics, indicating loss of 
the mutagenic plasmid after the initial integration, leaving behind the intact gene. PC  was 
used to validate proper cat insertion in the mutants. 
 Mutagenesis of sloR was done with pC , using the same procedure as before 
when generating the EII mutant library. The only difference was the antibiotic used during 
passages, using kanamycin instead of spectinomycin. Again, mutants were confirmed using 
PC  using slo  luc F and 1 11 (Table 3.2). 
Generation of glucose metabolic pathway mutants 
 MGAS5005.∆glcU (Table 3.1) was created by using the pC S system described 
in the earlier section to create an polar insertional inactivation mutant. MGAS5005.∆nagC 
(Table 3.1) was created using allelic exchange with the swap of nagC for a kanamycin 
resistant cassette (from pC ). This cassette was introduced by pC S, where GAS 
transformants were passaged in THY with Sp and m for two days at 0oC. These cells 
were then passaged in THY with m, plated, and screened for kanamycin resistance 
and spectinomycin sensitivity at oC. evertants were saved that were sensitive to both 
drugs, indicating reversion to wildtype nagC. Km50 was used for passaging this strain, 
based on presumably weak expression of the kanamycin resistance gene. e created a 
MGAS5005.∆glcU∆ptsI by transforming a mutagenic pC  plasmid with a region of 
homology corresponding to glcU into the MGAS5005.∆ptsI strain (Gera et al., 014). 
Positive double mutants were resistant to both Sp100 and Km300.  
DNA manipulations
 Polymerase Chain eaction (PC ) was performed using either Ta  DNA 
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MGAS5005 i.i. of glcU a.e. of ptsI
MGAS5005.∆ C	revertant 
MGAS5005.∆ lc 	revertant
5448 a.e of fruR 
5448 a.e of fruB




MGAS5005 i.i. of Spy0148 
MGAS5005 i.i. of Spy04 5 
MGAS5005 i.i.of Spy10 9 
MGAS5005 i.i. of Spy1 44 
MGAS5005 i.i. of fruA 
MGAS5005 i.i. of Spy1 99 
MGAS5005 i.i. of lacE.2 
MGAS5005 i.i. of malT 
MGAS5005 i.i. of Spy166  
MGAS5005 i.i. of ptsC
Reference
Hanahan et. al, 198
Sumby et. al, 005
Gera et. al, 014 
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Chatellier et. al, 2000 
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  






Valdes et. al, 016 
Valdes et. al, 016 
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01
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Table 3.1 con’t: Bacterial strains
Bacterial Strain





∆ -keto-L-gulonate  














MGAS5005 i.i. of manM 
MGAS5005 i.i. of Spy5 0 
MGAS5005 i.i. of scrA 
MGAS5005 i.i. of Spy1 84 
∆ -keto-L-gulonate rescue














Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01
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* i.i = Insertional Inactivation
** a.e.= allelic exchange
polymerase (NEB) for diagnostic assays, or using Accuprime Pfx (Life Technologies) for 
cloning. Both were carried our according to the manufacturer s protocol. Se uencing was 
done through Genewiz, Inc. Genomic DNA was extracted from GAS strains using the Master-
Pure complete DNA and NA purification kit for Gram-positive bacteria (Epicentre). izard 
Plus S  miniprep kit was used to extract plasmids from E. coli. DNA fragments from agarose 
gels or PC  reactions were purified using the izard S  gel and PC  cleanup kit (Promega). 
 Ligations were performed using a T4 ligase. eactions were set up as a 16:1 
ratio between insert and plasmid, and reactions were incubated in a 16oC water bath for 
1 day. estriction digests were also performed for  hours in buffers and temperatures 
recommended by the manufacturer (NEB). Plasmids used are listed on Table 3.4.  





Spy4 5  
Spy5 0L 
Spy5 0  
Spy66 L 
Spy66  
Spy 8 L 
Spy 8  
Spy10 9L 
Spy10 9  
Spy1 99L 












Spy1 44  
Spy1 84L 
Spy1 84
mplification of region of homolog  for  mutagenic plasmids






























CDS of Spy148 
CDS of Spy4 5 
CDS of Spy5 0 
CDS of Spy66  
CDS of Spy 8  
CDS of Spy 10 9 
CDS of Spy1 99 
CDS of Spy1480 
CDS of Spy154  
CDS of Spy16  
CDS of Spy166  
CDS of Spy169  
CDS of Spy1 44 
CDS of Spy1 84























5  of CDS of 
Spy148 
5  of CDS of 
Spy4 5 
5  of CDS of 
Spy5 0 
5  of CDS of 
Spy66  
5  of CDS of 
Spy 8  
5  of CDS of 
Spy10 9 
5  of CDS of 
Spy1 99


























5  of CDS of 
Spy1480 
5  of CDS of 
Spy154  
5  of CDS of 
Spy16  
5  of CDS of 
Spy166  
5  of CDS of 
Spy169  
5  of CDS of 
Spy1 44 
5  of CDS of 
Spy1 84

















5  of CDS of 
manM 
5  of CDS of 
manN













CDS of manL 
CDS of manM
CDS of manN 
CDS of manO
Fructose EII operon mutagenesis
oA Spy0660.5 
oA Spy0660.  
oA Spy0660.  
oA Spy0660.6
oA Spy0661.1 
oA Spy0661.  
oA Spy0661.  
oA Spy0661.4
oA Spy066 .1 
oA Spy066 .  


























Table 3.2 con’t: Primers used
Primer
slo  InIn F 
slo  InIn 
























Fru  luc 1 
Fru  luc 4
slo  luc F
















Glucose pathway mutants mutagenic primers and validation
oA 1 11-1
oA 1 11- k





















5  of CDS of 
nagC 




































 fruB M1 
T 
fru  M1 
T L
 fru  M1 
T 
ptsI M1 T L





slo  M1T1 
T L 
slo  M1T1 
T 














































* bp in bold denote restriction sites
** Underlined bp denote areas of overlap with a resistance cassette for PCR soeing
Transformation
Electrocompetent cell preparation
 To prepare MGAS5005 and 5448 for transformation, we made electrocompetent 
cells as described earlier (Le Breton  McIver, 01 ). Briefly, GAS strains were grown in 
THY  0mM glycine at oC overnight. .5 mls of the overnight culture was added to 150 
mls of THY  0mM glycine and grown at oC until an OD600 of 0. -0.4. Cells were then 
pelleted, washed in ice-cold EP-solution (100  glycerol) and pelleted again before a final 
46
resuspension in glycerol. Cells were then stored at -80oC. 
Electroporation
 Plasmids used in this dissertation are listed in Table 3.4. To prevent arcing during 
electroporation, DNA was drop dialyzed with dH2O on a 0.0 5 mm membrane filter 
(Millipore). This was done for either 0 minutes (E.coli) or 1 hour (GAS). Electroporation 
was performed using a GenePulser cell (Bio ad). DNA was added to 100 ml of competent 
cells in a  mm cuvette placed on ice. The cuvette was then electroporated using .5 k , 00 
 and 5 F for E.coli, or 1. 5k , 400  and 5 F  for GAS. Cells were then transferred 
to 1 ml of LB (E.coli) and incubated shaking at oC for 1 hour, or to 10 mls of THY 
(GAS)  and incubated statically at 0oC for 4 hours. Cells were then centrifuged at 6000g, 
resuspended in 100 ml of their respective medias, and plated on antibiotic selection.
Metabolic Assays 
Growth Curves
 GAS growth was monitored using the FLUOstar Omega microplate 
spectrophotometer (BMG). OD600 measurements were taken every 0 minutes for 4 or 
48 hours. Plates were shaken for 10 seconds prior to each reading. Overnight cultures 
were grown in 10 mls of THY (with without antibiotic), pelleted, and washed in saline. 
The OD600 of the cultures was then ad usted to 0.  in saline. 50 ml of culture was added to 
each well of either a 4 or 48 well plate (Corning Costar) containing CDM  1  of a PTS 
carbohydrate (0.5  for glucose). Plates were sealed with plate tape (Bio- ad), and then 
incubated in the microplate spectrophotometer for 4 or 48 hours. 
 Growth curves were analyzed by dividing the OD600 measurements of the mutant by 
the T at each time point to generate a set of  T. The median and inter uartile range of 
this data set was calculated. Mutants were determined to have significant growth defects in 
carbon sources in which growth was more than  fold below T. Mutants were determined 
to have growth above T in carbon sources that have  fold growth above T. ∆OD was 





Spy4 5  
Spy5 0L 
Spy5 0  
Spy66 L 
Spy66  
Spy 8 L 
Spy 8  
Spy10 9L 


























16 mutantconf 1 
166 mutantconf1 
169 mutantconf1 





Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01













oA Spy0660.  
oA Spy0660.  
oA Spy0660.6
oA Spy0661.1 
oA Spy0661.  
oA Spy0661.  
oA Spy0661.4
oA Spy066 .1 
oA Spy066 .  
oA Spy066 .  
oA Spy066 .4
slo  InIn F 





Fru  luc 1 
Fru  luc 4
slo  luc F




manL M1T1 T L
manL M1T1 T  
manM M1T1 T L 
manM M1T1 T  
manN M1T1 T L 
manN M1T1 T 
fruA M1 T L
fruA M1 T 
fruB M1 T L
Reference
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016 
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
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Table 3.3 con’t: Primer origin
Primer
  fruB M1 T 
fru  M1 T L
 fru  M1 T 
ptsI
ptsI 
gyrA M1 T-L 
gyrA M1 T-
slo  M1T1 T L 








oA 1 11- k







Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Gera et. al, 014
Gera et. al, 014
ibardo et. al, 004
ibardo et. al, 004
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016












determined by deducting the initial OD600 
from the max OD600. Data presented is the 
average of at least  biological replicates, 
done in technical duplicates. Significance 
was determined by unpaired Student t 
test (p-value 0.5). In some cases, a lett-
Summerson colorimeter (A filter) was used 
to monitor growth. ather than OD600, 
growth was monitored using lett units. 
Briefly, 10 mls of media was added to a 
lett tube with each strain inoculated at 
1: 0 and grown at oC. Growth rates were 
calculated by dividing the ∆ lett from two 
timepoints during exponential growth.
 
 ssa s 
 ∆OD calculated in certain cases (glucose test strip utilization assays) was performed 
in a different manner than described above. Overnight GAS cultures were added to 1: 0 
to 5 mls of either THY or CDM  PTS carbohydrate. 1 ml was removed from each tube, 
and the OD600 was measured. The final OD600 was then measured by allowing each tube 
to incubate at oC for 4 hours before removing another 1 ml. The initial OD600 was 
subtracted from the final OD600 to yield the ∆OD600 of the mutant strain grown in either in 
THY or CDM  a single PTS carbohydrate. Sugar concentration readings using the glucose 
test strips (AimStrip  Plus) were measured at both 0 and 4 hours.
Growth in whole human blood
 A modified growth experiment was carried out in whole human blood to determine 
if low nutrient content lead to the activity of Streptolysin S. GAS strains were inoculated 









p SM95  









p SM96  

















Temperature-sensitive conditional vector  Sp
Temperature-sensitive conditional vector  m
Suicide plasmid for stable i.i.  Sp
Temperature-sensitive conditional helper vector  
Km  
Vector contaiming Cm  gene
Spy0148 mutagenic plasmid  pC S
Spy04 5 mutagenic plasmid  pC S
Spy05 0 mutagenic plasmid  pC S
fruA mutagenic plasmid  pC S 
ptsC mutagenic plasmid  pC S 
Spy10 9 mutagenic plasmid  pC S 
Spy1 99 mutagenic plasmid  pC S
manL mutagenic plasmid  pSinS 
manM mutagenic plasmid  pC S
manM mutagenic plasmid  pSinS
manN mutagenic plasmid  pC S 
manN mutagenic plasmid  pSinS 
scrA mutagenic plasmid  pC S 
lacE.2 mutagenic plasmid  pC S 
Spy166  mutagenic plasmid  pC S 
malT mutagenic plasmid  pC S 
Spy1 44 mutagenic plasmid  pC S 
Spy1 84 mutagenic plasmid  pC S
nagC mutagenic plasmid with nonpolar m  pC S
glcU mutagenic plasmid for i.i.  pC S
glcU mutagenic plasmid for i.i.  pC
∆fruR mutagenic plasmid  nonpolar cat
∆fruB mutagenic plasmid  nonpolar cat
∆fruA mutagenic plasmid  nonpolar cat
GAS replicating plasmid with promoterless firefly 
luciferase (luc) and ribosomal binding site
GAS replicating plasmid with full length Pfru driv-
ing expression of luc
GAS replicating plasmid with Pfru no Fru  consen-
sus driving expression of luc
GAS replicating plasmid with PsloR driving expres-
sion of luc
Reference
Le Breton et. al, 01
Le Breton et. al, 01
Le Breton et. al, 015
Le Breton et. al, 015
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01  
Sundar et. al, 01
Sundar et. al, 01  




Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
Valdes et. al, 016
1: 0 in 10 mls fresh whole human blood, rotating for at least 6 hours. Samples were taken 
every hour from 0 h. The blood sugar concentration was taken using the glucose test strips 
using the procedure described earlier. Samples were then vortexed for 10 minutes, diluted, 
and plated on THY for viable counts. 
The API®50 CH system 
 The API 50 CH system (Biom rieux) was used to assess utilization of carbon 
sources by GAS using the procedure described previously ( aldes et al., 016). Briefly, 
strains were cultured overnight on blood agar plates, scraped and resuspended in 1 ml 
of saline, and vortexed for  minutes. Cultures were then diluted and added to 10 ml of 
API 50CHL medium (BioM rieux). This was then added to the 50 cupules in the assay 
kit, and incubated at oC (5  CO2). Utilization scores were determined at both 4 and 48 
hours, with each strain given either a  for utilization, and -  for partial utilization, 
and a -  for no utilization. To calculate the utilization scores for each strain for a particular 
carbon source,  was given a 1, -  was given a 0.5, and -  was given a 0. ith two 
measurements per assay, scores for each carbon source ranged from 0- .
Biolog Carbon Utilization Panel
 Carbohydrate metabolic profiles of GAS strains was determined via the Biolog 
Omnilog (Biolog, Inc.) as previously described (Gera et al., 014). Briefly, the metabolic 
profile of each strain was assessed using the PM1 and PM A carbon panels (96-well 
microplate). This system allows the interrogation of the utilization of 190 carbon sources, 
with each plate containing 95 carbon sources and one negative control. Each GAS strain 
was cultured on blood agar plates and resuspended in inoculating fluid (Biolog) to an OD600 
of 0.14. 100 ml of the cell suspension was added to each well of the PM microplates before 
each plate was incubated at oC for 48h. Utilization of a carbon source was determined by 
a change in a colorimetric dye present in the inoculating fluid via an Omnilog  instrument 
located at the FDA center for Food and Applied Nutrition (CFSAN). The data was analyzed 
using the Omnilog software (Biolog). 
Sugar Utilization Monitored by Glucose Test Strips  
 Sugar utilization was also monitored by the use of a blood glucose testing system 
(AimStrip  Plus). Although typically used to monitor blood sugar, we used this apparatus 
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to monitor sugar concentration of THY, CDM, and whole human blood during GAS growth. 
alues are given in mg dl. eadings were taken by first inserting a test strip (AimStrip  
Plus) into the monitor, placing the test strip into the culture to draw up li uid droplets, and 
waiting for 10 seconds for the final reading. 
ue ce	 cores 
 The influence an EII has on the metabolism of a carbon source was illustrated by 
determining an Influence Score. The Influence Score is an arbitrary value assigned to each 
EII for each PTS carbohydrate, and has no bearing on the metabolic potential or efficiency. 
It is simply a ualitative method to visualize the potential impact an EII might have on the 
transport and metabolism of a carbon source by combining the results of all the growth and 
metabolic assays performed. 
The nfluence Score was calculated as followed: 
 Growth curve score  Median  T of growth
  score  Mean of  T of ∆OD600
 API score   T of utilization score
nfluence score
 0.5 0.5 (Growth curve score)  0.5 (  score)   0.5 (API score) 
Luciferase Assays 
 Strains for luciferase assays were created as follows. Pfru was amplified from 
5448 gDNA using Fru luc 1 and Fru luc 4 primers (Table 3.2). The PC  fragments 
was digested using BglII hoI and ligated into p SM 0 cut with the same restriction 
enzymes (p SM944  Table 3.4). A truncated PfruR was also amplified from 5448 gDNA 
using Fru luc  and Fru luc 4, which deletes the putative Fru  binding site from 
the promoter region (Table 3.2). This PC  fragments was also digested and ligated in 
p SM 0(p SM945), similarly to the full length PfruR. PsloR was amplified form 5448 
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gDNA using slo luc F , digested and ligated in the same manner to form p SM948 
(Table 3.4). 
 The Luciferase assay was carried out as previously described ( aldes et al., 016). 
5448 and 5448.∆fruR were transformed with the luciferase plasmids (Table 3.1). This was 
grown in CDM  0.5  glucose or 1  fructose, mannose, or sucrose with spectinomycin at 
oC. 500 mL samples were taken every 0 kletts (beginning at 50), pelleted, supernatant 
was discarded, and samples were placed at 0oC overnight. Using a luciferase assay system 
(Promega), pellets were resuspended in lysis buffer. These were then normalized to cell units 
using the e uation: 4.5(x ml)(65 lett units ), where x  sample volume. The luciferase 
assay was read using a Centro S  LB 960 luminometer (Berthold Technologies), into 
which 50 ml of Luciferin-D reagent was in ected. Three biological replicates in each sugar 
was performed.  
Hemolysis Assays 
 The hemolysis assay was carried out as previously described with some 
modifications (Gera et al., 014). GAS strains were grown in THY supplemented with 
10  heat inactivated serum, with samples taken every hour for 8 hours. Samples were then 
pelleted and 50 ml of the cell free supernatant was added to 950 ml of difibrinated sheep red 
blood cells ( BCs). To prepare the BCs, 500 ml was washed in phosphate-buffered saline 
(PBS) three times. Once the supernatant was added to the red blood cells, these cultures 
were incubated for 1 h at oC. The cultures were then centrifuged at 000g to clear intact 
BCs. The OD541 of the supernatant was measured to determine the release of hemoglobin 
from lysed BCs. OD541 above 0.  were considered positive BC lysis. A modifies version 
of this assay was also carried out where samples were taken every 0 min, rather than every 
hour. Data shown is a combination of at least three biological replicates. 
Virulence Assays  
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ancefield Bactericidal ssa  
 GAS survival in whole human blood was assessed as previously described (Le 
Breton et al., 01 ). Briefly, GAS was grown in THY to early mid-exponential phase 
(OD600  0.10) and is serially diluted in saline. 50 l of a 10
-4 dilution was added to 500 l 
of fresh heparinized whole human blood. Blood donation was approved by the University 
of Maryland Institutional eview Board (I B) (protocol 10-0 5). Approved consent was 
obtained from each donor, and records have been archived. Once inoculated with GAS, 
the blood was rotated for h at C. A multiplication factor was calculated by dividing 
the CFUs obtained after blood challenge by the initial CFU inoculation. Data are shown 
as percent wildtype, where multiplication factors of mutant strains were divided by the 
multiplication factors of the wildtype, multiplied by 100. Data are shown as the average 
of at least three biological replicates. Statistical significance was determined using an 
unpaired Student t test (p-value  0.05).  
Murine Infections 
 Animal work was performed in an AAALAC-accredited ABSL-  facility at the 
University of Maryland, College Park. IACUC-approved protocols ( -16-05) for humane 
treatment of animal sub ects in accordance with the Office of Laboratory Animal elfare 
(OLA ) at NIH, Public Health Service, and the Guide for the Care and Use of Laboratory 
Animals guidelines were used. Extreme care was taken to limit the distress and pain to the 
animals. 
 The subcutaneous murine infection model was carried out as previously described 
(Gera et al., 014). Overnight GAS cultures were used to inoculate 5 ml of THY at a 1: 0 
dilution. Cultures where then incubated at oC (5  CO2) until late-logarithimic phase 
( lett  100). 5-  week old female CD-1 mice (Charles iver Laboratories) was inoculated 
with   x 109 CFU ml-1, as determined by microscope counts. Inoculation counts were 
then verified by plating for viable colonies on THY plates. Before infecting each mouse, 
they were anesthetized with ketamine and hair was removed from a  cm2  area of one of 
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the haunches with Nair (Carter Products). A 100 ml of the GAS suspension in saline was 
in ected subcutaneously. The mice were then monitored three times daily for  days, and 
were euthanized by CO2 asphyxiation upon signs of morbidity. Image  was used to measure 
lesion sizes at 6 or 48 h post infection. Lesion severity was also determined by calculating 
the mean red pixel intensity among all the pixels present in the lesion selection. GraphPad 
Prism was used to analyze the data and an unpaired two-tailed Student t test was used to 
test for significance. Survival significance was determined by Mantel-Cox log rank test. 
The p-value was 0.5 for both statistical tests. CFUs from the extracted spleen were also 
calculated by resuspending spleens in 1 ml of PBS, disrupting the tissue, serially diluting 
the mixture, and then plating onto THY. Spleens were extracted  days post infection. 
Cell culture 
 Human polymorphonuclear leukocytes (PMNs) or monocytes were isolated from 
heparinized blood of volunteer donors (I B-approved protocol) using Polymorphprep 
(Axis-Shield) or Ficoll Pa ue plus (GE Healthcare), respectively, per the manufacturer s 
instructions. Contaminating red blood cells ( BCs) were removed by treatment with red 
cell lysis solution (Epicentre) and washing with Dulbecco s mod- ified phosphate-buffered 
saline (PBS) (Sigma). Isolated PMNs and monocytes were maintained in PMI 1640 cell 
culture medium (HyClone) supplemented with .05 mM L-glutamine and 0  plasma 
from donor blood for the duration of the killing assay. 
 The human-derived promyelocytic leukemia HL60 (Sigma) cell line was 
maintained as indicated in the UAB-GBS-OPA protocol (http: www.vaccine.uab.edu
UAB-GBS-OPA.pdf). Briefly, the HL60 cell line was maintained in PMI 1640 cell culture 
medium supplemented with .05 mM L-glutamine and 10  fetal bovine serum (FBS) 
(HyClone). Low-passage-number HL60 cells were differentiated into neutrophil-like cells 
for opsonophagocytic killing assays by supplementing culture medium with 1 M all-trans 
retinoic acid (AT A) in dimethyl sulfoxide (DMSO) (  mg ml stock solution). PMNs, 
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monocytes, and HL60 cells were maintained at C in 5  CO2. 
psonophagoc tic illing assa s 
 Isolated PMNs or differentiated HL60 cells were seeded at a density of 106 cells
ml in 4-well plates with PMI 1640 cell culture medium supplemented with .05 mM 
L-glutamine. GAS strains were grown overnight, and cultures were diluted into fresh THY 
and grown to mid-log phase (OD600 of 0.4). Bacteria were opsonized prior to neutrophil 
challenge by resuspension in donor plasma (PMN assays) or FBS (HL60 assays) for 0 
min at C. GAS then was added to seeded neutrophils to the desired multiplicity of 
infection (MOI of 0.1 unless otherwise indicated) in a final volume of 1 ml PMI 1640 cell 
culture medium (HyClone) plus .05 mM L-glutamine, 0  plasma, or FBS. Neutrophil-
challenged bacteria were incubated at C in 5  CO2 for  h. GAS also was incubated 
in PMI 1640 plus .05 mM L-glutamine, 0  plasma, or FBS in the absence of PMNs, 
monocytes, or differentiated HL60 cells for the purpose of survival comparison. 
 Following incubation, surviving GAS was harvested by collecting supernatants and 
neutrophils. Neutrophils were immediately lysed by resuspension in sterile H2O, and the 
intracellular contents were pelleted and recombined with corresponding well supernatants 
for plating on THY agar to obtain total viable bacterial counts after overnight incubation 
at C and 5  CO2. The resistance of GAS to opsonophagocytic killing following 
neutrophil challenge was assessed by comparing CFU obtained from the plating of viable 
bacteria isolated from killing assays to CFU obtained from GAS incubation in cell culture 
media in the absence of neutrophils (CFU obtained from PMNs divided by CFU obtained 
from medium times 100). All survival indices are normalized to the survival of wild-type 
(100 ) under the conditions tested. Data presented are the results of at least  biological 
replicates, each performed in triplicate, with P values determined by unpaired t test. 
RNA Analysis 
Reverse transcription PCR (RT-PCR) to determine transcriptional architecture
 Total NA isolated from GAS strains grown to late-logarithmic phase using 
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Triton -100 isolation as described previously (Sung et al., 00 ). Isolated NA was then 
treated with DNaseI, as per manufacturer s protocol. T-PC  was performed on 500 ng of 
DNase-treated NA with M-MuL  reverse transcriptase (NEB) using the manufacturer s 
protocol.  primers for each gene was used in the reaction for 1 hour at 4 oC, followed by 
enzyme inactivation at 90oC for 10 minutes to generate cDNA. PC  was then performed 
using Ta  polymerase and the relevant primer pairs. PC  was set-up as follow: 5 minutes 
at 95oC (initial activation)  45 cycles of 0 seconds at 95oC,  minutes at 55oC (60oC for full 
operon cDNA), 1.5 minutes at oC (PC ) and 5 min at oC (final extension). 
Quantitative real-time PCR (qRT-PCR)
 T-PC  experiments were carried out on NA extracted from GAS strains grown 
in various media conditions (Sung et al., 2003). Each strain was grown to late-logarithmic 
phase, and NA was isolated similarly to NA isolated for T-PC . Isolated NA was 
treated with DNaseI. 5 ng of treated NA was added to SYB  green master mix with 
6.5 ml of each gene specific real-time primer from a 0 nM stock solution. The experiment 
was carried out using the one-step protocol on a Light Cycler 480 ( oche). Primers were 
designed using ( obinson et al., 011) Primer  (http: biotools. umassmed.edu bioapps
primer www.cgi). Data shown is the average of at least  biological replicates. Significance 
was determined by two-fold change in expression. 
RNAseq 
 The following protocol was previously described in ( aldes et al., 016). For NA 
transcriptome se uencing ( NA-Se ), total NA was extracted using a Direct-zol NA 
miniprep kit ( ymo esearch) with a modified procedure to improve GAS cell disruption. 
Cells from frozen pellets were resuspended in 00 ml of T Izol supplemented with 
approximately 00 mg of acid-washed glass beads (Sigma Life Science) and disrupted by 
vortexing for 5 min. Beads were collected by brief centrifugation, and cell lysate was used 
for NA purification as recommended by the manufacturer. NA samples were treated 
with the Turbo DNase-free kit (Life Technologies) to avoid gDNA contamination. A total 
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of 5 g of DNase-treated NA was treated for r NA removal using the ibo- ero magnetic 
kit (Epicentre) for Gram-positive bacteria, and r NA-depleted NA then was purified with 
the NAClean P kit (Agencourt). Sample uality was assessed using a 100 Bioanalyzer 
(Agilent), and sample uantity was determined using a NanoDrop 8000 spectrophotometer 
(Thermo Scientific). 
 NA-Se  directional libraries were generated using the ScriptSe  v  NA-Se  
library preparation kit (Illumina) according to the manufacturer s recommendations. 
Briefly, 45 ng r NA-depleted NA was fragmented and used for reverse transcription 
with random primers containing a 5 -tagging se uence. The 5 -tagged cDNA then was 
modified at its  end by a terminal-tagging reaction to generate di-tagged, single-stranded 
cDNA that then was purified using the AMPure system (Agencourt). The purified di-tagged 
cDNA was used as a template to generate second-strand cDNA containing Illumina adaptor 
se uences, to incorporate index barcodes, and to amplify the library by limited-cycle PC . 
The resulting NA-Se  libraries were purified using the AMPure system (Agencourt), and 
NA-Se  library uality was verified as described above. A rapid-run 100-bp single-read 
DNA se uencing then was performed at the Institute for Bioscience and Biotechnology 
esearch (IBB ) Se uencing Facility at the University of Maryland, College Park, using 
the Illumina HiSe  1500 platform. Data were generated in the standard Sanger Fast  
format, and raw reads were deposited with the Se uence ead Archive (S A) at the 
National Center for Biotechnology Information (accession number P NA 9 518). 
 ead uality was measured using Fast C (http: www.bioinformatics.babraham.
ac.uk pro ects fast c ), filtered and trimmed using trimmomatic (Bolger et al., 014), 
and mapped against the MGAS5005 genome (accession number CP00001 ) using bowtie 
(Langmead, 010), bowtie  (Langmead  Salzberg, 01 , Trapnell et al., 01 ), and tophat 
(Trapnell et al., 01 ) with options to allow one mismatch and randomly map multihit 
reads. The resulting alignments were converted to sorted BAM alignments (Li et al., 009) 
and counted (Anders et al., 015) by coding and intergenic region. Initial visualizations 
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of the se uencing mapping were performed using the Integrative Genomics iewer (IG ) 
( obinson et al., 011). Differential expression analyses were performed following the 
size-factor and uantile normalization of read counts, and batch effect estimation was taken 
into account by including the date in the Limma ( itchie et al., 015) statistical model. The 
resulting metrics of expression were visualized using circos ( rzywinski et al., 009) and 
tested for ontology enrichment using EGG (Ogata et al., 1999), gose  (Young et al., 
010), clusterProfiler (Yu et al., 01 ), GOstats (Beissbarth  Speed, 004), and topGO 
(Alexa et al., 006). aw reads were deposited in the Se uence ead Archive (S A) at the 
National Center for Biotechnology Information under accession number P NA 9 518. 
5’ RACE
The following protocol was previously described in aldes et. al, 016. everse transcriptase 
PC  ( T- PC ) was carried out on 500 ng of total NA with Moloney murine leukemia 
virus reverse transcriptase (NEB) according to the manufacturer s protocol using primers 
FruA evTrans  and FruB evTrans  (Table . ). everse transcription was performed 
for 1 h at 4 C using 1 ml of cDNA as a template in the reaction mix, followed by enzyme 
inactivation at 90 C for 10 min. The subse uent PC  was done with the following 
parameters: 5 min at 95 C (initial activation)  0 cycles of 0 s at 95 C, 0 s at 55 C, and 
1.5 min at C (PC )  and a final extension step of 5 min at C. The 5  ACE kit 
( oche) was used according to the supplier s instructions. A 500-ng ali uot of DNase-
treated total NA was used to obtain the cDNA by primer extension with primer Fru  
SP1. Following the  tailing reaction with dATPs, the cDNA was amplified by PC  using 
the reverse primer Fru  SP  and oligo(dT) anchor (Table 3.2)  the forward primer was 
supplied with the kit. The 5  end of the transcript then was determined by se uencing the 
PC  product using the primer Fru  SP  (Table 3.2). 
Chapter 4: Characterization of the Contribution of individual 
EIICs to PTS carbohydrate metabolism, regulation of SLS-
mediated hemolysis, and GAS survival in whole human blood
 Portions of this chapter were published with the following authors: Ganesh S. 
Sundar, Emrul Islam, Kanika Gera, Yoann Le Breton and Kevin S. McIver (© 2016 John 
Wiley & Sons Ltd. Molecular Microbiology. doi: 10.1111/mmi.13573.). 
 Author contributions: GSS, KG, and KSM designed the study, GSS, YLB, and EI 
acquired and analyzed the data, and GSS, YLB, and KSM wrote the manuscript.
 Data contribution: all data presented in this chapter were obtained by GSS 
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Introduction
 Our previous work showed that a PTS null mutant (∆ptsI) in the M1T1 GAS strain 
MGAS5005 resulted in an increased size and severity of lesions at the site of infection in a 
murine soft tissue infection model due to the early onset of Streptolysin S (SLS) expression 
and activity during growth (Gera et al., 2014). We hypothesized that this was the result of 
the lack of access by GAS to a particular set of carbohydrates that served as the signal for 
SLS expression. Individual carbohydrates have been shown to be signals that contribute to 
the expression of virulence factors in other pathogens. For example, Salmonella enterica 
uses L-arabinose to modulate the expression of genes in the Salmonella pathogenicity 
island 1, encoding a Type 3 secretion system critical during systemic infection (López-
Garrido et al., 2015). Many fungal pathogens rely on carbohydrate metabolic pathways 
(trehalose in particular) for survival in different hosts (Foster et al., 2003, Petzold et al., 
2006, Lowe et al., 2009, Ngamskulrungroj et al., 2009, Tournu et al., 2013) Therefore, this 
could be the case for GAS as well.
 Enzyme II (EII) components provide the PTS with carbon specificity. Generally 
speaking, each EII transports and phosphorylates a small number of carbohydrates, except 
for the mannose-family EIIs which are known to have fairly broad substrates. However, 
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the sugar-specificity of each EII is typically assigned by se uence homology. In fact, the 
annotation of sugar-specific EII complexes in se uenced GAS genomes have seldom been 
experimentally verified. EII genes are often genes incorrectly annotated based on homology 
alone, exemplified by the initially annotated glucose-specific malT locus in M1 GAS that 
was shown experimentally to transport maltose (Shelburne et al., 2008b).  In this study, 
we insertionally inactivated each predicted EIIC transporter gene present in the M1T1 
MGAS5005 genome in order to characterize their metabolic profile and determined the 
EII complexes that contribute to the early expression of SLS observed in the ∆ptsI mutant. 
 The creation of an annotated PTS EII mutant library provides the ability to determine 
which sugars play an important role in different infection environments by uncovering any 
EIIs that are important for GAS survival in the host niches tested. To test this idea, we also 
screened the EIIC mutant library in whole human blood to uncover those EIICs that may 
play a role in survival in this important host environment. Identifying genes important 
for GAS survival in human blood is imperative, as iGAS travels from the local site of 
infection to other parts of the body through the bloodstream. Also, blood is a nutrient rich 
environment, so it is likely that EIIs may play a role in GAS survival. Several EIIs have 
already been shown to be upregulated in the presence of blood components (Sachla et 
al., 2014), or whole human blood (Graham et al., 2005), making this increasingly likely. 
Additionally, several metabolic genes, including 3 EII subunits (Cellobiose EIIC, Fructose 
EIIABC, Mannose EIID), were essential for M1T1 GAS 5448 survival in whole human 
blood in a transposon mutagenesis screen (Le Breton et al., 2013). No such screen has ever 
been carried out with MGAS5005. 
Results
Generation of an annotated EIIC mutant library in MGAS5005 
 We generated an annotated EIIC mutant library in the M1T1 MGAS5005 in order
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Figure 4.1 PTS EII present in the GAS M1T1 MGAS5005 annotated genome shown 
in predicted loci. Genes encompassing the sugar-specific EIIs are indicated in grey, and 
hypothetical genes are indicated in black. Sugar-specificities are based on annotation. 
EIICs are highlighted in red to represent those that were targeted for mutagenesis. Gene 
names are listed below the Spy numbers for those that are known. Since there are two 
predicted cellobiose EII loci, they are numbered 1 and 2 based on their order in the genome.
to experimentally verify the sugar specificities of each EII. e insertionally inactivated 
the gene encoding the EIIC transporter within all 14 annotated EII loci (Fig 4.1). The 
mutations were made with pCRS as indicated in chapter 3, so each mutation is polar, 
thereby potentially affecting the expression of downstream genes. The EIIB gene was 
mutagenized for the annotated mannitol-specific EII (Spy 1664 Spy 166 ) since there is 
currently no annotated EIIC for this particular EII (Fig 4.1). Confirmed mutants were then 
used to create rescue strains as a control (see chapter 3). 
EIIC library reveals inherent redundancy among PTS transporters for growth on 
PTS carbohydrates
 To confirm the PTS carbohydrates utilized by wild type (WT) MGAS5005, it
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was grown in chemically defined medium (CDM) with a given PTS carbohydrate as the 
sole carbon source (see chapter 3). MGAS5005 only grew on 8 of the 11 established PTS 
carbohydrates (Gera et al., 2014)(Fig 4.2 A and B); therefore, the 3 sugars not supporting 
growth of the wild type MGAS5005 (e.g., cellobiose, galactose and mannitol) were 
eliminated from further analysis (Fig 4.2 A and B). Although ascorbic acid was not known 
to be a PTS carbohydrate for GAS, a recent study found that the -keto- L-gulonate-specific 
EIIC (Fig. 4.1  Spy 0148) might actually transport ascorbic acid (Afzal et al., 2015). In 
support of this, the MGAS5005.∆ptsI mutant exhibited impaired growth compared with 
WT MGAS5005 in CDM + 1% ascorbic acid, indicating it is indeed a PTS-dependent 
carbohydrate for GAS (Fig. 4.2 C). 
 The MGAS5005 EIIC mutant library was then compared with WT MGAS5005 
grown in CDM with each of the 9 PTS carbohydrates determined above. Growth 
data are shown in  Fig. 4.3 A–N and Fig. 4.4, and summary of the data is shown 
in Fig. 4.5. Six of the EIIC mutants (Fig. 4.1  ∆ -keto-L-gulonate, ∆Cellobiose(1),
∆Galactose, ∆Lactose, ∆Mannitol, ∆Trehalose) grew comparable to MGAS5005 in all PTS 
carbohydrates tested (Fig. 4.5A, all clear boxes). Four EIIC mutants (Fig. 4.1  ∆b-glucoside, 
∆N-acetylgalactosamine, ∆Fructose, ∆Maltose) grew better than MGAS5005 in at least 
one PTS carbohydrate (Fig. 4.5A, green boxes). In addition, four EIIC mutants (Fig. 
4.1  ∆b-glucoside, ∆Fructose, ∆Mannose Fructose, ∆Mannose) exhibited altered growth 
compared with MGAS5005 in more than one carbohydrate (Fig. 4.5A, yellow/red/green 
boxes). Only the ∆Sucrose EIIC mutant showed altered growth in the carbohydrate for 
which it was annotated to transport, strongly indicating redundancy for transport of any 
given sugar (Fig. 4.5A). In fact, salicin, maltose, and ascorbic acid, were the only PTS 
carbohydrates tested that did not show a significant defect in more than one EII mutant 
(Fig. 4.5A). Surprisingly,  EIIC mutants (∆N-acetylgalactosamine, ∆Fructose) showed 
increased growth profiles in glucose as compared with MGAS5005, which was unexpected 
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given that the MGAS5005.∆ptsI mutant lacking PTS signaling grows comparable to WT in 
glucose (Fig. 4.5A). Total yield (∆OD600) after 24h of growth was used as another indicator 
of the impact of each EIIC on growth in PTS carbohydrates (Fig. 4.4 and Fig. 4.5B). 
Only two EIIC mutants (∆Galactose, ∆Cellobiose( )) exhibited the same total yield as 
WT MGAS5005 in every PTS carbohydrate tested. Overall, most of the EIIC mutants 
grew to a different yield than MGAS5005 in multiple PTS carbohydrates, again suggesting 
that there is an inherent redundancy among the EIIs for carbohydrate transport. This is 
further supported by the fact that reductions in total yield of many EIIC mutants showed 
intermediate phenotypes, instead of a total loss of growth, which is not indicative of a 
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igure . . rowth profile of M S  in PTS carboh drates. ) PTS carbohy-
drates that facilitate growth of MGAS5005 and used for the characterization of the EIIC 
mutant library. Growth was assayed a described in chapter 3. B) Three PTS carbohydrates 
unable to facilitate reasonable growth of MGAS5005 and were eliminated from further 
analysis. ) Growth of MGAS5005 and MGAS5005.∆ptsI in CDM + 1% ascorbic acid.
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Figure 4.3. Growth of the MGAS5005 EIIC mutant library in 9 PTS carbohydrates. 
Each growth curve panel represents the average of at least 3 independent biological 
replicates. ( - ) EIIC mutants were grown in CDM + 1% PTS carbohydrate (0.5% for
glucose) as indicated in chapter 3. Black lines represent WT MGAS5005 growth, whereas red 
lines represent growth of the EIIC mutant. ) Rescue strains (EIICR) for each mutant were 
grown only in carbohydrates for which a significant growth phenotype was observed ( - ). 
Black lines indicate growth of WT MGAS5005 and blue lines depict growth of each EIICR 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































igure . .  of the M S   mutant librar  grown in  PTS carboh drates.
Each graph represents the average of at least 3 independent biological replicates. Data 
is normalized to MGAS5005 as indicated in chapter 3. ( - ) EIIC mutants were grown 
in CDM + 1% PTS carbohydrate (0.5% for glucose) as indicated in chapter 3. Black 
bars represent T ∆OD, whereas red bars represent ∆OD of the EII mutant that is 
significantly lower than T. Green bars represent ∆OD of the EII mutant that is 
significantly higher than T. Grey bars depict ∆OD of the EII mutant that is similar to T.
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Total yield (DOD600) after 24 h of growth was used as
another indicator of the impact of each EIIC on growth
in PTS carbohydrates (Fig. 2B and Supporting Informa-
tion Fig. S3A–I). Only two EIIC mutants (DGalactose,
DCellobiose-2) exhibited the same total yield as WT
MGAS5005 in every PTS carbohydrate tested. Overall,
most of the EIIC mutants grew to a different yield than
MGAS5005 in multiple PTS carbohydrates, again sug-
gesting that there is an inherent redundancy among the
EIIs for carbohydrate transport. This is further supported
by the fact that reductions in total yield of many EIIC
mutants showed intermediate phenotypes, instead of a
total loss of growth, which is not indicative of a system
where a given transporter was responsible for a single
carbohydrate transport (Fig. 2B).
Carbohydrate utilization by the MGAS5005 PTS EIIC
mutant library also supports redundancy in transport of
PTS sugars
To ascertain if the growth phenotypes seen with the EIIC
mutants were the result of altered uptake and metabolism
of specific carbohydrates, the library was assayed for utili-
zation of 49 different carbon sources using a BioMerieux
APIVR 50 CH panel. This system detects changes in pH in
the presence of each given carbon source as a sensitive
readout for metabolic utilization, but does not require
growth (see section on “Experimental Procedures”). As
expected, MGAS5005.DptsI was unable to utilize most
(81%) of the carbon sources metabolized by MGAS5005
(Fig. 3). Although overall growth in mannose, fructose and
trehalose were altered in several EIIC mutants (Fig. 2),
utilization of these carbohydrates was largely unaffected
(Fig. 3). As with the growth assays, overlap was evident
among the EIIC loci for their ability to transport and utilize
multiple PTS carbohydrates. Moreover, there appears to
be significant interplay between different carbohydrate uti-
lization pathways, as 10/14 of the EIIC mutants alter utili-
zation of at least 25% of the carbohydrates tested (Fig.
3). Although neither of the 2 Cellobiose EIIC mutants
(Fig. 1) had an extensive effect on the growth of GAS on
PTS carbohydrates, these EIIC mutants showed the sec-
ond largest effect on carbon utilization (31%), along with
DMannose/Fructose and Db-Glucoside (Fig. 3). Finally,
the mannose-specific EII mutant had the largest effect on
carbon utilization (Fig. 3).
To represent the overall effect of an EIIC on the
metabolism of PTS carbohydrates by GAS, we devel-
oped an Influence Score (Fig. 4), an arbitrary measure
that combines both the growth and utilization data for
each EIIC mutant to provide a visual representation of
the overall impact of an EIIC protein on the metabolism
Fig. 2. Growth profiles of the PTS EII mutant library in MGAS5005. (A) Normalized growth analyses were performed as fully described in
Experimental Procedures. Growth in a particular PTS sugar of the mutant above WT (two-fold, green), below WT (two-fold, yellow), well below
WT (>two-fold, red), or similar to WT (Grey) are indicated. (B) Total yield (DOD) was calculated as described in Experimental Procedures.
DOD of mutants in a particular PTS sugar that were above WT (green, p-value <0.05) or below WT (red, p-value <0.05) are indicated. Only
PTS sugars facilitating growth of MGAS5005 are shown. All results represent at least three independent biological replicates.
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igure . . PTS  mutant librar  growth profiles. ( ) As described in chapter 3, 
growth of each EII mutant was normalized to WT MGAS5005. Growth of the mutant in 
a PTS sugar above WT (two-fold, green), below WT (two-fold, yellow), well below WT 
(>two-fold, red) are indicated. (B) Total yield (∆OD) was calculated as described (See 
Chapter ). ∆OD in mutants above T (green) or below T (red) are indicated (p-value 
<0.05). All results represent at least three independent biological replicates, and only sugars 
that facilitate growth of MGAS5005 are shown.
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arboh drate tili ation profiles of the  mutant librar  also supports redundancy
 To ascertain if the growth phenotypes seen with the EIIC mutants were the result 
of altered uptake and metabolism of sp cific carbohydrates, the library was ass y d for 
utilization of 49 diff rent carbon sources using a BioMérieux API®50 H panel. This 
system detects changes in pH in the presence of each given carbon source as a sensitive 
readout for metabolic utilization, but does not require growth (see Chapter 3). As expected, 
MGAS5005.∆ptsI was u able to utilize most (81%) of the carbon sources metabolized by 
MGAS5005 (Fig. 4.6). Although overall growth in mannose, fructos  and trehalose were 
altered in several EIIC mutants (Fig. 4.5A and B), utilization of these carbohydrates was 
largely unaffected (Fig. 4.6). As with the growth assays, overlap was evident among the 
EIIC loci for their ability to transport and utilize multiple PTS carbohydrates. Moreover, 
there appears to be significant interplay between different carbohydrate utilization
of a PTS carbohydrate. An EIIC would show a positive
influence (red) if its mutation resulted in a growth defect
and/or inefficient utilization of a PTS carbohydrate com-
pared with WT MGAS5005. In contrast, an EIIC would
have a negative influence (green) if its mutation resulted
in a growth/utilization profile above that of WT. Only
PTS carbohydrates found in both the growth and utiliza-
tion assays (Figs. 2 and 3) were used in determining
the Influence Score and intensity of color reflects the
relative impact. As expected, the complete PTS strongly
influences the metabolism of all the PTS carbohydrates
except for glucose (Fig. 4). Although there are certain
instances where an EII has a strong influence on the
metabolism of a given carbohydrate (i.e., Sucrose EII on
sucrose), most of the EII complexes have an intermedi-
ate to minor influence on the metabolism of several car-
bohydrates; supporting redundancy among the EIIC
systems in MGAS5005 for the transport and utilization
of PTS carbohydrates (Fig. 4).
Multiple EIIC proteins contribute to the PTS-related
growth phase expression of sagA and hemolytic activity
in MGAS5005
We previously found that a PTS-defective MGAS5005.
DptsI mutant expressed sagA and produced Streptolysin
S-mediated hemolytic activity much earlier in growth
than WT MGAS5005, leading to increased lesion size
and severity in a murine model of GAS soft tissue infec-
tion (Gera et al., 2014). Since the PTS is a carbohydrate
transport system, we hypothesized that one or several
specific EIIC mutants may contribute to the
MGAS5005.DptsI hemolysis phenotype due to the
reduced ability to metabolize specific carbohydrates.
Fig. 3. Carbohydrate utilization profile of the PTS EIIC mutant library in MGAS5005. Utilization of select carbon sources as determined using
the APIVR 50CH system as described in “Experimental Procedures.” Only carbon sources that are utilized by at least one of the strains tested
are shown. White boxes indicate utilization (1), gray boxes indicate partial utilization (6), and black boxes indicate no utilization (2). Readings
for each strain are given for 24 h (left box) and 48 h (right box).
Mannose PTS EII in Streptococcus pyogenes 5
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igure . . arboh drate utili ation profile of the PTS  mutant librar  in 
MGAS5005 . The API®50CH system was used to determine the utilization of select 
carbon sources as described in chapter 3. Only carbon sources that are utilized by at least 
one strain tested are displayed. White boxes indicate utilization (+), grey boxes indicate 
partial utilization (+/-), and black boxes indicate no utilization (-). Readings for each strain 
presented with the 24h rea g on the l ft box, and the 48h reading on the right box. 
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pathways, as 10/14 of the EIIC mutants alter utilization of at least 25% of the carbohydrates 
tested (Fig. 4.6). Although neither of the 2 Cellobiose EIIC mutants (Fig. 4.1) had an 
extensive effect on the growth of GAS o  PTS carbohydrates, these EIIC mutants showed 
the second larg st effect n carbon utilization ( 1 ), along with ∆Mannose Fructose and 
∆b-Glucoside (Fig. 4.6). Finally, the man ose-specific EII mutant mutant had the largest 
effect n carbon utilization (Fig. 4.6).
Thus, we assayed the onset of hemolysis for each of
the EIIC mutants compared with WT MGAS5005 and
the PTS-null MGAS5005.DptsI mutant (see Experimen-
tal Procedures). Hemolysis activity of cell-free superna-
tants was determined for each strain across growth and
the results displayed as a hemolytic profile showing the
occurrence of significant activity (OD541> 0.2) on the Y-
axis versus growth (OD600) on the X-axis (Fig. 5). WT
MGAS5005 produces high levels of secreted hemolytic
activity only at transition to stationary phase
(OD600! 1.0; Fig. 5, black bars) whereas the PTS
mutant showed high levels early in exponential phase
Fig. 4. Influence of each EII
on the metabolism of PTS
carbohydrates. Heat map of
the relative influence of each
EII on growth in a particular
PTS sugar (Influence Score)
was calculated as described in
“Experimental Procedures.”
Green indicates a negative
influence of an EII for the
metabolism of a PTS sugar,
red indicates a positive
influence of an EII for the
metabolism of a PTS sugar,
and white indicates no
influence. Relative influence is
reflected by intensity of color.
Fig. 5. Hemolysis profile of the EII mutant library in MGAS5005. Hemolytic activity of culture lysates against red blood cells (RBCs) was
assayed as described in Experimental Procedures. Data from three biological replicates is shown comparing occurrence of hemolysis (defined
as OD541> 0.2) on the X-axis and the relative level of hemolytic activity observed on the Y-axis. Hemolysis at an OD600 above 1 was
considered normal based on WT MGAS5005 (black bars to right of dotted line). Occurrence of hemolysis was noted as early if it occurred
before OD600 of 1 (red bars left of dotted line).
6 G. S. Sundar et al. !
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igure . . nfluence of each  on the metabolism of each PTS sugar. Influence scores 
for each EII in a particular PTS carbohydrate is r presented as a heat map. Green indicates 
a negative influence of an EII for the metabolism of a PTS sugar, red indicates a positive 
influence of an EII for the metabolism of a PTS sugar, and white indicates no influence. 
Intensity of color r presents relative influence of an EII.
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nfluence scores reveal the extensive overlap among PTS proteins on carbohydrate 
metabolic pathways
 To represent the overall effect of an EIIC on the metabolism of PTS carbohydrates 
by GAS, we developed an Influence Score (Fig. 4.7), an arbitrary measure that combines 
both the growth and utilization data for each EIIC mutant to provide a visual representation 
of the overall impact of an EIIC protein on the metabolism of a PTS carbohydrate. An 
EIIC would show a positive influence (red) if its mutation resulted in a growth defect 
and or inefficient utilization of a PTS carbohydrate compared with T MGAS5005. In 
contrast, an EIIC would have a negative influence (green) if its mutation resulted in a 
growth utilization profile above that of T. Only PTS carbohydrates found in both the 
growth and utilization assays (Figs. 4.3-4.6) were used in determining the Influence Score 
and intensity of color reflects the relative impact. As expected, the complete PTS strongly 
influences the metabolism of all the PTS carbohydrates except for glucose (Fig. 4.7).
Although there are certain instances where an EII has a strong influence on the metabolism 
of a given carbohydrate (i.e., Sucrose EII on sucrose), most of the EII complexes have an 
intermediate to minor influence on the metabolism of several carbohydrates  supporting 
redundancy among the EIIC systems in MGAS5005 for the transport and utilization of PTS 
carbohydrates (Fig. 4.7).
Multiple EIICs contribute to the early onset of SLS-mediated hemolysis observed in 
∆ptsI
 In previous work, it was shown that ∆ptsI exhibited earlier growth phase expression 
of sagA as compared to the WT MGAS5005, which in turn lead to the early onset of SLS-
mediated hemolysis (Gera et al., 2014). This lead to an increase in lesion size and severity 
when GAS was injected subcutaneously in CD-1 female mice (a GAS soft tissue infection 
model) (Gera et al., 2014). Although the PTS does participate in signal transduction, it 
is first and foremost a carbohydrate transport system. Therefore, we hypothesized that 
one or several specific EIIC mutants potentially contribute to the early onset of hemolysis 
observed in MGAS5005.∆ptsI as a result of the lack of the metabolism of particular 
carbohydrates. In an effort to address this question, we compared the onset of hemolysis 
for the EIIC mutant library to MGAS5005 and MGAS5005.∆ptsI, as described in chapter 
3. All EIIC mutants grew similarly to the WT (Fig 4.8). As expected, MGAS5005.∆ptsI 
exhibited high levels of SLS-mediated hemolysis in exponential phase and throughout 
growth, whereas MGAS5005 only exhibited activity in the transition to stationary phase 
(Fig. 4.9), as previously shown (Gera et al., 2014). Although there was not an individual 
EII that fully recapitulated the hemolytic profile of the PTS mutant, seven EIIC mutants 
exhibited at least one early hemolytic time point (∆ -keto-L-Gulonate, ∆b-Glucoside, 
∆N-Acetylgalactosamine, ∆Mannose Fructose, ∆Cellobiose(1), ∆Galactose, ∆Mannose) 
(Fig 4.8). This suggests that multiple EIIs contribute to PTS-regulation of SLS-mediated 
hemolysis, possibly indicating the incorporation of multiple environmental signals. Of 
note, two EIIC mutants (∆Trehalose, ∆Cellobiose) produced significantly lower hemolysis 
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Figure 4.8  Growth of the MGAS5005 EIIC mutant  library for  hemolysis  assays.
Each graph represents the average of at least 3 independent biological replicates. Strains 
were grown in THY as indicated in chapter 3. Black lines represent growth of MGSA5005, 
red lines depict growth of MGAS5005.∆ptsI, and grey lines represent growth of each EII 
mutant. 
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overall compared to MGAS5005 (Fig 4.8). The reason for this phenotype is currently 
unknown. Interestingly, three of the seven EIIC mutants that exhibited early hemolysis 
belong the the Mannose-family of PTS transporters.  
Multiple EIICs are important for the survival of GAS in whole human blood
 With the creation of an annotated EIIC mutant library, we had the ability to screen 
components of the PTS system through different host niches to test the different roles 
each component plays in GAS pathogenesis. We screened the EIIC mutant library and 
MGAS5005.∆ptsI in a Lancefield bactericidal assay (see chapter ) to test the involvement 
of the PTS system for GAS survival in whole human blood, as this is the environment 
that iGAS must encounter during systemic infections. We only found two EIIC mutants 
(∆b-glucoside and ∆Fructose) that have lower survival as compared to MGAS5005 
(Fig 4.10). However, MGAS5005.∆ptsI has significantly lower fitness in whole
igure .  Hemol sis profile of the  mutant librar  in M S . Culture lysates 
were measured for hemolytic activity by incubating them with red blood cells (RBCs) as 
indicated in chapter 3. Data from three biological replicates are shown. Occurrence of 
hemolysis (defined as OD541 > 0.2) on the X-axis and the relative level of hemolytic activity 
observed on the Y-axis. Dotted line represents an OD600 of 1, where positive hemolysis to 
the left of this line is considered early (red bars). Positive hemolysis to the right of this line 
is considered normal (black bars).
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human blood compared to its parental strain (Fig 4.10). This is surprising considering 
that the main carbohydrate present in human blood is glucose, whose metabolism in 
MGAS5005.∆ptsI was shown to be unaffected (Wishart et. al., 2013, Wishart et. al., 2009, 
Wishart et. al. , 2007, Gera et al., 014). This suggests that the PTS may influence the 
expression of other genes that are important for survival in this infection environment, 
or that the low amount of PTS sugars available in blood affects GAS virulence.
Discussion
In this study, we generated a PTS EIIC mutant library based on the annotated loci 





























































































































































Figure 4.10  EIIC mutant library survival in whole human blood. The EIIC mutant 
library was sub ected to a Lancefield bactericidal assay. Data is the average of three 
biological replicates. Multiplication factors (MF) were calculated as indicated in chapter 3, 
and shown compared to MFs from MGAS5005. Red bars indicate MFs of mutants that are 
significantly different from that of MGAS5005.Grey bars indicate those EIICs that survive 
































































































































each transporter and to uncover those that contribute to the growth phase expression of 
Streptolysin S (SLS). By experimentally verifying growth and metabolism of PTS sugars, 
we discovered that each EII has varying influences on the metabolism of PTS sugars, with 
Mannose-family EIIs having the broadest influence. Several EIIC mutants, including the 
Mannose-family EIIs, contributed to an early onset of SLS-mediated hemolysis during 
growth in vitro, as previously observed with the PTS-defective MGAS5005.∆ptsI GAS 
mutant (Gera et al., 2014).
 The sugar-specificities of a few individual EII systems have been assessed 
in streptococci, revealing imperfect annotations of their carbohydrate targets 
(Shelburne et al., 2008b, Bidossi et al., 2012). Applying an extensive metabolic panel to 
the full complement of EII loci identified in the GAS genome, we found that the level of 
influence that any given EII had on the metabolism of each PTS carbohydrate varied (Fig. 
4.7). In fact, several EIIC transporters appear to have very little influence on PTS sugar 
metabolism (Fig. 4.7), either because they are not involved in sugar transport or that the 
substrates of these EIIC components are shared between multiple EII complexes. Some of 
these EIIs (e.g., Trehalose-specific EII, N-acetylgalactosamine-specific EII, Cellobiose-
specific EII(1)) are either lacking a key component gene or have multiple genes encoding 
a single subunit; indicating that they may not be involved in sugar transport (Fig. 4.1). The 
annotated Galactose-specific EII appears to have virtually no effect on PTS carbohydrate 
metabolism (Fig. 4.7). The lacD.1 gene, encoding a tagatose-bisphosphate aldolase, was 
shown previously to regulate SpeB expression, and no longer participated directly in 
carbohydrate metabolism (Loughman  Caparon, 006). Since the Galactose-specific EII 
is found at this genetic locus, it may no longer be contributing to carbohydrate uptake. 
Instead, it may have adapted to regulate SLS-mediated hemolysis as the ∆Galactose 
exhibits early hemolysis (Fig. 4.9). Several EIIs negatively influenced the metabolism of 
PTS carbohydrates, indicating that perhaps GAS uses EIICs to prioritize the hierarchal 
metabolism of less preferred carbohydrates (Fig. 4.7). It is clear, however, that annotation 
alone does not accurately define the sugar specificity of a particular EII, and that each must 
be experimentally verified.
 Seven different PTS EIIC mutants in M1T1 MGAS5005 were found to result in 
SLS-mediated hemolytic activity early in the growth phase (Fig. 4.9). Since no single EIIC 
mutant fully recapitulated the early hemolytic activity phenotype seen with the PTS-defective 
MGAS5005.∆ptsI, there appears to be an additive effect of these EIIs. The  mechanism for 
how these EIICs may influence SLS release is currently being investigated. Given that 
there are no PTS sugars commonly influenced by all seven EIIC identified, the possibility 
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that the lack of utilization of a single PTS carbohydrate is responsible for hemolysis is 
unlikely. This does not rule out the possibility of a non-PTS carbon source that is able to 
be utilized by these EIIs, a distinct possibility as MGAS5005.∆ptsI and ∆Mannose EIIC 
mutant also affects the utilization of several non-PTS carbon sources (Gera et al., 2014) 
(data not shown). It is also possible that these seven EIIs interact with a common set of 
PTS-regulatory domain (PRD)-containing regulators, where disruption of this regulatory 
interaction could lead to early hemolysis. Studies have shown that EIIBs are capable of 
interacting with other regulators that may influence pathogenesis ( oyet et al., 2013). 
Whichever the mechanism, it appears that components of carbohydrate metabolic networks 
are important for timely hemolytic activity in GAS. Interestingly, GAS mutants in the 
catabolite control protein CcpA (∆ccpA) exhibited early and sustained hemolysis (Kinkel 
& McIver, 2008, Shelburne et al., 2008a), although this does not appear to involve CcpA 
directly (Kietzman & Caparon, 2010).
 e found two EII mutants (∆b-glucoside and ∆Fructose) as important for survival 
in whole human blood. Both these EIIs are fusion proteins of all three subunits (EIIABC), 
and both affect growth of GAS in fructose as the sole carbon source. Although typically 
thought of as an environment rich in glucose, there are trace amounts of fructose available 
in blood (Wishart et. al., 2013, Wishart et. al, 2009, Wishart et. al. , 2007). This would 
suggest that perhaps fructose metabolism plays a role for GAS survival in whole human 
blood, a possibility that  will be further interrogated in Chapter 6. However, it was curious 
that although MGAS5005.∆ptsI was unable to survive in human blood as compared to 
MGAS5005, ∆Mannose did survive to the same extent as the wildtype (Fig 4.10). This 
would suggest that perhaps partial utilization of PTS carbohydrates is enough to allow for 
growth in whole human blood, with the most likely candidate being fructose. In the case 
of MGAS5005.∆ptsI, GAS is unable to utilize any PTS sugar other than glucose, so this 
may either hinder its ability to grow in blood, or more likely hinder its expression of other
83
virulence factors important for survival in whole blood by affecting PRD-containing 
regulatory proteins.
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hapter : The Mannose-Specific  locus is a central to S 
carboh drate metabolism and virulence  but in a strain specific 
manner
 Portions of this chapter were published with the following authors: Ganesh S. 
Sundar, Emrul Islam, Kanika Gera, Yoann Le Breton and Kevin S. McIver (© 2016 John 
Wiley & Sons Ltd. Molecular Microbiology. doi: 10.1111/mmi.13573.). 
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acquired and analyzed the data, and GSS, YLB, and KSM wrote the manuscript.
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Introduction
 Several PTS EII complexes are known to be important for the pathogenic 
processes of Gram-positive pathogens (Iyer & Camilli, 2007, Shelburne et al., 2008b, 
McAllister et al., 2012, Pridgeon et al., 01 ). The mannose-specific EII, composed of 
ManL (EIIAB), ManM (EIIC) and ManN (EIID), repeatedly appears to play important 
roles in pathogenesis, leading to the suggestion that it helps facilitate bacterial residence 
in animals (Zuniga et al., 2005). Mannose-family EII complexes can have broad substrate 
specificities, making them potential candidates to influence pathogenesis by incorporating 
numerous nutritional inputs and acting as a sensor to induce other metabolic operons 
(Fleming & Camilli, 2016). In Streptococcus mutans, ∆manL strains are not able to form 
biofilms in the presence of glucose, show reduced competency, and reduced acid tolerance 
(Abranches et al., 006). Interestingly, the mannose-specific EII is actually the target for 
class IIa bacteriocins, highlighting the importance of carbohydrate metabolism to the 
survival of microbes in the host (Kjos et al., 2011) .Therefore, mannose EII subunits have 
the potential to play important virulence roles in streptococcal pathogens. e identified 
the mannose-specific EII, encoded by manLMN, as an important EII that displayed a 
wide influence on sugar metabolism (see Chapter 4). Inactivation of this Mannose-family 
EII contributed to the early onset of SLS activity, and increased lesion severity in a
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strain specific manner. Mannose-family members of bacterial EIIC proteins are known to 
transport the widest range of substrates compared with other PTS EIIC transporters (Zuniga 
et al., 005). Of the 14 EIIC mutants tested in our MGAS5005 library, only ∆Mannose and 
∆Mannose Fructose showed growth defects and total yields below or significantly below 
T in at least four different PTS carbohydrates (see Chapter 4). Of the two, the mannose 
EIIC (ManM) exhibited the greatest influence over carbon utilization of any other PTS 
system, with 6  of carbon sources displaying altered utilization patterns in the ∆Mannose 
mutant compared with MGAS5005 (see Chapter 4). Although ∆N-acetylgalactosamine 
represents a third mannose family EIIC present in the MGAS5005 genome (see chapter 4), 
it only impacted one to two substrates for growth and utilization. Therefore, the Mannose 
and the Mannose/Fructose EIIC transporters have the broadest impact on the metabolism of 
PTS sugars in MGAS5005 (see Chapter 4), suggesting their central role in GAS physiology. 
Since ∆Mannose had the greatest influence on PTS carbohydrate metabolism, we decided 
to further examine its role in GAS physiology and virulence in two different M1T1 GAS 
strains.
Results  
manLMN forms an operon that is induced in the presence of mannose 
 The mannose-specific EII is made up of three distinct subunits: EIIAB (manL, 
cytosolic), EIIC (manM, membrane transporter), and an EIID (manN, membrane transporter 
exclusive to Mannose-family EII systems) ( ig. .1 ). The transcriptional architecture of 
manLMN was interrogated using RT-PCR to determine if these genes are expressed as an 
operon, using the primers as shown in ig. .1 . At the end of the predicted operon is a 
gene (manO) encoding a hypothetical protein; however, only manLMN were found to be 
co-transcribed ( ig. .1B, data not shown). As a result, insertional inactivation mutants 
of the manL and manM, would be expected to be polar, affecting the expression of the 
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although both sets of mutants in MGAS5005 and 5448
appear to influence the utilization of the same number of
carbon sources, they do vary in the degree in which they
affect utilization (Fig. 7C). MGAS5005 mannose-specific
EII components had a largely positive influence on PTS
sugar metabolism, whereas these proteins in 5448 exhib-
ited either a positive or negative influence, depending on
the specific sugar (Fig. 7D). Overall, the influence of
ManL, ManM and ManN on the metabolism of PTS car-
bohydrates varied between M1T1 GAS strains and sug-
gests a versatile EII that may adapt to the specific needs
of the individual genetic background.
DMannose EIIC induces hemolysis early in growth,
although ManL and ManN contribute in a strain-specific
manner
The individual subunits of the mannose-specific
EII complex (ManLMN) were interrogated for their
role in early onset of hemolysis. In order to more
accurately profile the point of growth where hemolysis
began for each of the mutants, supernatants from
samples taken every 20 minutes were tested. In
MGAS5005, early hemolysis was observed in the
DMannose EIIC mutant, as expected from the initial
screen in the EII mutant library, and slightly in
MGAS5005.DmanN. The overall level of hemolysis in
MGAS5005.DmanLMN was relatively lower compared
with WT MGAS5005, which was not the case for
5448.DmanLMN compared with WT 5448. Although
5448.DmanMN also exhibited the early hemolytic
activity, 5448.DmanN presented hemolytic profile simi-
lar to 5448 and different from that observed for the
same mutant in MGAS5005 (Fig. 8). Therefore,
ManM plays a consistent role in the regulation of
growth-phase dependent expression of SLS; however
the contribution of ManL and ManN to this phenotype
appears to be strain specific.
Fig. 6. Transcriptional architecture of the mannose PTS EII operon. (A) Graphical representation of the mannose-specific EII genetic locus.
Primers for RT-PCR are also shown (arrows) (B) RT-PCR was performed on RNA isolated from MGAS5005 grown to late-logarithmic phase in
THY using primers in gene pairs as indicated below. Bands indicate genes are transcribed together. (C) Polarity of each mannose EII subunit
was assessed using qPCR. Primers are located in the middle of each gene. (D) Induction of the mannose operon when GAS is grown in
mannose was determined. RNA was isolated in MGAS5005 grown in glucose and mannose, and relative transcript levels were compared
using qPCR. Each bar is the average of three independent biological replicates, depicted with the standard error. Dotted lines represent
two-fold difference in expression.
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igure .1 The transcriptio al architecture of t e mannose PTS  locus. ( ) Primers 
for T-PC  are shown on the graphical representation of the mannose-specific EII genetic 
locus. (B) RNA was isolated from MGAS5005 grown in THY to late-logarithmic phase. 
RT-PCR wa  performed us ng primers in gene pairs as shown below. Bands indicate 
presence of transcript, indicating the genes are transcribed together. ( ) Since mutagenesis 
appr ach s were potentially polar, this was assessed using qRT-PCR. Primers are located 
in the middle of e ch gene. ( ) Inducti n of the mannose operon of GAS cells grown 
in mannose was determined. MGAS5005 was grown in glucose and mannose, RNA was 
extracted, and relative transcript levels were compared. Each bar depicts the average of at 
least three biological replicates with its respective standard error. Dotted lines represent a 
two-fold differe ce in expression. 
dow stream operon gen s ( ig. .1 ). Since this EII is annotated  m nnose-specific, 
we hypothesized that the expression of manLMN should be induced in the presence of 
mannose. As expected, manM and manN are both induced when MGAS5005 is gr wn 
in CDM + 1% mannose as compared with growth in glucose ( ig. .1 ). manL is not as 
highly induced as manM and manN when MGAS5005 is grown in mannose ( ig. .1 ),
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suggesting the presence of a second promoter between manL and manM that is more highly 
induced in the presence of mannose. 
The mannose-specific  subunits have var ing influences on the metabolism of PTS 
carboh drates in different M1T1 strains 
 The mannose-specific EII subunit mutants in MGAS5005 were assayed for their 
individual influence on the metabolism of PTS sugars. Since the EIIC ManM was established 
earlier as a promiscuous transporter (see Chapter 4), we were interested to see if this was 
consistent for the EIIAB and EIID subunits as well. Surprisingly, MGAS5005.∆manLMN 
did not grow comparable to WT MGAS5005 in glucose, sucrose, maltose, and salicin, 
despite having no such phenotype in the ∆Mannose EIIC mutant ( hapter ig. .  and 
ig . ). MGAS5005.∆manLMN grew in lactose similar to WT, which was not the case for 
the ∆Mannose EIIC mutant ( ig . ). However, both strains did have a reduced total yield 
in lactose ( ig. . B; ig . ). MGAS5005.∆manN had no effect on the overall growth of 
GAS in PTS carbohydrates, but did affect the total yield in 4 PTS carbohydrates. Of these, 
the only sugar that is specific to ManN was ascorbic acid ( ig. .  and B). As expected, 
total yield in mannose was affected in all three mutant strains, further validating this EII as 
mannose-specific ( ig. . B  ig . ). 
 In contrast, the same manL, manM and manN mutants introduced into another M1T1 
strain, 5448 (covS+), had a different influence on the metabolism of PTS carbohydrates. 
5448.∆manMN and 5448.∆manLMN had altered growth in fewer PTS carbohydrates 
than their respective counterparts in the covS-deficient MGAS5005 ( ig. . ). In fact, 
5448.∆manMN and 5448.∆manLMN grew better in 3 PTS carbohydrates, indicating 
that ManL and ManM negatively influence the metabolism of these carbohydrates by an 
unknown mechanism ( ig. . B). In addition, although both sets of mutants in MGAS5005 
and 5448 appear to influence the utilization of the same number of carbon sources, they 
do vary in the degree in which they affect utilization ( ig. . ). MGAS5005 mannose-
specific EII components had a largely positive influence on PTS sugar metabolism, 
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whereas these proteins in 5448 exhibited either a positive or negative influence, depending 
on the specific sugar ( ig. . ). Overall, the influence of ManL, ManM and ManN on 
the metabolism of PTS carbohydrates varied between M1T1 GAS strains and suggests a 
versatile EII that may adapt to the specific needs of the individual genetic background. 
Mannose  induces hemol sis earl  in growth  although Man  and Man  
contribute in a strain-specific manner
 The individual subunits of the mannose-specific EII complex (ManLMN) were 
interrogated for their role in early onset of hemolysis. In order to more accurately profile the 
point of growth where hemolysis began for each of the mutants, supernatants from samples 
taken every 20 minutes were tested. In MGAS5005, early hemolysis was observed in the 
∆Mannose EIIC mutant, as expected from the initial screen in the EII mutant library, and 
slightly in MGAS5005.∆manN. The overall level of hemolysis in MGAS5005.∆manLMN 
was relatively lower compared with WT MGAS5005, which was not the case for 
5448.∆manLMN compared with T 5448. Although 5448.∆manMN also exhibited the 
early hemolytic activity, 5448.∆manN presented hemolytic profile similar to 5448 and 
different from that observed for the same mutant in MGAS5005 ( ig. . ). Therefore, 
ManM plays a consistent role in the regulation of growth-phase dependent expression of 
SLS; however the contribution of ManL and ManN to this phenotype appears to be strain 
specific.
ontribution of ManM  ( ) to the pathogenesis of M1T1 M S  in a soft 
tissue infection model
 The pathogenesis of the ∆Mannose EIIC mutant was assessed in a murine soft 
tissue infection model, where lesion size and survival from invasive disease was monitored 
as described (see Chapter ). MGAS5005 lacking a functional PTS (MGAS5005.∆ptsI) 
was previously shown to elicit larger and more severe lesions than those induced by 
MGAS5005 in the subcutaneous model (Gera et al., 014). Although the ∆Mannose EIIC 
mutant exhibited similar lesion sizes to that of MGAS5005, the severity of the lesions (see
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Contribution of ManMN (EIICD) to the pathogenesis of
M1T1 MGAS5005 in a soft tissue infection model
The pathogenesis of the DMannose EIIC mutant was
assessed in a murine soft tissue infection model, where
lesion size and survival from invasive disease was moni-
tored as described (see section on “Experimental
Procedures”). MGAS5005 lacking a functional PTS
(MGAS5005.DptsI) was previously shown to elicit larger
and more severe lesions than those induced by
MGAS5005 in the subcutaneous model (Gera et al.,
2014). Although the DMannose EIIC mutant exhibited
similar lesion sizes to that of MGAS5005, the severity of
the lesions (see section on “Experimental Procedures”) in
the mutant was increased significantly as compared with
MGAS5005 and the DMannoseR rescued strain (Fig.
9A,B). As was the case for MGAS5005.DptsI, the
Fig. 7. Metabolic profile of the mannose EII subunit mutants. (A) Growth curve analyses were performed as fully described in Experimental
Procedures for manLMN mutants in 5448 (right) or MGAS5005 (left). Growth in a particular PTS sugar of the mutant above WT (green),
below WT (yellow), significantly below WT (red), or similar to WT (white) are indicated. (B) Change in growth (DOD) of manLMN mutants was
calculated as described in “Experimental Procedures.” DOD of mutants in a particular PTS sugar that were significantly above WT (green,
p-value <0.05) or below WT (red, p-value <0.05) are indicated. Only PTS sugars facilitating growth of MGAS5005 are shown. All results
represent at least three independent biological replicates. (C) Utilization of select carbon sources by manLMN mutants as determined using
the APIVR 50CH system and described in “Experimental Procedures.” Only carbon sources that are utilized by at least one of the strains tested
are shown. White boxes indicate utilization (1), gray boxes indicate partial utilization (6), and black boxes indicate no utilization (2). Readings
for each strain are given for 24 h (left box) and 48 h (right box). (D) Heat map of the relative influence of manLMN mutants on growth in a
particular PTS sugar (Influence Score) was calculated as described in “Experimental Procedures.” Green indicates a negative influence of an
EII for the metabolism of a PTS sugar, red indicates a positive influence of an EII for the metabolism of a PTS sugar, and white indicates no
influence. Relative influence is reflected by intensity of color.
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igure .  Metabolic profile of the mannose-specific  subunit mutants. ( ) Growth 
curves for the mannose-specific EII subunit mutants were analyzed as described in chpater 
3.  Normalized growth above WT (gree , two-fold above), below WT ( ellow, two-fold 
below), and w ll below (red, >two-fold below) are indicat d. (B) Total yield (∆OD) of the 
subunit mutants were calculated as indicated in chapter . ∆OD significantly above T 
were shown in green, whereas ∆OD significantly below T are shown in red. ∆OD that 
are not s gnificantly different in the m tant as compared to the T are shown in white. 
Significance was determined by Student s t-test (p-value 0.05). Data represent the average 
of at least three biological replicates. ( ) The API®50CH system was used to determine the 
utilization profiles of the ma nos -specific EII mutants, as indica ed in chapter . Carbon 
sources presented are utilized in at least one strain tested. White boxes indicate utilization (+), 
grey boxes i dicate partial utilization (+/-), and black boxes indicate no utilization (-). Two 
reading were taken for each strain in each sugar, depicted as 4h on the left and 48h on the 
right. ( ) Influence scores for ManLMN in both 5005 and 5448 were calculated as indicated 
in chapter . Positi e influence on the m tabolism of a PTS carbohydrate is indicated in red, 
whereas a negative influence is indicated in green. elative intensity of each color represents 
the relative degree of influence of each protein on the metabolism of a carbohydrate.
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Figure S4. Growth of MGAS5005 manLMN EII mutants in 9 PTS carbohydrates. Each graph represents the 
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igure . . rowth of M S  man M   mutants in  PTS carboh drates. 
Each graph represents the average of at least 3 independent biological replicates. ( - ) EII 
mutants were grown in CDM + 1% PTS carbohydrate (0.5% for glucose) as indicated in 
chapter 3. Black lines represent WT growth, whereas red lines represent growth of the EII 
mutant. 
Chapter ) in the mutant was increased significantly as compared with MGAS5005 and the 
∆MannoseR rescued strain ( ig. . B  ig . ). As was the case for MGAS5005.∆ptsI 
the increased localized lesion severity did not lead to increased mortality ( ig. . ). 
ather, survival was slightly increased in the ∆Mannose EIIC mutant compared with, WT 
MGAS5005. Thus, the loss of manMN (EIICD) results in enhanced necrosis during soft-
tissue infection.
Discussion
 Characterization of the mannose-specific EIIABCD components 




















































































































































































































































































































igure . .  of the mannose subunit mutant in two M1T1s. Each graph represents 
the average of at least 3 independent biological replicates. Data is normalized to wildtype 
as indicated in chapter 3. ( B) Mutants were grown in CDM + 1% PTS carbohydrate 
(0.5% for glucose) as indicated in chapter 3. Color of bars depict strain as indicated. 
 p-value  0.05  p-value 0.01 p-value 0.005 
specific role for PTS sugar metabolism and growth phase-related production of SLS-
mediated hemolysis. e identified the Mannose-specific EII system as a central 
component to the metabolism of a large number of PTS carbohydrates in MGAS5005. 
In Streptococcus pneumoniae, a manLMN mutant was recently shown to be unable to 
grow on non-preferred carbohydrates due to the lack of induction of other metabolic 
operons (Fleming & Camilli, 2016). In contrast, ManLMN has been shown to have a 
large number of substrates in other bacteria and plays a more direct role in metabolism 
of these sugars (Tong et al., 2011, Port et al., 014). The exact mechanism by which the 
mannose-specific EII affects the metabolism of other carbohydrates in GAS is not known. 
In MGAS5005, there were 5 sugars whose metabolism was differentially affected between 
∆manLMN and the ∆Mannose EIICD (∆manMN) mutant ( ig .  ig . ). Thus, an intact 
manL (EIIAB) alone facilitates optimal growth of GAS on maltose, salicin, glucose and
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increased localized lesion severity did not lead to
increased mortality (Fig. 9C). Rather, survival was slightly
increased in the DMannose EIIC mutant compared with
WT MGAS5005. Thus, the loss of ManMN (EIICD)
results in enhanced necrosis during soft-tissue infection.
Discussion
In this study, we generated a PTS EIIC mutant library
based on the annotated loci in the M1T1 GAS strain
MGAS5005 to help assign the carbohydrate-specific tar-
gets for each transporter and to uncover those that con-
tribute to the growth phase expression of Streptolysin S
(SLS). By experimentally verifying growth and metabo-
lism of PTS sugars, we discovered that each EII has
varying influences on the metabolism of PTS sugars,
with Mannose-family EIIs having the broadest influence.
Several EIIC mutants, including the Mannose-family EIIs,
contributed to an early onset of SLS-mediated hemolysis
during growth in vitro and increased severity of skin lesions
in vivo, as previously observed with the PTS-defective
MGAS5005.DptsI GAS mutant. Characterization of the
mannose-specific EIIABCD components (manLMN) in two
different M1T1 GAS strains revealed that they played a
strain-specific role for PTS sugar metabolism and growth
phase-related production of SLS-mediated hemolysis.
The sugar-specificities of a few individual EII systems
have been assessed in streptococci, revealing imperfect
annotations of their carbohydrate targets (Shelburne
et al., 2008b; Bidossi et al., 2012). Applying an exten-
sive metabolic panel to the full complement of EII loci
identified in the GAS genome, we found that the level of
influence that any given EII had on the metabolism of
each PTS carbohydrate varied across the board (Fig.
4). In fact, several EIIC transporters appear to have
very little influence on PTS sugar metabolism (Fig. 4),
either because they are not involved in sugar transport
or that the substrates of these EIIC components are
shared between multiple EII complexes. Some of these
EIIs (e.g., Trehalose-specific EII, N-acetylgalactosamine-
specific EII, Cellobiose-specific EII-1) are either lacking
a key component gene or have multiple genes encoding
a single subunit; indicating that they may not be involved
in sugar transport (Fig. 1). The annotated Galactose EII
appears to have virtually no effect on PTS carbohydrate
Fig. 8. Hemolytic activity of the mannose EII subunit mutants. Hemolytic activity of culture lysates against red blood cells (RBCs) for
manLMN mutants in 5448 and MGAS5005 was assayed as described in Experimental Procedures. Data from three biological replicates is
shown comparing occurrence of hemolysis (defined as OD541> 0.2) on the X-axis and the relative level of hemolytic activity observed on the
Y-axis. Hemolysis at an OD600 above 1 was considered normal based on WT 5448 or MGAS5005 (black bars to right of dotted line).
Occurrence of hemolysis was noted as early if it occurred before OD600 of 1 (red bars left of dotted line).
10 G. S. Sundar et al. !
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i ure .  Hemol tic activit  of the annose-specific  subunit mutants. As 
described in hapt r 3, culture ly ates from GAS grown cells were in ubated with r d 
blood c lls (RBCs) t  measure hemolytic activity. D ta from thr e biological replicates is 
shown. The occurrence of hemolysis (OD541 > 0.2) on the X-axis is compared to the relative 
amount of hemolytic activity observed on the Y-axis. Red bars (to the left of the dotted 
line) represent hemolysis at an OD600 below 1, indicating early hemolytic ctivity. Black 
bars (to the right of t  dotted line) represent hemolysis occurring at an OD600 > 1, which 
is considered normal based on T 5448 or MGAS5005. 
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sucrose. Lack of manL prevents GAS from growing in these sugars efficiently, but it 
does allow for wil  type growth in lactose ( ig . ). This would suggest that either 
ManL (EIIAB) can interact with other EII systems, or that M nL (EIIAB) interacts with a 
protein(s) that influence other metabolic pathways. ManN (EIID) in MGAS5005 had very 
little influence on PTS sugar metabolism, likely due to the presence of an intact EIIABC 
that would still allow for transport of PTS substrates ( ig . ). 
 The specific rol s of th  ManLMN subunits were not consistent between the two 
M1T1 strains tested, MGAS5005 and 5448, even though their manLMN gene sequences 
are identical. The ∆Mannose EIIC mutant had a much more limited effect on the growth of
metabolism (Fig. 4). The lacD.1 gene, encoding a
tagatose-bisphosphate aldolase, was shown previously
to regulate SpeB expression, and no longer participated
directly in carbohydrate metabolism (Loughman and
Caparon, 2006). Since the galactose-specific EII is
found at this genetic locus, it may no longer be contrib-
uting to carbohydrate uptake. Instead, it may have
adapted to regulate SLS-mediated hemolysis as the
DGalactose exhibits early hemolysis (Fig. 5). Several
EIIs negatively influenced the metabolism of PTS carbo-
hydrates, indicating that perhaps GAS uses EIICs to pri-
oritize the hierarchal metabolism of less preferred
carbohydrates (Fig. 4). It is clear, however, that annota-
tion alone does not accurately define the sugar specific-
ity of a particular EII, and that each must be
experimentally verified.
We identified the Mannose-specific EII system as a
central component to the metabolism of a large number
of PTS carbohydrates in MGAS5005. In Streptococcus
pneumoniae, a DmanLMN mutant was recently shown
to be unable to grow on non-preferred carbohydrates
due to the lack of induction of other metabolic operons
(Fleming and Camilli, 2016). In contrast, ManLMN has
been shown to have a large number of substrates in
other bacteria and plays a more direct role in
metabolism of these sugars (Tong et al., 2011; Port
et al., 2014). The exact mechanism by which the
mannose-specific EII affects the metabolism of other
carbohydrates in GAS is not known. In MGAS5005,
there were 5 sugars whose metabolism was differentially
affected between DmanLMN and the DMannose EIICD
(manMN) mutant (Fig. 7A). Thus, an intact manL
(EIIAB) alone facilitates optimal growth of GAS on malt-
ose, salicin, glucose and sucrose. Lack of manL pre-
vents GAS from growing in these sugars efficiently, but
it does allow for wild type growth in lactose (Fig. 7A).
This would suggest that either ManL (EIIAB) can inter-
act with other EII systems, or that ManL (EIIAB) inter-
acts with a protein(s) that influence other metabolic
pathways. ManN (EIID) in MGAS5005 had very little
influence on PTS sugar metabolism, likely due to the
presence of an intact EIIABC that would still allow for
transport of PTS substrates.
The specific roles of the ManLMN subunits were not
consistent between the two M1T1 strains tested,
MGAS5005 and 5448, even though their manLMN gene
sequences are identical. The DMannose EIIC mutant
had a much more limited effect on the growth of GAS in
PTS carbohydrates in 5448 compared with the same
manMN mutant in MGAS5005 (Fig. 7). Overall,
Fig. 9. Contribution to virulence of the mannose EII subunits mutants. The mannose EIIC subunit mutant was assayed using a murine
subcutaneous infection model. Lesion size and survival of mice were monitored for 7 days. Each strain was tested in at least 10 mice.
(A) Depicted representative images of lesions taken at 2 and 3 days post infection. (B) Lesion size and severity was measured using ImageJ.
Each data point represents a single mouse lesion measured at each time point. (C) Survival was monitored for 7 days. Significance was
determined as described in “Experimental Procedures.”
Mannose PTS EII in Streptococcus pyogenes 11
VC 2016 John Wiley & Sons Ltd, Molecular Microbiology, 00, 00–00
igure .  Subcu aneous murine infections of Ma nos . Lesion size and survival of 
mice were monitored for 7 days. Each strain was tested in at least 10 female CD-1 mice. 
( ) Representative images of lesions taken at 2 and 3 days post infection. (B) Lesion size 
was measured as indicated in chapter 3 at 2 and 3 days post infection using ImageJ. Each 
data point represents a single mouse lesion ( ) Mouse survival was monitored for 7 days. 
Significance was determined as described in chapter . 
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GAS in PTS arbohydrates in 5448 c mpared with the same m nMN muta t in MGAS5005 
( ig. .  ig . ). Overal , Mannose EII compone  mutants in 5448 only affected growt  
of GAS in 1 or 2 sugars, which was not t  case for the same mutants in MGAS5005, with 
the exception of MGAS5005.∆manN ( ig .  and B). Diff rences in overall PTS sugar 
metabolism have been observed between different GAS strains, specifically M14 HSC5 
and M1T1 MGAS5005 (Port et al., 014). A mutation in the fructose-specific EII (∆fruA) 
in MGAS5005 exhibited increased growth in both glucose and lactose, which was not 
seen for the same mutant in 5448 (chapter 6). e have also observed differences in carbon 
utilization between MGAS5005 and 5448 (data not shown), indicating that different 
strains may require different nutrients and have subsequently altered the roles of similar 
proteins. Thus, GAS strains may be able to infect several different host niches because
igure .  Mannose subcutaneous murine infections lead to the development of 
more severe lesions. ( ) Lesion severity, as described in chapter 3, was determined by 
analyzing the average red pixel intensity of the lesion selection. Increased tissue necrosis 
(∆Mannose lesions) lead to scarring which appear darker on the image, making the pixel 
intensity closer to the black end of the scale. Less necrotic lesions retain the appearance of 
the body of a mouse (pink/red), therefore the pixel intensity is closer to the light red end of 
the scale. (B) Average pixel intensity for at least 10 independent lesions were scored and 
displayed. p-value  0.005. 
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of their metabolic versatility. The role of ManL and ManN, but not ManM, in regulating 
hemolytic activity is potentially strain specific. A ∆manLMN mutant in 5448 exhibited early 
hemolysis, which was not seen for the same mutant produced in MGAS5005. However, 
∆manN in MGAS5005 exhibited early hemolytic activity to a certain extent, which was not 
seen for the same respective mutant in 5448. One explanation could be the covS status of each 
strain. MGAS5005 is a covS mutant whereas 5448 is wild type for covS, so the presence of 
a functional CovS may influence the roles of ManL and ManN. To address this possibility, 
the roles of ManLMN in hemolytic activity are currently being evaluated in 5448AP 
(covS-).
 The lesions that develop from ∆Mannose EII system GAS infections in a mouse 
model of soft tissue disease are more severe in their necrosis than those that develop from
a wild type MGAS5005 infection ( ig. .  ig. . ). Although the lesion sizes from 
∆Mannose mutant infections trend larger than those from MGAS5005 infections, the 
differences are not statistically significant ( ig. . B). Since 6 other EIIC mutants exhibited 
early hemolytic activity as well, this suggests that the increased lesion sized observed in 
MGAS5005.∆ptsI infections could be the result of the additive contribution of several 
EIIs on SLS expression (see chapter 4). As seen with the PTS-defective MGAS5005.∆ptsI 
mutant (Gera et al., 014), a ∆Mannose EIIC mutant does not impact lethality compared 
with MGAS5005 in vivo ( ig. . ). Thus, the influence of the PTS on GAS pathogenesis 
may be localized to the site of infection, indicating the potential for GAS to use specific 
carbon metabolic pathways in each distinct host niche in order to govern its pathogenesis. 
 In conclusion, the Mannose-specific EIIC plays a central role in PTS carbohydrate 
metabolism and regulates SLS-mediated hemolysis. This could be a mechanism to obtain 
sugars in nutrient poor host conditions. Although ManM acts to reduce the lesion severity 
in soft tissue infections, the overall role of the PTS to mediate lesion severity appears to be 
the additive effect of multiple EIIs. 
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hapter : omparing the role of the fructose-specific  in 
GAS PTS carbohydrate metabolism and virulence between two 
M1T1s
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Introduction
 fruA encodes one of the 14 EII PTS sugar transporters found in the GAS M1T1 
genome (Shelburne et al., 2008b) and is predicted to be located within a conserved 
three-gene fru operon conserved across low GC Gram-positive bacteria. In the model 
organism Lactococcus lactis, the fru operon is composed of fruR, encoding a DeoR 
family transcriptional repressor; fruK (fruB in GAS), a 1-phosphofructokinase; and 
fruA, an  EIIABC PTS sugar transporter (Barriere et al., 2005). Interestingly, fruA has 
been implicated in the pathogenesis of other streptococcal species. In the oral pathogen 
Streptococcus gordonii, the fructose EIIABC (fruA) has been linked to biofilm formation 
(Loo et al., 2003). In the zoonotic pathogen Streptococcus iniae, fruA was found in the 
genomes of five virulent strains but was absent from nonvirulent strains (Pridgeon et al., 
2013). In GAS, the transcription of fruA was induced in an analysis of global heme stress 
in GAS (Sachla et al., 2014), a condition likely encountered during bloodstream infection. 
Therefore, understanding its different roles in GAS virulence is useful to understand the 
development of invasive disease. 
Results 
Fructose metabolic operon genes are important for survival from neutrophil killing
 In a previous study, the fructose-specific metabolic operon was implicated 
in resistance to neutrophil killing of GAS (Valdes et al., 2016). Neutrophils are the 
predominant cell type that act as a first line of defense at the site of infection, and they 
can kill pathogens through multiple extra- or intracellular means, such as antimicrobial 
peptides, phagocytosis, and DNA neutrophil extracellular traps (NETs). We subjected 
5448.∆fruR, 5448.∆fruB, and 5448.∆fruA strains to opsonophagocytic killing assays using 
the human-derived promyelocytic leukemia cell line HL60 differentiated into neutrophil-
like cells (Fig. 6.1 A) and freshly isolated human PMNs (Fig. 6.1B). Both neutrophil-like
HL60 cells and human-isolated PMNs were infected using an MOI of 0.1, and strains were 
plated for survival and compared to the parental 5448. hen either the 5448.∆fruR or 
5448.∆fruB mutant was incubated with HL60 cells, each showed a significant decrease in 
survival compared to that of 5448 (Fig. 6.1A). However, the 5448.∆fruA mutant survived at 
levels comparable to that of the wild-type GAS. Importantly, 5448.∆fruRR and 5448.∆fruBR 
revertant strains either partially or completely restored the phenotype to wild-type levels 
(Fig. 6.1A). These phenotypes were recapitulated with freshly isolated human PMNs (Fig. 
6.1B), supporting a requirement for FruB and FruR, but not FruA, for survival in human 
neutrophils. There was also a survival defect observed for the 5448.∆fruR or 5448.∆fruB 
mutant, but not the 5448.∆fruA mutant, in human monocytes, suggesting a role for these fru 
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for a defect in growth for any of the fru operon mutants, we also grew each strain in RPMI 
plus 20% plasma and saw no growth defect compared to the parental 5448 (Fig 6.1 D and 
). Thus, fruR and fruB, but not fruA, are important for GAS resistance to killing by human 
neutrophils and primary monocytes.  
 This suggests that the fructose-specific metabolic operon plays an important role for 
GAS to survive in whole human blood. This was rather curious, as fructose is not present 
in high amounts in human blood or in RBCs, although there are trace amounts (Wishart 
et. al., 2013, Wishart et. al, 2009, Wishart et. al, 2007). We assayed the components of 
the fructose metabolic operon in whole human blood, and determined that only fruR and 
fruB were required for GAS survival in whole human blood and exhibited small colony 
phenotypes when streaked on blood agar plates, which was not the case for fruA (Fig 6.2A 
and B). Importantly, the revertants have similar survival to wildtype 5448. Interestingly, 
∆Fructose (∆fruA in MGAS5005; Chapter 4) is impaired in its ability to survive in whole 
human blood. This would again suggest that there is a strain specific behavior that EIIs 
possess in their roles in pathogenesis. Similar to ∆Mannose (Chapter 5), we sought to 
determine if this differential phenotype observed was the result of altered metabolic
influences of FruA between MGAS5005 and 5448. Since the metabolic influence of FruA 
was already determined for MGAS5005, we characterized the fructose-specific EII in 5448. 
ructose-Specific  operon induced b  the presence of fructose 
 As seen in Chapter 4 and 5, EIIs do not always solely affect the metabolism of the 
PTS carbohydrate based on their respective annotation. This, combined with the fact that 
fructose metabolic genes were implicated in GAS survival against neutrophil killing, led 
us to assess the effect of fructose on GAS gene expression, with the hope of elucidating 
pathways that may provide an explanation for the observed phenotype. We conducted RNA 
transcriptome sequencing (RNA-Seq) on total RNA isolated from wild-type 5448 grown 
in chemically defined medium (CDM) supplemented with 0.5  glucose or 1  fructose 
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Figure 6.1 Role of fructose-metabolic genes in immune evasion. (A) Survival in 
neutrophil-like HL60 cells. GAS (1x105 CFU/well) and HL60 cells (1x106 CFU/well) were 
incubated for 2 h at 37°C. Cells were lysed and the percentage of surviving GAS CFU was 
determined relative to the level of survival for 5448. (B) Survival in human neutrophils 
(PMNs). GAS (1x105 CFU/well) and neutrophils (1x106 CFU/well) were incubated for 2 
h at 37°C. Neutrophils then were lysed, and the percentage of surviving GAS CFU was 
determined and is shown as survival relative to that of the WT (5448). (C) Survival in 
human monocytes. GAS (1x105 CFU/well) and human monocytic cells (1x106 CFU/well) 
were incubated for 2 h at 37°C. Cells were lysed, and the percentage of surviving GAS 
CFU was determined relative to that for survival of 5448. Error bars in panels A to C 
represent means SD of the results from three biological replicates performed in triplicate. 
Significance for panels A to C was determined by unpaired t test (P  0.05). Each fru 
mutant was grown along with the parental strain 5448 in RPMI + 20% plasma. Data from 
6 independent experiments, with at least three replicates for each fru operon mutant in 
comparison to WT 5448 are shown in (D). The cumulative results of (D) are shown as an 
average of the replicates in ( ). *Performed by L.A.V.
to late logarithmic phase in two biological replicates and processed for RNA-Seq. Data 
obtained from fructose-grown cells were compared to those of glucose-grown cells (WT-
glu/WT-fru), with changes in gene expression over 2-fold (log2 -1.0 or log2 1.0) being
considered significant (Table 6.1). A total of 195 genes (103 nonphage genes; 5.5% of genome) 
were altered  (Table 6.1). Several predicted and established sugar metabolism operons were 
highly induced during growth in fructose (Table 6.1, shaded gray), including the lacD.1 and
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A.                     B.                       C. 
although it trended downward and was variable. The revertant
strains for all three mutants showed a restoration of growth com-
parable to the level for wild-type 5448 (Fig. 5A). Thus, although
our TraSH screen had indicated that fruA was needed for GAS
survival in human blood (15), our data using defined nonpolar
mutants in the fru operon indicate that fruR and fruB are mostly
responsible for this phenotype.
fruR and fruB are important for GAS 5448 survival in neutro-
phils and monocytes. The phenotype exhibited by 5448.!fruR
and 5448.!fruB strains in whole human blood can be attributed to
defects in metabolic processes or in immune evasion. To clarify
this question, we subjected 5448.!fruR and 5448.!fruB strains to
opsonophagocytic killing assays using the human-derived promy-
elocytic leukemia cell line HL60 differentiated into neutrophil-
like cells (Fig. 5B) and freshly isolated human PMNs (Fig. 5C).
Neutrophils are the predominant cell type that act as a first line of
defense at the site of infection, and they can kill pathogens through
multiple extra- or intracellular means, such as antimicrobial pep-
tides, phagocytosis, and DNA neutrophil extracellular traps
(NETs) (46). Both neutrophil-like HL60 cells and human-isolated
PMNs were infected using an MOI of 0.1, and strains were plated
for survival and compared to the parental 5448. When ei her the
5448.!fruR or 5448.!fruB mutant was incubated with HL60 cells,
each showed a significant decrease in survival compared to that of
5448 (Fig. 5B). However, the 5448.!fruA mutant survived at levels
comparable to that of the wild-type GAS. Importantly, 5448.fruRR
and 5448.fruBR revertant strains either partially or completely re-
stored the phenotype to wild-type levels (Fig. 5B). These pheno-
types were recapitulated with freshly isolated human PMNs (Fig.
5C), supporting a requirement for FruB and FruR, but not FruA,
for survival in human neutrophils. There was also a survival defect
observed for the 5448.!fruR or 5448.!fruB mutant, but not the
5448.!fruA mutant, in human monocytes, suggesting a role for
these fru operon genes in evading killing by different phagocytic
cell types (Fig. 5D). To account for a defect in growth for any of the
fru operon mutants, we also grew each strain in RPMI plus 20%
plasma and saw no growth defect compared to the parental 5448


































































































































































FIG 5 fruR and fruB are important for survival in human blood and phagocytic cells. In all assays, wild-type 5448 (black bars) was compared to 5448.!fruR
(white bars), 5448.!fruB (light gray bars), and 5448.!fruA (dark gray bars) mutants for growth and survival. The respective rescued mutant strains are indicated
with diagonal lines. (A) Lancefield bactericidal assay was performed by monitoring growth in whole hum n blood with rotation at 37°C for 3 h. Data are
presented as percent growth in blood corresponding to the multiplication factor (MF) of the mutant divided by the MF of the wild type times 100. Error bars
represent means " SD of the results of six independent experiments. (B) Survival in neutrophil-like HL60 cells. GAS (1 # 105 CFU/well) and HL60 cells (1 # 106
CFU/well) were incubated for 2 h at 37°C. Cells were lysed and the percentage of surviving GAS CFU was determined relative to the level of survival for 5448. (C)
Survival in human neutrophils (PMNs). GAS (1 # 105 CFU/well) and neutrophils (1 # 106 CFU/well) were incubated for 2 h at 37°C. Neutrophils then were
lysed, and the percentage of surviving GAS CFU was determined and is shown as survival relative to that of the WT (5448). (D) Survival in human monocytes.
GAS (1 # 105 CFU/well) and human monocytic cells (1 # 106 CFU/well) were incubated for 2 h at 37°C. Cells were lysed, and the percentage of surviving GAS
CFU was determined relative to that for survival of 5448. Error bars in panels B to D represent means " SD of the results from three biological replicates
performed in triplicate. Significance for panel A was determined using a Student t test (P ! 0.0015), while significance for panels B to D was determined by
unpaired t test (P $ 0.05).
Valdes et al.
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although it trended downward and was variable. The revertant
strains for all th ee mutants showed a restoration of growth com-
parable to the level for wild-type 5448 (Fig. 5A). Thus, although
our TraSH screen had indicated that fruA was needed for GAS
survi al in human blood (15), our data using defined nonpolar
mu ants in th fru operon indicate that fruR and fruB are mostly
responsible for this phenotype.
fruR and fruB are important for GAS 5448 survival in neutro-
hils and monocytes. The phenotype exhibited by 5448.!fruR
and 5448.!fruB strains in whole human blood can be attributed to
defects in metabolic processes or in immune evasion. To clarify
this question, we subjected 5448.!fruR and 5448.!fruB strains to
opson ph gocytic killing assays using the human-derived promy-
elocytic leukemia cell line HL60 differentiated into neutrophil-
like cells (Fig. 5B) and freshly isolated hum n PMNs (Fig. 5C).
Neutrophils are the predominant cell type that act as a first line of
defense at the site of infection, and they can kill pathogens through
multiple extra- or intracellular means, such as antimicrobial pep-
tides, phagocytosis, and DNA neutrophil extracellular traps
(NETs) (46). Both neutrophil-like HL60 cells and human-isolated
PMNs were infected using an MOI of 0.1, and strains were plated
for survival and compar d to th parental 5448. When either the
5448.!fruR or 5448.!fruB mutant was incubated with HL60 cells,
each showed a significant decrease in survival compared to that of
5448 (Fig. 5B). Howev r, the 5448.!fruA mutant survived at levels
comparable to that of the wild-type GAS. Importantly, 5448.fruRR
and 5448.fruBR revertant strains either partially or completely re-
stored the phenotype to wild-type levels (Fig. 5B). These pheno-
types were recapitulated with freshly isolated human PMNs (Fig.
5C), supporting a requirement for FruB and FruR, but not FruA,
for survival in human neutrophils. There was also a survival defect
observed for the 5448.!fruR or 5448.!fruB mutant, but not the
5448.!fruA mutant, in human monocytes, suggesting a role for
these fru operon ge s in evading killing by different phagocytic
cell types (Fig. 5D). To account for a defect in growth for any of the
fru operon mutants, we also grew each strain in RPMI plus 20%
plasma and saw no growth defect compared to the parental 5448


































































































































































FIG 5 fruR and fruB are important for survival in human blood and phagocytic cells. In all assays, wild-type 5448 (black bars) was compared to 5448.!fruR
(white bars), 5448.!fruB (light gray bars), and 5448.!fruA (dark gray bars) mutants for growth and survival. The respective rescued mutant strains are indicated
with diagonal lines. (A) Lancefield bactericidal assay was performed by monitoring growth in whole human blood with rotation at 37°C for 3 h. Data are
presented as percent growth in blood corresponding to the multiplication factor (MF) of the mutant divided by the MF of the wild type times 100. Error bars
represent means " SD of the results of six independent experiments. (B) Survival in neutrophil-like HL60 cells. GAS (1 # 105 CFU/well) and HL60 cells (1 # 106
CFU/well) were incubated for 2 h at 37°C. Cells were lysed and the percentage of surviving GAS CFU was determined relative to the level of survival for 5448. (C)
Survival in human neutrophils (PMNs). GAS (1 # 105 CFU/well) and neutrophils (1 # 106 CFU/well) were incubated for 2 h at 37°C. Neutrophils then were
lysed, and the percentage of surviving GAS CFU was determined and is shown as survival relative to that of the WT (5448). (D) Survival in human monocytes.
GAS (1 # 105 CFU/well) and human monocytic cells (1 # 106 CFU/well) were incubated for 2 h at 37°C. Cells were lysed, and the percentage of surviving GAS
CFU was determined relative to that for survival of 5448. Error bars in panels B to D represent means " SD of the results from three biological replicates
performed in triplicate. Significance for panel A was determined using a Student t test (P ! 0.0015), while significance for panels B to D was determined by
unpaired t test (P $ 0.05).
Valdes et al.
1026 iai.asm.org April 2016 Volume 84 Number 4Infection and Immunity







although it trended downward and was variable. The revertant
strains for all three mutants sho ed a restoration of growth com-
parable to the level for wild-type 5448 (Fig. 5A). Thus, although
our TraSH screen ad indicated that fruA was needed for GAS
survival in human blood (15), our data using defined nonpolar
mutants in the fru opero i dic te that fruR and fruB are mostly
responsible for this phenoty .
fruR and fruB are important for GAS 5448 survival in neutro-
phils and monocytes. The phenotype exhibited by 5448.!fruR
and 5448.!fruB strai s in whole human blood can be attributed to
defects in metabolic processes or in immune evasion. To clarify
this question, we subjected 5448.!fruR and 5448.!fruB strains to
opsonophagocytic killing assays using the human-derived promy-
elocytic leukemia cell line HL60 differentiated into neutrophil-
like cells (Fig. 5B) and freshly isolated human PMNs (Fig. 5C).
Neutrophils are the predominant cell type that act as a first line of
defense at the site of infection, and they can kill pathogens through
multiple extra- or intracellular means, such as antimicr bial pep-
tides, phagocytosis, and DNA neutrophil extracellular traps
(NETs) (46). Both neutrophil-like HL60 cells and human-isolated
PMNs were infected using an MOI of 0.1, and strains were plated
for survival and compared to the pare tal 5448. When either the
5448.!fruR or 5448.!fruB mutant was incubated with HL60 cells,
each showed a significant decrease in survival compared to that of
5448 (Fig. 5B). H ver, the 5448.!fruA muta t s r i ed at levels
c mparable to that of the wild-type GAS. Importantly, 5448.fr RR
and 5448.fruBR revertant strains either partially or co letely re-
stored the phenotype to wild-type levels (Fig. 5B). These phen -
types were recapitulated with freshly isolated human PMNs (Fig.
5C), supporting a requirement for FruB and FruR, but not FruA,
for survival in human neutrophils. There was also a survival defect
observed for the 5448.!fruR or 5448.!fruB mutant, but not the
5448.!fruA mutant, in human monocytes, suggesting a role for
these fru operon genes in evading killing by different phagocytic
cell types (Fig. 5D). To account for a defect in growth for any of the
fru operon mutants, we also grew each strain in RPMI plus 20%
lasma and saw no growth defect compared to the parental 5448


































































































































































FIG 5 fruR and fruB are important for survival in human blood and phagocytic cells. In all assays, wild-type 5448 (black bars) was compared to 5448.!fruR
(white bars), 5448.!fruB (light gray bars), and 5448.!fruA (dark gray bars) mutants for growth and survival. The respective rescued mutant strains are indicated
with diagonal lines. (A) Lancefield bactericidal assay was performed by monitoring growth in whole human blood with rotation at 37°C for 3 h. Data are
presented as percent growth in blood corresponding to the multiplication factor (MF) of the mutant divided by the MF of the wild type times 100. Error bars
represent means " SD of the results of six independent experiments. (B) Survival in neutrophil-like HL60 cells. GAS (1 # 105 CFU/well) and HL60 cells (1 # 106
CFU/well) were incubated for 2 h at 37°C. Cells were lysed and the percentage of surviving GAS CFU was determined relative to the level of survival for 5448. (C)
Survival in human neutrophils (PMNs). GAS (1 # 105 CFU/well) and neutrophils (1 # 106 CFU/well) were incubated for 2 h at 37°C. Neutrophils then were
lysed, and the percentage of surviving GAS CFU was determined and is shown as survival relative to that of the WT (5448). (D) Survival in human monocytes.
GAS (1 # 105 CFU/well) and human monocytic cells (1 # 106 CFU/well) were incubated for 2 h at 37°C. Cells were lysed, and the percentage of surviving GAS
CFU was determined relative to that for survival of 5448. Error bars in panels B to D represent means " SD of the results from three biological replicates
performed in triplicate. Significance for panel A was determined using a Student t test (P ! 0.0015), while significance for panels B to D was determined by
unpaired t test (P $ 0.05).
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Figure S7: 5448 and ∆fruRBA Growth in RPMI+ 20% Plasma. Each fru mutant was grown along with the 
parental strain 5448 in RPMI + 20% plasma. Data from 6 independent experiments, with at least three 
replicates for each fru operon mutant in comparison to WT 5448 are show  in (A). The cumulative results o  
(A) are shown as an average of the replicates in (B).   
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Figure S7: 5448 and ∆fruRBA Growth in RPMI+ 20% Plasma. Each fru mu ant was grown along with the 
parental strain 5448 in RPMI + 20% plasma. Data from 6 ind pendent experiments, with at least three 
replicates for each fru operon mutant in comparison to WT 5448 are show  in (A). The c mulative results of 
(A) are shown as an average of th  replicates in (B).   
Figure 6.2. fruR and fruB are important for survival in human blood. Wild-type 5448 
(black bars) was compared to 5448.∆fruR (white bars), 5448.∆fruB (light gray bars), and 
5448.∆fruA (dark gray bars) mutants for growth and survival. The respective rescued 
mutant strains are indicated with diagonal lines. (A) Lancefield bactericidal assay was 
performed by monitoring growth in whole human blood with rotation at 37°C for 3 h. Data 
are presented as percent growth in blood corresponding to the multiplication factor (MF) 
of the mutant divided by the MF of the wild type times 100. Error bars represent means SD 
of the results of six independent experiments. (B) Colony morphology of each fru mutant 
was streaked on blood agar (TSA + 5% sheep blood) plates, cultured overnight at 37oC + 
5% CO2 and imaged. * Performed by Y.L.B and K.M.V 
lacD.2-specific PTS operons, the maltose-specific ABC transport system (malADC), and 
the predicted fructose operon (fruRBA). Of these, the putative fruRBA operon was the most 
highly induced by fructose, with more than a 5-fold increase in expression (Table 6.1). In 
addition, several members of the SerR regulon involved in serine metabolism were induced 
by fructose (LaSarre & Federle, 2011), including genes encoding the putative regulator 
SloR, the V-type sodium ATP synthase (ntp) operon, and the serine dehydratase (sdhAB) 
operon. Interestingly, sloR is predicted to encode a transmembrane protein that exhibits 
homology to the EIIC domain of the putative FruA PTS transporter. Notably, only six 
genes, including nagB and nagA, involved in N-acetylglucosamine metabolism, appeared 
to be repressed in the presence of fructose. Overall, the two largest gene ontology categories 
found to be induced by fructose were carbohydrate transport and metabolism (33 genes;
103
32% COGxxxxG) and energy production conversion (9 genes; 9% COGxxxxC). Therefore, 
the presence of fructose influences the expression of a subset of sugar metabolism genes, 
particularly the predicted fruRBA fructose utilization operon.
fruRBA is transcribed as an operon
 In the 5448 genome, the fru locus is comprised of three contiguous genes (Fig. 6.3 
and Table 6.1): fruR, encoding a predicted transcriptional repressor; fruB, encoding the 
enzyme 1-phosphofructokinase; and fruA, encoding a predicted fructose-specific EIIABC 
component of the sugar PTS. Each of the three genes slightly overlap, with the start codon 
of the gene downstream being found in the upstream gene, suggesting they form an operon. 
RT-PCR of transcripts from 5448 grown in CDM plus 1% fructose showed transcriptional 
linkage between fruB-fruA and fruR-fruB, and a 1.5-kb full- length transcript was 
detected between fruR and fruA (Fig. 6.3A). These data demonstrate that fruRBA genes 
are expressed as an operon during inducing growth in fructose as the sole carbon source. 
 To determine the transcriptional start site (TSS) of the fru operon, 5’-RACE 
was used in conjunction with a primer complementary to fruR (FruR SP1) (Table 3.2). 
A TSS that was located near the classical -10 (TATAAT) and -35 (TTGACT) promoter 
hexamers was identified 56 bp upstream of the start codon for fruR (Fig. 6.3B). A 
predicted CcpA-binding site (cre) site (Kietzman & Caparon, 2010) and FruR-binding 
site (Barriere et al., 005) also were identified overlapping and upstream of the promoter, 
respectively (Fig. 6.3C). Finally, a putative rho-independent terminator was detected 
downstream of fruA, consistent with the generation of the full-length fruRBA transcript 
(Fig. 6.3C). Thus, the promoter of the fruRBA operon appears to be under CcpA-
mediated catabolite repression by glucose and FruR-mediated induction by fructose. 
 To interrogate each gene in the fru operon for its role in fructose metabolism and 
virulence, we generated nonpolar deletions for fruR, fruB, and fruA by allelic exchange 
in the 5448 genome with an chloramphenicol resistance cassette (cat) (Rose, 1988), 
104
Table 6.1. Subset of genes differentially expressed in fructose *Performed by K.M.V
generating the 5448.∆fru , 5448.∆fruB, and 5448.∆fruA mutant strains (Table 3.1). These 
mutations subse uently were verified by PC  (data not shown). Due to the translational 
overlap between the genes in the fru operon, we wanted to further ensure that the mutations 
generated for each individual gene did not influence the expression of the gene downstream. 
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TABLE 3 Subset of genes differentially expressed in fructoseb
Spy no. Annotation Gene name Log2 fold change
a
Induced by fructose
M5005_Spy_0039 Alcohol dehydrogenase/acetaldehyde dehydrogenase adh.2 !2.10
M5005_Spy_0123 Translation initiation inhibitor !1.82
M5005_Spy_0124 Serine catabolism regulator; FruA-like EIIC domain protein sloR !2.32
M5005_Spy_0125 Hypothetical protein !1.09
M5005_Spy_0126 V-type sodium ATP synthase subunit I ntpI !2.01
M5005_Spy_0127 V-type sodium ATP synthase subunit K ntpK !1.97
M5005_Spy_0128 V-type sodium ATP synthase subunit E ntpE !2.22
M5005_Spy_0129 V-type sodium ATP synthase subunit C ntpC !1.79
M5005_Spy_0130 V-type sodium ATP synthase subunit F ntpF !1.22
M5005_Spy_0131 V-type sodium ATP synthase subunit A ntpA !1.24
M5005_Spy_0132 V-type sodium ATP synthase subunit B ntpB !0.96
M5005_Spy_0133 V-type sodium ATP synthase subunit D ntpD !1.21
M5005_Spy_0150 PTS, 3-keto-l-gulonate-specific IIA ptxA !0.99
M5005_Spy_0474 Transcription antiterminator, BglG family licT !1.36
M5005_Spy_0476 6-Phospho-beta-glucosidase bglA !1.22
M5005_Spy_0521 PTS, N-acetylgalactosamine-specific IIB agaV !1.75
M5005_Spy_0660 Fructose repressor fruR !1.95
M5005_Spy_0661 1-Phosphofructokinase fruB !2.52
M5005_Spy_0662 PTS, fructose-specific IIABC fruA !3.33
M5005_Spy_0798 IFN response binding factor 1 !1.01
M5005_Spy_1062 Maltodextrose utilization protein malA !1.12
M5005_Spy_1063 ABC cyclomaltodextrin permease protein malD !1.17
M5005_Spy_1081 PTS, cellobiose-specific IIA component !0.98
M5005_Spy_1307 Hypothetical membrane spanning protein !1.02
M5005_Spy_1308 ABC unknown sugar-binding protein !1.16
M5005_Spy_1309 ABC unknown sugar permease protein !1.82
M5005_Spy_1310 ABC unknown sugar permease protein !1.40
M5005_Spy_1395 Tagatose-bisphosphate aldolase; SpeB regulator lacD.1 !1.01
M5005_Spy_1396 Tagatose-6-phosphate kinase; regulatory lacC.1 !1.35
M5005_Spy_1397 Galactose-6-phosphate isomerase LacB subunit; regulatory lacB.1 !1.54
M5005_Spy_1400 PTS, galactose-specific IIB component !1.45
M5005_Spy_1401 PTS, galactose-specific IIA component !1.14
M5005_Spy_1509 Pyruvate, phosphate dikinase !1.36
M5005_Spy_1510 Pyruvate, phosphate dikinase !1.26
M5005_Spy_1629 Lantibiotic transport ATP-binding protein salX !1.89
M5005_Spy_1631 Lantibiotic salivaricin A salA !1.67
M5005_Spy_1632 6-Phospho-beta-galactosidase lacG !1.66
M5005_Spy_1633 PTS, lactose-specific IIBC component lacE !2.73
M5005_Spy_1634 PTS, lactose-specific IIA component lacF !2.22
M5005_Spy_1635 Tagatose-bisphosphate aldolase lacD.2 !2.18
M5005_Spy_1636 Tagatose-6-phosphate kinase lacC.2 !1.49
M5005_Spy_1637 Galactose-6-phosphate isomerase LacB subunit lacB.2 !1.67
M5005_Spy_1638 Galactose-6-phosphate isomerase LacA subunit lacA.2 !1.50
M5005_Spy_1663 PTS, mannitol-specific IIB component !1.69
M5005_Spy_1744 PTS, cellobiose-specific IIC component celC !1.34
M5005_Spy_1745 PTS, cellobiose-specific IIB component celB !0.95
M5005_Spy_1841 l-Serine dehydratase sdhB !1.06
M5005_Spy_1842 l-Serine dehydratase sdhA !1.27
Repressed by fructose
M5005_Spy_0667 Exotoxin type C precursor 2.07
M5005_Spy_1139 Glucosamine-6-phosphate isomerase nagB 0.98
M5005_Spy_1388 N-Acetylglucosamine-6-phosphate deacetylase nagA 0.97
M5005_Spy_1574 Universal stress protein family 2.05
M5005_Spy_1575 Quinolone resistance protein norA 2.33
M5005_Spy_1746 PTS, cellobiose-specific IIA component celA 1.02
a Log2 fold changes were determined by comparing CDM-glu/CDM-fru values.
b Entries in boldface type indicate the fruRBA operon.
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aLog2 fold changes were determined by comparing CDM-glu/CDM-fru values
b Entries in boldface type indicatemthe fruRBA operon
* shading indicates metabolic genes
106
mutation (5448.fruAR) restored growth in fructose back to wild-
type levels (Fig. 2B and E; also see Fig. S5). Both 5448.!fruR and
5448.!fruB strains also displayed significant growth defects in
CDM supplemented with 1% fructose that were restored in the
revertant (Fig. 2C and D). These data suggest that FruA is the
primary EII transporter of fructose in GAS 5448 and that FruB and
FruR also are required for growth on fructose as the sole carbon
source.
Due to the growth defect that was exhibited by a !fruA mutant,
we also wanted to ascertain if fruA affects the utilization of other
carbon sources. We used Biolog PM1 and PM2A phenotype mi-
croarrays (PMs) to monitor the metabolism of 190 different car-
bon sources of the !fruA strain. The parental GAS 5448 and
5448.!fruA strains were different in their utilization of 72 carbon
sources (data not shown), 3 of which are designated PTS sugars
(N-acetyl-D-galactosamine, cellobiose, and mannitol) (Table 4).
Surprisingly, fructose was not identified in the Biolog assay as
having a defect in metabolism (Table 4). This suggests that there is
another PTS transporter that is able to transport fructose, al-
though at levels that do not sustain wild-type growth (Fig. 2B and
E; also see Fig. S5 in the supplemental material). To confirm this
observation, wild-type 5448 and 5448.!fruA strains also were
tested using a bioMérieux API 50 strip that tests the utilization of
a subset of 50 carbohydrates (Fig. 3). As seen with Biolog, the
5448.!fruA strain was able to utilize fructose similarly to 5448 in
this assay; however, the fructose utilization is insufficient to sup-
port growth. We also tested 5448.!fruB and 5448.!fruR strains
using the API 50 strips. Like the 5448.!fruA strain, both the !fruR
and !fruB mutants were able to utilize fructose, even though nei-
ther was able to grow on fructose as the sole carbon source (Fig. 3).
Taken together, these data suggest that fruA is required for opti-
mal growth on fructose and that FruA is the main fructose trans-
porter for GAS. Since a PTS-defective mutant (!ptsI) of M1T1
GAS is defective for the utilization of fructose in the Biolog assay
(12), there appears to be another PTS EII that is able to transport
fructose to be metabolized, albeit not at the levels necessary to
support GAS growth on fructose. Finally, the loss of fruA affects
the utilization of other carbon sources; however, this is unsurpris-
ing, because a !ptsI mutant also affects the utilization of non-PTS
carbon sources through currently unknown mechanisms.
Effect of fructose on sloR. The RNA-Seq data (Table 3)
showed that several members of the SerR regulon (43) were up-
regulated in fructose, including sloR, the putative streptolysin O
regulator (44). In silico analysis of sloR showed nine transmem-
brane domains that exhibited a high degree of homology to a
fructose-specific EIIC. Given that a !fruA mutant still could uti-
lize fructose (Table 4 and Fig. 2E and 3; also see Fig. S5 in the
supplemental material), we wanted to explore the role of SloR in
fructose utilization and transport in addition to confirming its
regulation in fructose.
An insertional inactivation mutant of sloR (5448.!sloR strain;
Table 1) was generated using a temperature-sensitive replicating
plasmid. The growth of the 5448.!sloR mutant in CDM plus 1%
fructose was found to be comparable to that of wild-type 5448 (see
Fig. S6B in the supplemental material), suggesting that SloR does
not play a role in fructose uptake. We also tested the effect SloR
ATTTGATAGATTTTGAAAGGTTATGCTTGACTTTTAGTTATAAAATAGTATAATAATTGTAAACGATTTCAGTTAGGGGTGGTT
-35 -10 cre site FruR site +1 





































































FIG 1 Expression of fruRBA genes in individual fru mutants and their rescue strains in THY. (A) Genetic organization of fruR (encoding a transcriptional
regulator), fruB (encoding 1-phosphofructokinase), and fruA (encoding PTS fructose-specific EIIABC) is shown. The magnified region indicates promoter
sequences, including putative FruR and CcpA (cre) binding sites (underlined). Solid lines indicate transcription linkage found by RT-PCR. The transcriptional
start site is indicated by an arrow, and the "10 and "35 positions are shown. (B to D) Real-time qPCR analyses of relative transcript levels for each gene in the
fru operon in individual mutants and their respective rescue strains in fruR (B), fruB (C), and fruA (D) compared to levels for wild-type 5448 grown in THY to
late log phase. Probes targeted gene regions as indicated by the dotted line in panel A. Error bars represent the standard errors from three biological replicates.
Dashed lines indicate 2-fold significance. Significance was determined using comparisons of transcript levels relative to those of the gyrA gene.
Characterization of the fruRBA Operon in M1T1 GAS
April 2016 Volume 84 Number 4 iai.asm.org 1023Infection and Immunity







mutation (5448.fruAR) restored growth in fructose back to wild-
type levels (Fig. 2B and E; also see Fig. S5). Both 5448.!fruR and
5448.!fruB strains also displayed significant growth defects in
CDM supplemented with 1% fructose that were restored in the
revertant (Fig. 2C and D). These data suggest that FruA is the
primary EII transporter of fructose in GAS 5448 and that FruB and
FruR also are required for growth on fructose as the sole carbon
source.
Due to the growth defect that was exhibited by a !fruA mutant,
we also wanted to ascertain if fruA affects the utilization of other
carbon sources. We used Biolog PM1 and PM2A phenotype mi-
croarrays (PMs) to monitor the metabolism of 190 different car-
bon sources of the !fruA strain. The parental GAS 5448 and
5448.!fruA strains were different in their utilization of 72 carbon
sources (data not shown), 3 of which are designated PTS sugars
(N-acetyl-D-galactosamine, cellobiose, and mannitol) (Table 4).
Surprisingly, fructose was not identified in the Biolog assay as
having a defect in metabolism (Table 4). This suggests that there is
another PTS transporter that is able to transport fructose, al-
t ough at levels that do not sustain wild-type growth (Fig. 2B and
E; also see Fig. S5 in the supplemental material). T confirm this
observation, wild-type 5448 and 5448.!fruA strains also were
tested using a bioMérieux API 50 strip hat tests the utilization of
a subset of 50 carbohydrates (Fig. 3). As seen with Biolog, the
5448.!fruA strain was able to utilize fructose similarly to 5448 in
this assay; however, the fructose utilization is insufficient to sup-
port growth. We also tested 5448.!fruB and 5448.!fruR strains
using the API 50 strips. Like the 5448.!fruA strain, both the !fruR
and !fruB mutants were able to utilize fructose, even though nei-
ther was able to grow on fructose as the sole carbon source (Fig. 3).
Taken together, these data suggest that fruA is required for opti-
mal growth on fructose and that FruA is the main fructose trans-
porter for GAS. Since a PTS-defective mutant (!ptsI) of M1T1
GAS is defective for the utilization of fructose in the Biolog assay
(12), there appears to be another PTS EII that is able to transport
fructose to be metabolized, albeit not at the levels necessary to
support GAS growth on fructose. Finally, the loss of fruA affects
the utilization of other carbon sources; however, this is unsurpris-
ing, because a !ptsI mutant also affects the utilization of non-PTS
carbon sources through currently unknown mechanisms.
Effect of fructose on sloR. The RNA-Seq data (Table 3)
showed that several members of the SerR regulon (43) were up-
regulated in fructose, including sloR, the putative streptolysin O
regulator (44). In silico analysis of sloR showed nine transmem-
brane domains that exhibited a high degree of ho ology to a
fructose-specific EIIC. Given that a !fru utant still could uti-
lize fructose (Table 4 and Fig. 2E and 3; als see i . i t e
supplemental material), we wanted to expl r t l f l i
fructose utilization and transport in additi i its
regulation in fructose.
An insertional inactivation mutant of slo t i ;
Table 1) was generated using a temperature-s l ti g
plasmid. The growth of the 5 48.!sloR uta t i l s
fructose was found to be comparable to that of ild-type 5448 (see
Fig. S6B in the supplemental material), suggesting that SloR does
not play a role in fructose uptake. e also tested the effect SloR
ATTTGATAGATTTTGAAAGGTTATGCTTGACTTTTAGTTATAAAATAGTATAATAATTGTAAACGATTTCAGTTAGGGGTGGTT
-35 -10 cre site FruR site +1 





































































FIG 1 Expression of fruRBA genes in individual fru mutants and their rescue strains in THY. (A) Genetic organization of fruR (encoding a transcriptional
regulator), fruB (encoding 1-phosphofructokinase), and fruA (encoding PTS fructose-specific EIIABC) is shown. The magnified region indicates promoter
sequences, including putative FruR and CcpA (cre) binding sites (underlined). Solid lines indicate transcription linkage found by RT-PCR. The transcriptional
start site is indicated by an arrow, and the "10 and "35 positions are shown. (B to D) Real-time qPCR analyses of relative transcript levels for each gene in the
fru operon in individual mutants and their respective rescue strains in fruR (B), fruB (C), and fruA (D) compared to levels for wild-type 5448 grown in THY to
late log phase. Probes targeted gene regions as indicated by the dotted line in panel A. Error bars represent the standard errors from three biological replicates.
Dashed lines indicate 2-fold significance. Significance was determined using comparisons of transcript levels relative to those of the gyrA gene.
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Fig S3: fruRBA is an operon in GAS M1T1 5448. (A) RT-PCR on RNA isolated from 5448 grown in CDM + 1% fructose 
demonstrating transcriptional linkage between fruR/fruB, fruB/fruA, and fruR/fruA.  Reactions were run using specific 
primers (Table 2) either with reverse transcriptase (+RT), without reverse transcriptase (-RT) as a negative control, and  
using genomic DNA (gDNA) as a positive control.  Expected sizes of bands are indicated. (B) The transcriptional start site 
(+1) was determined by 5’-RACE and subsequent DNA sequencing (gray bar) from 5448 grown in THY and CDM + 1% 
fructose.  
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Fig S3: fruRBA is an operon in GAS M1T1 5448. (A) RT-PCR on RNA isolated from 5448 grown in CDM + 1% fructose 
demonstrating transcriptional linkage between fruR/fruB, fruB/fruA, and fruR/fruA.  Reactions were run using specific 
primers (Table 2) either with reverse transcriptase (+RT), without reverse transcriptase (-RT) as a negative control, and  
using genomic DNA (gDNA) as a positive control.  Expected sizes of bands are indicated. (B) The transcriptional start site 
(+1) was determined by 5’-RACE and subsequent DNA sequencing (gray bar) from 5448 grown in THY and CDM + 1% 
fructose.  
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Figure 6.3 fruRBA is an operon in GAS M1T1 5448 (A) RT-PCR on RNA isolated 
from 5448 grown in CDM + 1% fructose demonstrating transcriptional linkage between 
fruR/fruB, fruB/fruA, and fruR/fruA. eactions were run using specific primers (Table 
3.1) either with reverse transcriptase (+RT), without reverse transcriptase (-RT) as a 
negative control, and using genomic DNA (gDNA) as a positive control. Expected sizes 
of bands are indicated. (B) The transcriptional start site (+1) was determined by 5’-RACE 
and subsequent DNA sequencing (gray bar) from 5448 grown in THY and CDM + 1% 
fructose. (C) Genetic organization of fruR (encoding a transcriptional regulator), fruB 
(encoding 1-phosphofructokinase), and fruA (encod ing PTS fructose-specific EIIABC) 
is shown. The magnified region indicates promoter se uences, including putative Fru  
and CcpA (cre) binding sites (underlined). Solid lines indicate transcription linkage found 
by RT-PCR. Dashed lines represent probes for qRT-PCR to measure transcript levels. The 
transcriptional start site is indicated by an arrow, and the 10 and 35 positions are shown. 
(D to F) Real-time qPCR analyses of relative transcript levels for each gene in the fru 
operon in individual mutants and their respective rescue strains in fruR (D), fruB ( ), and 
fruA (F) compared to levels for wild-type 5448 grown in THY to late log phase. Probes 
targeted gene regions as indicated by the dotted line in panel A. Error bars represent the 
standard errors from three biological replicates. Dashed lines indicate -fold significance. 
Significance was determined using comparisons of transcript levels relative to those of the 
gyrA gene. *Performed by K.M.V
qRT-PCR was utilized to assess this using probes centered on each gene, as shown in Fig. 
6.3C, for each individual mutant with RNA isolated during late-logarithmic phase in THY. 
The data for fruR, fruB, and fruA mutants show that the transcript levels for each mutant 
were significantly reduced (Fig. 6.3D-F). Revertant strains for each mutant restored the 
transcript levels of that gene. Importantly, the transcript levels of the other genes in the 
operon were unaffected by other individual mutations, as expected due to the operon being 
under CCR in THY. Thus, the mutations made in the fru operon genes were nonpolar, and 
their transcript levels could be restored via reversion (Fig 6.3D-F).
FruR is a repressor of the fruRBA operon
 In other streptococci, fruR encodes a putative DeoR-like repressor in the family 
of carbohydrate regulatory proteins (Loo et al., 2003, Barriere et al., 2005, Wen et al., 
001). To confirm that Fru  is a repressor of the fru operon, we grew wild-type 5448 and 
the 5448.∆fruR mutant under both catabolite-repressing (glucose) and inducing (fructose) 
conditions in order to isolate RNA for qRT-PCR. Growth in CDM plus 0.5% glucose (Fig. 
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6.4A) was successful; however, when fructose was the sole carbon source available, the 
fruR strain failed to grow (Fig. 6.4A and 6.8B). In order to generate appropriate cell density 
to extract NA, we applied a modified diauxic growth condition. Both the T and the fruR 
strain were grown in CDM plus 0.5% glucose to late logarithmic phase, washed twice, and 
transferred for growth in either CDM plus 1% fructose or CDM plus 0.5% glucose for 1 
h. PC  was used to determine the effect of the 5448.∆fruR mutant on the transcription 
of fruB and fruA using RNA from cells grown in either fructose or glucose. When we 
compared WT 5448 growth in glucose to that in fructose, we saw an increase in transcript 
levels across the entire operon (Fig. 6.4B, black bars), mirroring what we saw in the RNA-
Seq results (Table 6.1). Comparing T 5448 grown in fructose to the 5448.∆fruR mutant 
grown in fructose, an increase in fruB and fruA transcript levels is observed, indicating 
that FruR acts as a repressor of this operon (Fig. 6.4B, checkered bars). Furthermore, an
even larger increase in transcript levels for fruB and fruA in the 5448.∆fruR mutant was 
observed when it was grown in glucose than when it was grown in fructose, indicating that 
the operon is also under carbon catabolite repression (CCR) (Fig. 6.4B, diagonal bars).
 To confirm the role of Fru  in the repression of the fru operon, a luciferase reporter 
assay was performed using the mapped promoter region of the operon (PfruR). A significant 
increase in luciferase activity was observed only when WT 5448 containing the PfruR-luc 
construct was grown in CDM plus 1% fructose as opposed to 0.5% glucose or 1% sucrose 
or mannose (Fig. 6.4C), indicating the induction of the operon is fructose dependent. 
When the same assay was performed in the fruR background, there was an overall increase 
in luciferase activity for all sugars tested (Fig. 6.4C). Therefore, both FruR and CcpA 
negatively control the expression of the fru operon, and fructose (after conversion to 
fructose-1-phosphate) likely acts as an inducer of the operon through inactivation of FruR.
FruA is required for optimal growth and utilization of fructose by GAS 5448
 FruA is predicted to be a fusion of the EIIA, EIIB, and EIIC enzyme subunits
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Figure 6.4. FruR represses expression of the fruRBA operon. (A) Growth of 5448 
(black) or the 5448.∆fruR mutant (gray) strain under modified diauxic conditions. Cells 
were grown in CDM plus 0.5% glucose (solid line) to late log phase (To), washed, and 
transferred into CDM with either 0.5% glucose (solid line) or 1% fructose (dashed 
line). Cells were outgrown for 1 h (T1h) in either sugar for RNA extraction. (B) 
Transcript levels of fru operon genes were measured by qRT- PCR with respect to growth
condition. 5448 grown in fructose compared to growth in glucose (black bars), the 
5448.∆fruR mutant grown in fructose compared to growth in glucose (diagonal bars), and 
the 5448.∆fruR mutant grown in fructose compared to growth in WT 5448 (checkered 
bars) are shown. Error bars represent the standard errors from two biological replicates. 
Differences greater than 2-fold in expression for the mutant compared with that of the wild 
type (denoted by a dashed line) are considered significant. Significance was determined 
using comparisons of transcript levels relative to those of the gene gyrA. (C) PfruR promoter 
activity in WT 5448 containing the PfruR-luc luciferase reporter plasmid was grown in 
CDM containing 0.5% glucose or 1% fructose, mannose, or sucrose. Samples were taken 
at the mid-logarithmic phase of growth and assayed for luciferase production, expressed 
in relative luciferase units (LU). Error bars represent means standard deviations (SD) of 
results from three biological replicates performed in triplicate. Significance for panel C 
was determined by comparison of results for growth in fructose, mannose, or sucrose to 
those for growth in glucose using an unpaired t test (P 0.001). Performed by .M. .
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S2, blue bar). Additionally, an expression reporter plasmid was
constructed by cloning the promoter of sloR (PsloR) upstream of
the firefly luciferase gene (luc), and activity was determined
through the quantification of relative luciferase units (LU). A sig-
nificant increase in PsloR-luciferase activity was observed when
cells were grown in fructose compared to sucrose (see Fig. S6A).
To rule out that FruR regulates sloR, we also tested sloR transcript
levels in a !fruR strain grown in fructose and glucose using qPCR
and saw no observable difference (data not shown). Taken to-
gether, we show that sloR induction is a fructose-specific pheno-
type; however, this induction is independent of FruR. We also
show that sloR is not an alternative transporter of fructose.
FruR is a repressor of the fruRBA operon. In other strepto-
cocci, fruR encodes a putative DeoR-like repressor in the family of
carbohydrate regulatory proteins (13, 18, 45). To confirm that
FruR is a repressor of the fru operon, we grew wild-type 5448 and
the 5448.!fruR mutant under both catabolite-repressing (glu-
cose) and -inducing (fructose) conditions in order to isolate RNA
for qPCR. Growth in CDM plus 0.5% glucose (Fig. 4A) was suc-
cessful; however, when fructose was the sole carbon source avail-
able, the !fruR strain failed to grow (Fig. 2C and 4A). In order to
generate appropriate cell density to extract RNA, we applied a
modified diauxic growth condition. Both the WT and the !fruR
strain were grown in CDM plus 0.5% glucose to late logarithmic
phase, washed twice, and transferred for growth in either CDM
plus 1% fructose or CDM plus 0.5% glucose for 1 h. qPCR was
used to determine the effect of the 5448.!fruR mutant on the
transcription of fruB and fruA using RNA from cells grown in
either fructose or glucose. When we compared WT 5448 growth in
glucose to that in fructose, we saw an increase in transcript levels
across the entire operon (Fig. 4B, black bars), mirroring what we
saw in the RNA-Seq results (Table 3). Comparing WT 5448 grown
in fructose to the 5448.!fruR mutant grown in fructose, an in-
crease in fruB and fruA transcript levels is observed, indicating that
FruR acts as a repressor of this operon (Fig. 4B, checkered bars).
Furthermore, an even larger increase in transcript levels for fruB
and fruA in the 5448.!fruR mutant was observed when it was
grown in glucose than when it was grown in fructose, indicating
that the operon is also under carbon catabolite repression (CCR)
(Fig. 4B, diagonal bars).
To confirm the role of FruR in the repression of the fru operon,
a luciferase reporter assay was performed using the mapped pro-
moter region of the operon (PfruR). A significant increase in lu-
ciferase activity was observed only when WT 5448 containing the
PfruR-luc construct was grown in CDM plus 1% fructose as op-
posed to 0.5% glucose or 1% sucrose or mannose (Fig. 4C), indi-
cating the induction of the operon is fructose dependent. When
the same assay was performed in the !fruR background, there was
an overall increase in luciferase activity for all sugars tested (Fig.
4C). Therefore, both FruR and CcpA negatively control the ex-
pression of the fru operon, and fructose (after conversion to fruc-
tose-1-phosphate) likely acts as an inducer of the operon through
inactivation of FruR.
fruB and fruR, but not fruA, are important for 5448 survival
in whole human blood. The fruA gene was identified as being
important for GAS survival in whole human blood during a ge-
nome-wide TraSH screen (15). To determine the step in fructose
utilization that might be involved in GAS survival in blood, we
performed Lancefield bactericidal assays on each of the nonpolar
fru operon mutants and their respective revertant strains. Inter-
estingly, both 5448.!fruR and 5448.!fruB strains exhibited de-
creased survival in whole human blood relative to that of the pa-
rental GAS 5448 (Fig. 5A). Surprisingly, the 5448.!fruA mutant
did not show a significant decrease in survival in human blood,























































































5448. fruR + pKSM944
FIG 4 FruR represses expression of the fruRBA operon. (A) Growth of 5448
(black) or the 5448.!fruR mutant (gray) strain under modified diauxic condi-
tions. Cells were grown in CDM plus 0.5% glucose (solid line) to late log phase
(To), washed, and transferred into CDM with either 0.5% glucose (solid line) or
1% fructose (dashed line). Cells were outgrown for 1 h (T1 h) in either sugar for
RNA extraction. (B) Transcript levels of fru operon genes were measured by qRT-
PCR with respect to growth condition. 5448 grown in fructose compared to
growth in glucose (black bars), the 5448.!fruR mutant grown in fructose com-
pared to growth in glucose (diagonal bars), and the 5448.!fruR mutant grown in
fructose compared to growth in WT 5448 (checkered bars) are shown. Error bars
represent the standard errors from two biological replicates. Differences greater
than 2-fold in expression for the mutant compared with that of the wild type
(denoted by a dashed line) are considered significant. Significance was determined
using comparisons of tra script levels relative to those of the gene gyrA. (C) PfruR
promoter activity in WT 5448 containing the PfruR-luc luciferase reporter plasmid
was grown in CDM containing 0.5% glucose or 1% fructose, mannose, or sucrose.
Samples were taken at the mid-logarithmic phase of growth and assayed for lucif-
erase production, expressed in relative luciferase units (LU). Error bars represent
means " standard deviations (SD) of results from three biological replicates per-
formed in triplicate. Significance for panel C was determined by comparison of
results for growth in fructose, mannose, or sucrose to those for growth in glucose
using an unpaired t test (P ! 0.001).
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S2, blue bar). Additionally, an expression reporter plasmid was
constructed by cloning the promoter of sloR (PsloR) upstream of
the firefly luciferase gene (luc), and activity was determined
through the quantification of relative luciferase units (LU). A sig-
nificant increase in PsloR-luciferase activity was observed when
cells were grown in fructose compared to sucrose (see Fig. S6A).
To rule out that FruR regulates sloR, we also tested sloR transcript
levels in a !fruR strain grown in fructose and glucose using qPCR
and saw no observable difference (data not shown). Taken to-
gether, we show that sloR induction is a fructose-specific pheno-
type; however, this induction is independent of FruR. We also
show that sloR is not an alternative transporter of fructose.
FruR is a repressor of the fruRBA operon. In other strepto-
cocci, fruR encodes a putative DeoR-like repressor in the family of
carbohydrate regulatory proteins (13, 18, 45). To confirm that
FruR is a repressor of the fru operon, we grew wild-type 5448 and
the 5448.!fruR mutant under both catabolite-repressing (glu-
cose) and -inducing (fructose) conditions in order to isolate RNA
for qPCR. Growth in CDM plus 0.5% glucose (Fig. 4A) was suc-
cessful; however, when fructose was the sole carbon source avail-
able, the !fruR strain failed to grow (Fig. 2C and 4A). In order to
generate appropriate cell density to extract RNA, we applied a
modified diauxic growth condition. Both the WT and the !fruR
strain were grown in CDM plus 0.5% glucose to late logarithmic
phase, washed twice, and transferred for growth in either CDM
plus 1% fructose or CDM plus 0.5% glucose for 1 h. qPCR was
used to determine the effect of the 5448.!fruR mutant on the
transcription of fruB and fruA using RNA from cells grown in
either fructose or glucose. When we compared WT 5448 growth in
glucose to that in fructose, we saw an increase in transcript levels
across the entire operon (Fig. 4B, black bars), mirroring what we
saw in the RNA-Seq results (Table 3). Comparing WT 5448 grown
in fructose to the 5448.!fruR mutant grown in fructose, an in-
crease in fruB and fruA transcript levels is observed, indicating that
FruR acts as a repressor of this operon (Fig. 4B, checkered bars).
Furthermore, an even larger increase in transcript levels for fruB
and fruA in the 5448.!fruR mutant was observed when it was
grown in glucose than when it was grown in fructose, indicating
that the operon is also under carbon catabolite repression (CCR)
(Fig. 4B, diagonal bars).
To confirm the role of FruR in the repression of the fru operon,
a luciferase reporter assay was performed using the mapped pro-
moter region of the operon (PfruR). A significant increase in lu-
ciferase activity was observed only when WT 5448 containing the
PfruR-luc construct was grown in CDM plus 1% fructose as op-
posed to 0.5% glucose or 1% s crose or mann se (Fig. 4C), indi-
cating the induction of the operon is fruct se dependent. When
the same assay was performed in the !fruR background, there was
an overall increase in luciferase activity for all sugars tested (Fig.
4C). Therefore, both FruR and CcpA negatively control the ex-
pression of the fru op ron, and fructose (after conversi to fruc-
tose-1-phosphate) likely acts as an inducer of the operon through
inactivation of FruR.
fruB and fruR, but not fruA, are important for 5448 survival
in whole human blood. Th fruA gene was identified as being
important for GAS survival in wh le human blood during a ge-
nome-wide TraSH screen (15). To determine the step in fructose
utilization that might be involved in GAS survival in blood, we
performed Lancefield bacterici al assays on ach of the nonpol r
fru operon muta ts and their respective revert nt strains. Int r-
estingly, both 5448.!fruR and 5448.!fruB strains exhibited de-
creased survival in whole human blood relative to that of the pa-
rental GAS 5448 (Fig. 5A). Surprisingly, the 5448.!fruA mutant
did not show a significant decrease in survival in human blood,























































































5448. fruR + pKSM944
FIG 4 FruR represses expression of the fruRBA operon. (A) Growth of 5448
(black) or the 5448.!fruR mutant (gray) strain under modified diauxic condi-
tions. Cells were grown in CDM plus 0.5% glucose (solid line) to late log phase
(To), washed, and transferred into CDM with either 0.5% glucose (solid line) or
1% fructose (dashed line). Cells were outgrown for 1 h (T1 h) in either sugar for
RNA extraction. (B) Transcript levels of fru operon genes were measured by qRT-
PCR with respect to growth condition. 5448 grown in fructose compared to
growth in glucose (black bars), the 5448.!fruR mutant grown in fructose com-
pared to growth in glucose (diagonal bars), and the 5448.!fruR mutant grown in
fructose compared to growth in WT 5448 (checkered bars) are shown. Error bars
represent the standard errors from two biological replicates. Differences greater
than 2-fold in expression for the mutant compared with that of the wild type
(denoted by a dashed line) are considered significant. Significance was determined
using comparisons of transcript levels relative to those of the gene gyrA. (C) PfruR
promoter activity in WT 5448 containing the PfruR-luc luciferase reporter plasmid
was grown in CDM containing 0.5% glucose or 1% fructose, mannose, or sucrose.
Samples were taken at the mid-logarithmic phase of growth and assayed for lucif-
erase production, expressed in relative luciferase units (LU). Error bars represent
means " standard deviations (SD) of results from three biological replicates per-
formed in triplicate. Significance for panel C was determined by comparison of
results for growth in fructose, mannose, or sucrose to those for growth in glucose
using an unpaired t test (P ! 0.001).
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S2, blue bar). Additionally, an expression reporter plasmid was
constructed by cloning the promoter of sloR (PsloR) upstream of
the firefly luciferase gene (luc), and activity was determined
through the quantification of relative luciferase units (LU). A sig-
nificant increase in PsloR-luciferase activity was observed when
cells were grown in fructose compared to sucrose (see Fig. S6A).
To rule out that FruR regulates sloR, we also tested sloR transcript
levels in a !fruR strain grown in fructose and glucose using qPCR
and saw no observable difference (data not shown). Taken to-
gether, we show that sloR induction is a fructose-specific pheno-
type; however, this induction is independent of FruR. We also
show that sloR is not an alternative transporter of fructose.
FruR is a repressor of the fruRBA operon. In other strepto-
cocci, fruR encodes a putative DeoR-like repressor in the family of
carbohydrate regulatory proteins (13, 18, 45). To confirm that
FruR is a repressor of the fru operon, we grew wild-typ 5448 and
the 5448.!fruR mutant under both catabolite-repressing (glu-
cose) and -inducing (fructose) conditions in order to isolate NA
for qPCR. Growth in CDM plus 0.5% glucose (Fig. 4A) was suc-
cessful; however, when fructose was the sole carbon source avail-
able, the !fruR strain failed to grow (Fig. 2C and 4A). In order to
generate appropriate cell density to extract RNA, we applied a
modified diauxic growth condition. Both the WT and the !fruR
strain were grown in CDM plus 0.5% glucose to late logarithmic
phase, washed twice, and transferred for growth in either CDM
plus 1% fructose or CDM plus 0.5% glucose for 1 . qPCR was
used to det rmine the effect of the 5448.!fruR mutant on the
transc i tion of fruB and fruA using RNA from cells grown in
either fructose or glucose. When we compared WT 5448 growth in
glucose to that in fructose, we saw an increase in ranscript levels
across the entire operon (Fig. 4B, black bars), mirroring what we
saw in the RNA-Seq results (Table 3). Comparing WT 5448 grown
in fructose to the 5448.!fruR mutant grown in fructose, an in-
crease in fruB and fruA transcript levels is observed, indicating that
FruR acts as a repressor of this operon (Fig. 4B, checkered bars).
Furthermore, an even larger increase in transcript levels fo fruB
and fruA in the 5448.!fruR mutant was observed when it was
grown in glucose than when it was grown in fructose, indicating
that the operon is also under carbon catabolite repression (CCR)
(Fig. 4B, diagonal bars).
To confirm the role of FruR in the repression of the fru operon,
a luciferase reporter assay was performed using the mapped pro-
moter region of the operon (PfruR). A significant increase in lu-
ciferase activity was observed only when WT 5448 containing the
PfruR-luc construct was grown in CDM plus 1% fructose as op-
posed to 0.5% glucose or 1% sucrose or mannose (Fig. 4C), indi-
cati g the i uction of the operon is fructose ependent. W en
the same assay was performed in the !fruR background, there was
an overall incr ase in luciferase ctivity for all sugars tested (Fig.
4C). Therefore, both FruR and CcpA negatively control the ex-
pression of the fru opero , and fruct se (afte conversion to fruc-
tose-1-phosphate) likely acts as a inducer of the opero through
inactivation of FruR.
fruB and fruR, but not fruA, are important for 5448 survival
in whole human blood. The fruA gene was identified as bei g
important for GAS survival in whole human blood during a ge-
nome-wide TraSH screen (15). To determine the step in f uctose
utilization that might be involved in GAS survival in blood, we
performed Lancefield bactericidal assays on each of the nonpolar
fru operon mutants and their respective revertant strains. Inter-
estingly, both 5448.!fruR and 5448.!fr B strains ex ibite de-
crea ed survival in whol human blood relative that of the pa-
rental GAS 5448 (Fig. 5A). urprisingly, the 5448.!fruA mutant
did not show a signific nt decrease in survival in human blood,























































































5448. fruR + pKSM9 4
FIG 4 FruR represses expression of the fruRBA operon. (A) Growth of 5448
(black) or the 5448.!fruR mutant (gray) strain under modified diauxic condi-
tions. Cells were grown in CDM plus 0.5% glucose (solid line) to late log phase
(To), washed, and transferred into CDM with either 0.5% glucose (solid line) or
1% fructose (dashed line). Cells were outgrown for 1 h (T1 h) in either sugar for
RNA extraction. (B) Transcript levels of fru operon genes were measured by qRT-
PCR with respect to growth condition. 5448 grown in fructose compared to
growth i glu ose (b ack bars), the 5448.!f uR mutant g own in fructose com-
pared t growth in glucose (diagonal bars), and the 5448.!fruR mutant grown in
fructose compared to gro th in WT 5448 (checkered bars) are shown. Error bars
represent the standard errors from two biological replicates. Differences greater
than 2-fold in expression for the mutant compared with that of the wild type
(denoted by a dashed line) are considered significa t. Significance was determined
using comparisons of tra script levels r lative to those f the gene gyrA. (C) PfruR
promoter activity in WT 5448 containing the PfruR-luc luciferase reporter plasmid
was grown in CDM containing 0.5% glucose or 1% f uctos , ma nose, or sucrose.
Samples were taken at th mid-logarithmic phase of growth and assayed for lucif-
erase pr duction, expressed in relative luciferase units (LU). Error bars represent
means " standard deviat ons (SD) of results from three biological rep icates per-
formed in triplicate. Significance f r panel C was determined by comparison of
results for growth in fructose, mannose, or sucrose to those for growth in glucose
using an unpaired t test (P ! 0.001).
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of a fructose-specific PTS EII involved in import and concomitant phosphorylation 
of fructose. To confirm the role of FruA in the utilization of fructose, the 5448.∆fruA 
mutant was grown on a panel of PTS sugars and compared to the parental GAS 5448. 
In order to establish what PTS sugars are amenable to 5448 growth, growth curves in 
CDM supplemented with a 1% (0.5% for glucose) concentration of 11 readily available 
PTS sugars were determined (Fig. 6.5A). WT 5448 was able to grow in 9 of the 11 PTS 
sugars tested  however, mannitol and cellobiose were not conducive to significant growth 
of 5448 and were eliminated from further analysis. hen 5448.∆fruA was grown in the 
remaining 9 PTS sugars, only fructose resulted in reduced growth (Fig. 6.5B and C; Fig 
6.6). Importantly, reversion of the fruA mutation (5448.∆fruAR) restored growth in fructose 
back to wild-type levels (Fig. 6.5C; Fig. 6.6). Both 5448.fruR and 5448.fruB strains also 
displayed significant growth defects in CDM supplemented with 1  fructose that were 
restored in the revertant, but had growth comparable to 5448 in the rich media THY (Fig. 
6.7). These data suggest that FruA is the primary EII transporter of fructose in GAS 5448 
and that FruB and FruR also are required for growth on fructose as the sole carbon source.
 We also wanted to ascertain if fruA affects the utilization of other carbon
sources, as many EIIs were shown to affect the metabolism of multiple carbon sources (see 
Chapter 4). We used Biolog PM1 and PM2A phenotype microarrays (PMs) to monitor the 
metabolism of 190 different carbon sources of the fruA strain. The parental GAS 5448 and 
5448.∆fruA strains were different in their utilization of 72 carbon sources (data not shown), 
3 of which are designated PTS sugars (N-acetyl-D-galactosamine, cellobiose, and mannitol) 
(Table 6.2). Surprisingly, fructose was not identified in the Biolog assay as having a defect 
in metabolism (Table 6.2). This suggests that there is another PTS transporter that is able 
to transport fructose, although at levels that do not sustain wild-type growth (Fig. 6.6). To 
confirm this observation, wild-type 5448 and 5448.∆fruA strains also were tested using a 
bioMérieux API®50 strip that tests the utilization of a subset of 49 carbohydrates (Fig. 6.8). 
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Figure 6.5 Growth analysis of 5448 and fru operon mutants in PTS sugars. (A) Total 
yield was calculated for GAS 5448 grown for 26 h at 37°C with 5% CO2 in various PTS 
sugars as the sole carbon source. (B) Growth rates were determined for 5448 (black bars) 
and 5448.∆fruA (white bars) strains in 9 PTS sugars. The growth of the fruAR revertant 
(gray bar) was assessed for fructose only. Error bars represent standard errors of the means 
from three biological replicates. Statistical analysis was performed using an unpaired t 
test. (C) Growth curve comparison of 5448 to 5448.∆fruA across time. Klett unit relative 
to 5448 at each time point was calculated by taking the percent WT of each individual 
time point, and plotting the median percent WT along with the interquartile range (25-75% 
of the data set). Black bars represent sugars in which 5448.∆fruA grows similarly to the 
parental 5448. Gray bars indicate sugars in which 5448.∆fruA grows poorly compared to 
5448. Black s uare represents growth comparison of 5448.∆fruAR to wildtype. Dashed 
lines represent 2-fold growth above and below 5448.  
As seen with Biolog, the 5448.∆fruA strain was able to utilize fructose similarly to 5448 in 
this assay  however, the fructose utilization is insufficient to support growth. e also tested 
5448.∆fruB and 5448.∆fruR strains using the API 50 strips. Like the 5448.∆fruA strain, 














































































































igure .  fruA has diminished growth in fructose as the sole carbon source. 5448 
(black), ∆fruA (red), and ∆fruAR (blue) were grown in CDM + 1% PTS carbohydrate 
(0.5% glucose) for 26 hours. Error bars represent the standard error of the mean of at least 
three biological replicates. Only carbohydrates that facilitate growth of 5448 are shown. 
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grow on fructose as the sole carbon source (Fig. 6.8). Taken together, these data suggest that 
fruA is required for optimal growth on fructose and that FruA is the main fructose transporter 
for GAS. Since a PTS-defective mutant (∆ptsI) of M1T1 GAS is defective for the utilization 
of fructose in the Biolog assay (Gera et al., 2014),there appears to be another PTS EII that 
is able to transport fructose to be metabolized, albeit not at the levels necessary to support 
GAS growth on fructose. Finally, the loss of fruA affects the utilization of other carbon 
sources; however, this is unsurprising, because a ptsI mutant also affects the utilization 
of non-PTS carbon sources through currently unknown mechanisms (Gera et al., 2014). 
ffect of fructose on sloR
  The RNA-Seq data (Table 6.1) showed that several members of the SerR regulon
















































































































































igure .  rowth curves for the . fruR mutant and its . fruRR revertant, 
. fruB mutant and its . fruBR revertant  and . fruA and its . fruAR 
revertant. Growth in (A) THY or (B) chemically defined medium (CDM) supplemented 
with 1% fructose were measured by absorbance using a Klett-Summerson colorimeter 
(Klett units). Data are representative of three independent experiments. 
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(LaSarre & Federle, 2011) were up-regulated in fructose, including sloR, the putative 
streptolysin O regulator (Savic et al., 2002). In silico analysis of SloR showed nine 
transmembrane domains that exhibited a high degree of homology to a fructose-specific 
EIIC. Given that a fruA mutant still could utilize fructose (Table 6.2 and Fig. 6.8), we 
wanted to explore the role of SloR in fructose utilization and transport in addition to 
confirming its regulation in fructose. An insertional inactivation mutant of sloR (5448. 
∆sloR strain; Table 3.1) was generated using a temperature-sensitive replicating plasmid. 
The growth of the 5448.∆sloR mutant in CDM plus 1% fructose was found to be comparable 
to that of wild-type 5448 (Fig. 6.9B), suggesting that SloR does not play a role in fructose 
uptake. We also tested the effect SloR had on the metabolism of other sugar sources using 
the API®50 assay, and we saw no observable difference between a sloR strain and wild-
type 5448 (data not shown). Additionally, an expression reporter plasmid was constructed 
by cloning the promoter of sloR (PsloR) upstream of the firefly luciferase gene (luc), and 
activity was determined through the uantification of relative luciferase units (LU). A 










































































































Table . . arbon Sources with altered utili ation in . fruA
114
fructose compared to sucrose (Fig 6.9A). To rule out that FruR regulates sloR, we also
tested sloR transcript levels in a	∆fru  strain grown in fructose and glucose using qPCR 
and saw no observable difference (data not shown). Taken together, we show that sloR 
induction is a fructose-specific phenotype  however, this induction is independent of Fru . 
We also show that sloR is not an alternative transporter of fructose. 
FruA in 5448 has different role than in 5005
 We strived to determine if the differences in the role of fruA in the survival of 
GAS in whole human blood was a result of the different influences in metabolism 
between MGAS5005 and 5448. Unlike ∆Mannose, where the parental strain determined 
the influence on PTS carbohydrate metabolism, ∆fruA was only impaired on growth on 
fructose in both strains (Fig 6.6, see chapter 4).  Although ∆Fructose seems to grow slightly 
better in glucose and lactose (see chapter 4), the extent of metabolic differences of the 
mutant between both M1T1s is relatively small compared to ∆Mannose.  This can be 
seen in utilization as well, where although 5448.∆fruA has slightly altered utilization of 
CH3-aD-Glucopyranoside, cellobiose, starch, and glycogen when compared ∆Fructose as 
both are compared to their respective wildtype (Fig 6.8; see chapter 4), these differences 
had on the metabolism of other sugar sources using the API 50
assay, and we saw no observable difference between a !sloR strain
and wild-type 5448 (data not shown). However, the effect of fruc-

















































































































































FIG 2 Growth analysis of 5448 and fru operon mutants in PTS sugars. (A) Total yield was calculated for GAS 5448 grown for 26 h at 37°C with 5% CO2 in various
PTS sugars as the sole carbon source. (B) Growth rates were determined for 5448 (black bars) and 5448.!fruA (white bars) strains in 9 PTS sugars (P " 0.05). The
growth of the fruAR revertant (gray bar) was assessed for fructose only. Error bars represent standard errors of the means from three biological replicates.
Statistical analysis was performed using an unpaired t test. (C to E) Growth curves for the 5448.!fruR mutant and its 5448.fruRR revertant (C), 5448.!fruB
mutant and its 5448.fruBR revertant (D), and 5448.!fruA and its 5448.fruAR revertant (E) compared to that of 5448 in chemically defined medium (CDM)
supplemented with 1% fructose were measured by absorbance using a Klett-Summerson colorimeter (Klett units) and compared to results for wild-type 5448.
Data are representative of three independent experiments.


















a Only PTS carbon sources are listed.
b #, Omnilog value (OV) of &200; #/', 125 " OV " 200; ', OV " 125. Carbon















        
        
        
        
        
        
        
        
        
        
      
        
        










        
        
        
        
        
        
        
        
        
        
      
        
        






























FIG 3 Limited carbohydrate metabolism profile of 5448 and the fru operon
mutants. Wild-type 5448 and the 5448.!fruA, 5448.!fruB, and 5448.!fruR
mutants were assayed using API 50 CH results after incubation at 37°C for 24
h and 48 h. Listed are select carbon sources from a panel of 49 carbohydrate
sources: complete utilization (white boxes), partial utilization (gray boxes),
and no utilization (black boxes) based on the colorimetric indicator dye shown
for each.
Valdes et al.
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are not drastic. This suggests that the differences seen with survival of both mutants in 
whole human blood may be either unrelated to metabolism, or that there may be an indirect 
perturbation to GAS virulence that accounts for the difference. Either way, it is clear that 
EIIs play an important role in GAS pathogenesis, even if not the exact same role in all strains.
Discussion
 Our results reveal a fructose-induced fruRBA operon that was found to be required 
for the growth of GAS in fructose and implicate FruA as the primary transporter of fructose 
in GAS. FruR acts as a repressor at the fru operon promoter, likely along with CcpA, to 
allow for fructose induction of the system. 5448 mutants lacking fruR and fruB, but not fruA, 
exhibited diminished survvial in whole human blood and greater sensitivity to phagocytic 
killing by neutrophils and monocytes. Interestingly, this was not the case for ∆Fructose





































































Figure 6.9 The effect of fructose on sloR. (A) PsloR promoter activity in WT 5448 
containing the PsloR-luc luciferase reporter plasmid was grown in CDM containing either 
1% fructose (solid bars) or sucrose (diagonal bars). Samples were taken at three time points 
in logarithmic phase of growth (early: white bars; mid: light gray bars; late: dark gray bars) 
and assayed for luciferase production, expressed in relative luciferase units. Error bars for 
represent mean ± SD of the results from three biological replicates performed in triplicate. 
Significance for (A) was determined using a Student t test (p  0.01). (B) Growth of 5448. 
∆sloR in CDM + 1% fructose compared to 5448. *(A) Performed by K.M.V.
discrepancy is most likely not the result of altered metabolic roles of fruA in both strains. 
Fructose-induced regulon of GAS
Metabolic genes for utilization of alternative (non-glucose) sugars typically are 
induced only during times of low glucose (derepression of CCR) and in the presence 
of the inducing sugar. For pathogenic streptococci and related low-GC Gram-positive 
bacteria, a genome-wide fructose-induced regulon previously has been determined only 
for Streptococcus mutans and the probiotic Lactobacillus acidophilus (Ajdic & Pham, 
2007, Barrangou et al., 2006). In S. mutans, microarray analysis revealed 68 genes (3.5% 
of genome) that were differentially expressed at least 2-fold in fructose compared to 
expression in glucose, whereas a similar analysis in L. acidophilus found that 110 genes 
(6% of the genome) were regulated. Our RNA- Seq analysis discovered that GAS in CDM 
with fructose affected the transcription of roughly 5.5% of the nonprophage genome (102 
genes) compared to growth in glucose (Table 6.1). This is in line with what was observed in 
both L. acidophilus and S. mutans, highlighting a fairly focused fructose-specific response 
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Table 6.3 Differences in phenotypes between ∆  mutants in two M1T1 strains
in these cells. 
 The most highly fructose-induced genes in GAS were fruRBA, followed by 
several other sugar-specific PTS operons, such as lacD.1 and lacD.2. The comparable L. 
acidophilus fruRBA genes also were highly induced by fructose (Barrangou et al., 2006). 
In contrast, the S. mutans genes for fruRBA (Smu.0870-72) were constitutively expressed, 
and a separate mannose/fructose family PTS was found to be inducible (Ajdic & Pham, 
2007). There are three potential mechanisms by which fructose could enter GAS cells. (i) 
The predominant pathway in Gram-positive bacteria involves the canonical PTSfru EIIABC 
(fruA-fruI), a 1-phosphofructokinase (fruB-fruK), and a fructose-responsive regulator 
(fruR). (ii) An alternate PTS recognizes and translocates fructose as fructose-6-phosphate 
(F6P) with lower affinities than those of pathway i. (iii) Facilitated diffusion transport 
using a membrane-spanning permease would esterify free fructose at position 6 using ATP 
(Kornberg, 2001). The induction of fruRBA by fructose in GAS suggests pathway i is the 
main pathway; however, the induction of other PTSs (e.g., lacD.1 and lacD.2) suggests 
that pathway ii also plays a role in fructose utilization. This is supported by the fact that 
mutants lacking any of the fruRBA genes still are able to metabolize fructose (Fig. 6.8 and 
Table 6.2), albeit not to a level that supports growth (Fig. 6.7B). Thus, the role of other 
PTS operons in the utilization of fructose will need to be explored further.
 We also observed an increase in the expression of genes in the serine catabolism 
regulon, including sloR, sdhAB, and ntpA-K (LaSarre & Federle, 2011). We further 
validated the fructose induction of sloR expression via qPCR (data not shown) and through 
promoter-luciferase fusions (Fig. 6.5A). SloR initially was implicated in streptolysin O 
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expression (Savic et al., 2002), but more recently it was shown to be involved in serine 
ac uisition (LaSarre  Federle, 011). However, Slo  shows significant homology to a 
fructose EIIC transporter (Kelley & Sternberg, 2009), suggesting that it plays a role in the 
transport of fructose (pathway ii described above, i.e., intake as F6P) and potentially aids 
in signal transduction to coordinate gene expression. However, a sloR mutant did not show 
any significant effect on the utilization of fructose or any other PTS sugar by GAS (data not 
shown). In other Streptococcus and Listeria species, orphan EIICs have been suggested to 
act as environmental sensors that interact with other regulatory proteins to influence gene 
expression (Van den Bogert et al., 2013, Kreft & Vazquez-Boland, 2001). It is possible 
that SloR serves a similar sensory role in GAS, and this hypothesis is being explored.
Role of the fruRBA operon in fructose metabolism in 5448. 
 (i) FruA. The GAS M1T1 genome is predicted to encode 14 sugar-specific EII 
translocation components of the PTS. As seen in chapter 4, homology and subsequent
annotation do not necessarily clearly indicate functionality. In this study, we characterized 
fructose utilization and the contribution of the fruRBA operon, confirming its annotated 
role in fructose metabolism. We found that an in-frame mutant of fruA (5448.∆fruA strain), 
encoding the putative PTS EIIABC, exhibited a significant growth defect compared to the 
WT (5448), but it did show some residual growth on fructose (Fig. 6.6). Nonpolar mutants 
of fruB (5448.∆fruB strain), encoding 1-phosphofructokinase, and fruR (5448.∆fruR strain), 
a putative repressor, also showed a comparable defect in growth on fructose, confirming 
that the entire fru operon is necessary for total fructose utilization in GAS. As mentioned 
above, the residual growth and utilization of fructose may involve other PTS EII pathways 
(Fig. 6.7B and Table 6.2). However, since fruRBA is the only operon in the 5448 genome 
that encodes a 1-phosphofructokinase (M5005_Spy_0061; FruB), it strongly suggests 
that this operon, through FruA, is the primary operon for fructose transport utilization 
(Ferenci & Kornberg, 1971). This has been observed in several other other Gram-positive 
bacterial species (Loo et al., 2003, Barriere et al., 2005, Wen et al., 2001, Voigt et al., 2014)
 (ii) FruR. The DeoR-family transcriptional regulator FruR is directly involved 
in the repression of the fru operon in L. lactis (Barriere et al., 2005) and other Gram-
positive bacteria (Loo et al., 2003, Wen et al., 2001, Voigt et al., 2014). Through 
transcriptional analysis of the 5448.∆fruR mutant and its 5448.∆fruRR rescue strain, we 
demonstrated that FruR represses the transcription of the fruRBA operon through the 
fru promoter (Pfru) and that the promoter is required for fructose induction (Fig. 6.4). 
Furthermore, the expression of the operon exhibits evidence of CCR, likely through a 
CcpA-mediated CCR mechanism. In silico analysis of the fruR promoter region identified 
the presence of a putative FruR binding site (Barriere et al., 2005) upstream of the 35 
hexamer and a catabolite response element (cre) site for CcpA binding (Kinkel & McIver, 
2008, Shelburne et al., 2008a, Kietzman & Caparon, 2010) overlapping the start of
transcription (Fig. 5.3C). The physiological inducer of  FruR de-repression is fructose-
1-phosphate (F1P), and 1 mM F1P is sufficient to disrupt Fru  binding to its operator in 
Pseudomonas putida (Chavarria et al., 2014, Chavarria et al., 2011). Fructose-1-phosphate 
is also the inducer of the fruRBA operon in other Gram-positive species, such as L. lactis 
(Barriere et al., 2005). This correlates with FruR being a member of the DeoR family of 
repressors, which typically are induced by sugar phosphates produced by the regulatory 
pathway they control (Barriere et al., 2005, Loo et al., 2003, Deutscher et al., 2006).
Surpringly we found that 5448.∆fruR is  unable to grow on fructose. We surmise that this 
is becaused of the overexpression of fruB and fruA , leading to an increase in fructose 
transport and metabolism. This can potentially lead to growth arrest as this would create 
an imbalance of intracellular metabolites. It is also possible that FruR regulates other 
importnat genes for GAS growth.
 (iii) FruB. 1-phosphofructokinase (fruB) converts imported F1P to fructose-1,6-
bisphosphate (FBP), and our data show that it is also necessary for GAS growth on fructose 
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(Fig. 6.7B). This is likely due to the fact that the fruB mutant (5448.∆fruB strain) would 
be expected to build up F1P due to an inability to convert it to FBP following transport 
by FruA. Since the majority of intracellular fructose cannot be further metabolized, 
the generation of FBP for glycolysis would be blocked, resulting in growth arrest. The 
fruB mutant (5448.∆fruB strain) also exhibited a small-colony phenotype when plated 
on blood agar (see Fig.6.2B) and showed a slightly longer doubling time than the 
parental 5448 and its 5448.∆fruBR revertant, implicating this enzyme in playing a role 
outside the conversion of F1P to FBP. Although other PTS EII pathways exist in GAS 
that allow for the transport of fructose as F6P, as demonstrated by both the RNA-Seq 
and Biolog/API®50 CH metabolic data (Tables 6.1 and 6.2 and Fig. 6.8), the efficiency 
of transport is not able to support growth. In addition, when fructose is transported by 
alternative PTSs (pathway ii described above), a 6-phosphofructokinase (pfkA) enzyme 
would need to be present to convert F6P to FBP (Kornberg, 2001). However, pfkA was 
not upregulated when GAS was grown in fructose as the sole carbon source (Table 6.1).
lternate influences of fruA on GAS survival in whole human blood unlikely to be 
related to metabolism 
    e discovered that 5448.∆fruA is unaffected in survival in whole human blood, 
but was not the case for ∆Fructose (∆fruA in MGAS5005). We metabolically characterized 
5448.∆fruA to determine if there were drastic alterations in its influence on PTS carbohydrate 
metabolism. Potentially, this could explain the difference in survival in whole human blood 
between the two mutants, as could be the case for differences in hemolytic activity with 
the mannose-specific EII subunit mutants in MGAS5005 and 5448. However, unlike with 
those mutants, ∆fruA in both MGAS5005 and 5448 essentially only affect the metabolism 
of fructose (Table 6.3). Although there are slight differences in some carbohydrates’ 
metabolism between the two mutants as compared to their parental strains, this is unlikely 
to explain the stark difference seen in survival in whole human blood since they are subtle 
(Table 6.3). ather, it is more likely that fructose metabolism may influence the GAS 
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regulon differently in MGAS5005 than in 5448, and preventing fructose metabolism 
through the deletion of fruA subsequently has different impacts in the two strains. Gene 
regulation and genetic interaction differences between MGAS5005 and 5448 is an area we 
are currently exploring to understand the importance of a strain background for the context 
of the role of identical proteins.
Chapter 7: Assessing the Importance of PTS and non-PTS 
Glucose Utilization Pathways in GAS Pathogenesis
Introduction
 Glucose is abundant in nature. In the human body alone, glucose is present in 32 
of 4  biofluids or tissues studied so far, with the highest concentrations usually found 
in blood (Wishart et. al, 2013, Wishart et. al, 2009, Wishart et. al, 2007). As a result, 
human pathogens possess many mechanisms to transport and metabolize glucose 
(Cvitkovitch et al., 1995, Vitko et al., 2016).  In S. aureus, glucose can be metabolized 
either through the PTS or through a glucokinase, as a double mutant of both genes was 
unable to grow in glucose alone. Additionally, alterations to efficient glucose metabolism 
in this pathogen negatively affected pathogenesis (Vitko et al., 2016). Although little is 
known about glucose metabolism in GAS, it is hypothesized to be transported through 
the phosphoenolpyruvate-dependent phosphotransferase system (PTS), as shown in 
S. pneumonaie (Vitko et al., 2016) and deletion of some PTS transporters also leads 
to altered metabolism of glucose, strengthening this premise (Chapter 4). The GAS 
genome also encodes for a glucokinase (nagC), as well as a non-PTS glucose transporter 
(glcU), presumably for glucose transport and metabolism that is PTS independent. 
However, the actual contribution of each pathway to overall glucose metabolism has not 
been investigated. 
 SLS-mediated hemolysis was shown to be under the influence of the PTS, as a PTS-
null mutation (∆ptsI) led to SLS activity during early exponential phase as compared to 
early stationary phase for the parental strain MGAS5005 (Gera et al., 2014). We screened 
an annotated EIIC mutant library in a previous study, and discovered 7 EIIC mutants that 
had early onset hemolysis during growth as compared to MGAS5005 (Chapter 4). e 
carried out this screen in an effort to determine if the lack of utilization of a particular 
PTS carbon source was responsible for the dysregulation of SLS-mediated hemolysis.   
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 There was no carbohydrate whose metabolism was commonly affected in all  EIIC 
mutants that displayed early hemolysis (Chapter 4). However, all of these EIIs do appear 
in the CcpA regulon (DebRoy et al., 016) and, considering that a MGAS5005.∆ccpA 
mutant also exhibits early hemolysis (Kinkel & McIver, 2008, Shelburne et al., 2008), 
we hypothesized that disruption of efficient glucose metabolism could be the trigger for
SLS-mediated hemolysis. This is further strengthened by the fact that Mga was shown to 
regulate SLS and SLO only in conditions of low glucose, but this regulation disappeared 
once glucose was added ( aldes, 016). In this study, we characterized the routes 
of glucose metabolism and compared their influence on hemolysis, GAS survival in 
whole human blood, and GAS pathogenesis in a murine skin infection model. e also 
investigated whether glucose can be metabolized either through the PTS or via a non-
PTS metabolic pathway or both, and whose expression are correlated with each other.
Results
MGAS5005 ∆ptsI does not regulate hemolytic activity based on sugar concentration
 Earlier studies from our group showed that MGAS5005.∆ptsI exhibited early 
hemolytic activity as compared to MGAS5005 (Gera et al., 2014), likely due to the 
lack of access to a PTS carbohydrate. However, our screen of the GAS PTS pathways 
found 7 EIIs to exhibit early hemolytic activity that did not affect the metabolism of 
a particular carbohydrate (Chapter 4), and all of these EII loci are a part of the CcpA 
regulon (DebRoy et al., 2016).  Although MGAS5005 only exhibits hemolytic activity at 
late log-stationary phase when preferred sugar concentrations are low, a direct correlation 
between sugar concentration and hemolytic activity has not been explicitly shown in GAS. 
Therefore, we grew MGAS5005 in three glucose conditions and assayed at which glucose 
concentration that hemolysis begins to occur. MGAS5005 and MGAS5005.∆ptsI were 
grown for 8 h in THY 10  horse serum, horse serum alone, and in whole human blood. 
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Figure 7.1. Occurrence of hemolysis at low sugar concentration. Sugar concentrations, 
OD600, and hemolysis was measured as described (see chapter ). A) MGAS5005 grown in 
THY  10  horse serum. Blue circles represent sugar concentration. ed s uares represent 
positive hemolysis. B) MGAS5005 grown in Horse Serum alone. C) GAS grown in whole 
human blood. D) MGAS5005 and MGAS5005.∆ptsI grown in THY  10  horse serum. 
Red circles represent hemolytic values, and black circles represent sugar concentrations at 
each measured OD600 for MGAS5005 (D) and ∆ptsI (E). 
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Sugar concentrations, hemolytic values, and growth (OD600) were measured as 
indicated in chapter 3. In all three conditions, MGAS5005 did not display SLS-
mediated hemolysis until sugar concentrations was around 50 mg dl or lower 
(Fig. 7.1A-C). In the MGAS5005.∆ptsI mutant, hemolysis is detectable at 
sugar concentrations around 00 mg dl, suggesting that the lack of flux through 
glucose metabolism may be the trigger for SLS-mediated hemolysis (Fig 7.1D ). 
Glucose metabolism occurs primarily through the Non-PTS glucokinase NagC
Since regulation of SLS-mediated hemolysis does not seem to be affected by the 
metabolism of a PTS carbohydrate, but rather by the disruption of glucose-mediated gene 
regulation, we wanted to characterize the routes of glucose metabolism in MGAS5005. 
Previously, we had shown that MGAS5005.∆ptsI has no growth defect in CDM  0.5  
glucose, suggesting that the PTS system either does not transport glucose, or that there 
is an alternate glucose transport system that is specific to glucose in con unction with 
the PTS (Fig 7.2). To test this theory, we constructed mutants in a putative non-PTS 
glucose transporter (glcU) based on its role in other streptococcal species (Vitko et al., 
2016), and a putative glucokinase (nagC) that would be re uired to generate glucose-
6-phosphate following non-PTS glucose import. The MGAS5005 ∆glcU mutant was 
created by using the pC S mutagenic system (see chapter ), while an MGAS5005 
∆nagC mutant was created using allelic exchange to replace the glucokinase gene with 
a kanamycin resistance (aphA3) cassette. For both mutants, rescued strains were then 
created by curing the confirmed mutants of the mutagenic plasmid to restore the wild 
type genotype. The T MGAS5005, ∆glcU, ∆nagC and ∆ptsI GAS strains were grown 
in THY, a glucose-rich media, to evaluate growth defects of each mutant. e included 
∆manMN (∆Mannose) based on our findings suggesting that the mannose-specific EII is a 
high affinity glucose transporter (Chapter 5) (Fleming  Camilli, 016). Growth (∆OD600) 








Figure 7.2 Predicted glucose metabolic pathways in MGAS5005. Differential colors 
(blue orange) depict the two predicted pathways from glucose transport. ManMN is 
potentially the main glucose PTS transporter, based on current literature. However, this has 
yet to be shown in GAS. Black lines depict the routes of glucose transport. GlcU: glucose 
uptake protein  NagC: glucokinase.
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amount of sugar consumed (see chapter ) was slightly lower in ∆manMN and ∆glcU as 
compared to MGAS5005. Since THY is a complex rich media that potentially contains 
multiple sugars, we tested the same strains in CDM  0.5  glucose and monitored the 
amount of sugar consumed to determine if loss of any of these predicted glucose metabolic 
pathways reduced the efficiency of glucose metabolism. None of the mutants showed 
significantly increased glucose consumption when the total yield was standardized for all 
strains (Fig. 7.3B). e next determined the total yield of each mutant grown in different
concentrations of glucose, where GAS strains were incubated in CDM   of glucose 
as the sole carbon source for 48 hours, and growth and total yield (∆OD600) was calculated 
as described in chapter . ∆manMN and ∆glcU had very little effect on GAS growth on 
glucose (Fig 7.3C).
 The ∆ptsI mutation led to a consistent growth defect when grown in  glucose 
(Fig 7.3C), while at 0.5 , 0. 5 , and 1  glucose, growth was only affected early (1  h) 
and late (48 h) (Fig 7.3C). However, when looking ust the total yield at 1 , 4, 6 and 48 
Figure 7.3. Growth of various predicted glucose metabolic gene mutants in MGAS5005. 
A) GAS strains were grown in THY for 4 h. ∆OD600 is plotted on the left Y-axis. The total 
sugar consumed during growth in THY over 4 h was calculated as indicated in chapter , 
and plotted on the right Y-axis. Shading is indicative of strains. p-value 0.5. p-value 
0.005. B) Strains grown in CDM  0.5  glucose for 4 h. e calculated the total amount 
of sugar that would be consumed for a particular GAS strain to grow to an OD600 of 1 from 
an OD600 of 0 (see Chapter ). Grey bars depict strains with similar sugar consumption 
to MGAS5005. ed bars depict strains that were statistically significantly different from 
MGAS5005. C) Strains were grown in CDM  various  glucose. Each growth curve 
was analyzed at 1 , 4, 6, and 48 h and plotted as indicated. Green boxes depict growth 
above T, yellow boxes depict growth  fold below T, and red boxes depict growth 
more than  fold below T. hite boxes depict growth similar to MGAS5005 D) ∆OD600 
of growth performed in (C), and depicted similarly. hite boxes depict ∆OD600 similar to 
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h, growth of GAS on 0. 5  glucose had the most drastic effect (Fig 7.3D). In contrast, 
∆nagC had the lowest growth in all concentrations of glucose compared to wild type for all 
the mutants assayed over 48 h (Fig 7.3D). This would suggest that either the main route of 
glucose transport occurs through the non-PTS glucose transport system, or that deleting the 
glucokinase gene (∆nagC) somehow affects the expression of the PTS system, hindering 
overall glucose transport. 
Deletion of nagC leads to the inability of GAS to grow on certain PTS carbohydrates 
as the sole carbon source
 To investigate if the non-PTS alternate glucose metabolic pathway affects PTS 
function, we grew ∆nagC and ∆glcU in CDM  1  of a PTS carbohydrate as the sole carbon 
source for 48 h (see chapter ). Surprisingly, the ∆nagC glucokinase mutant did not grow as 
well as wild type in glucose, fructose, sucrose and maltose (Fig 7.4A). The ∆glcU permease 
mutant actually grew slightly better than MGAS5005 in both lactose and maltose, while both 
strains had reduced growth in mannose as compared to MGAS5005 (Fig 7.4A). However, 
when these strains were grown in C media  1  of a PTS carbohydrate (0.5  glucose), 
all of these phenotypes disappeared (Fig 7.4A). C-media contains a low concentration of 
glucose (0.05  w v), suggesting that ∆nagC and ∆glcU have growth defects in some PTS 
sugars only when it is presented as the sole carbon source. These growth defects were 
rescued by in the presence of 0.05  (w v) of glucose (Fig 7.4A) and this was reflected 
when comparing the total yield of these strains grown in these two different conditions 
(Fig 7.4B). However, since there are many differences between CDM and C-media (see 
chapter ), it is also likely that other factors contribute to the rescue of the growth defects 
observed.  Finally, ∆nagC had reduced growth and total yield in C media, further confirming 
that glucose metabolism seems to occur primarily through glucokinase (Fig 7.4AB). 
e next interrogated the utilization profile of the ∆nagC mutant to see if it reflected what 



































































































































































that ∆nagC had impaired utilization of 88  of the carbon sources tested (Fig. 7.4C). 
Comparing the utilization profile of ∆nagC to ∆ptsI, it is evident that both mutants have a 
drastic reduction in overall carbon utilization, as over 81  of carbon sources could not be 
utilized at 4 h, and over 56  at 48 h (Fig 7.4D). This suggests that similar to the PTS, NagC 
positively influences the metabolism of multiple carbohydrates. To investigate whether 
these metabolism defects in PTS sugars was observed due to lower PTS expression, we 
assessed the transcript levels of ptsI in ∆nagC and compared it to MGAS5005. We performed 
T-PC  on NA isolated from both strains grown in THY to late log, as indicated in
chapter 3. ptsI expression was significantly lower in ∆nagC than in MGAS5005, suggesting 
that this is the possible reason for the lack of growth on PTS sugars in the glucokinase 
mutant (Fig 7.4E). The mechanism by which this occurs, however, is currently unknown.
Route of glucose metabolism is important for survival of GAS in whole human blood, 
but not for SLS-mediated hemolysis
 Considering MGAS5005.∆ptsI exhibited early onset of hemolytic activity, we 
assayed whether ∆nagC and ∆glcU would also affect the timing of hemolysis during 
GAS growth. Surprisingly, both ∆glcU and, to a slightly greater extent, ∆nagC exhibited 
hemolytic activity early in growth (Fig. 7.5AB). Neither of these mutants resembled the level 
of early hemolytic activity observed by MGAS5005.∆ptsI, suggesting a lesser role for the 
alternate glucose metabolic pathway in regulating the timely expression of SLS  however, 
Figure 7.4. Deletion of nagC prohibits GAS growth in several PTS sugars. A) Growth 
of ∆nagC and ∆glcU in CDM  PTS sugar (left boxes). Color scheme similar to Fig . C. 
Growth was also carried out in C-media plus PTS sugar (right boxes), similarly to CDM. 
Growth curves were analyzed after 48 hours. B) ∆OD600 was calculated after 4 and 48 
h of growth in CDM or C-media  1  PTS sugar. Color scheme similar to Fig . D. 
C) Utilization profile of ∆nagC in MGAS5005. Utilization of select carbon sources as 
determined by the API 50CH system. hite boxes indicate utilization ( ), grey boxes 
indicate partial utilization ( -), and black boxes indicate no utilization (-). eadings for 
each strain are given for 24 and 48 h (left and right box respectively). D) Utilization patterns 
where analyzed by determining the percent of carbon sources listed that fall into utilization 
(green), partial utilization (yellow), and no utilization (red). E) Transcript level of ptsI in a 
∆nagC mutant compared to MGAS5005, measured through T-PC . Data presented are 
the average of three biological replicates. 
Figure 7.5. Deletion of the alternate glucose metabolic pathway components leads to 
altered blood phenotypes. (A,B) Black bars represent hemolytic values of MGAS5005. 
ed bars represent hemolytic values of ∆glcU. Orange bars depict hemolytic values of 
∆nagC. (C) Lancefield Bactericidal Assay. Multiplication factors are shown as compared 
to MGAS5005. Grey bars indicate strains where the MF is similar to wildtype. ed bars 
indicate strains where the the MF is statistically significantly different from MGAS5005. 
Data shown represent the average of at least three biological replicates. p-value 0.05. 
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this does suggest that SLS-mediated hemolysis is linked to glucose metabolism. Since 
both glucose transport and metabolic pathways exhibited some degree of early hemolytic 
activity, we wanted to determine if this would translate to increased survival in whole 
human blood, as producing more SLS should mean successful evasion of immune cells and 
access to nutrients. e found that although ∆nagC survives similarly to MGAS5005 when 
exposed to whole human blood for  h, ∆ptsI had severely reduced survival (Fig 7.5C). 
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that the route of glucose transport affects how GAS is able to survive in an important 
host environment. Although the reason for this discrepancy is unknown, there may be a 
difference in gene expression that could contribute to GAS survival in whole human blood. 
Despite the ∆manMN mutant exhibiting increased lesion severity in a murine subcutaneous 
infection model (Chapter 5), there was no phenotype observed in whole human blood (Fig 
7.5C), indicating that the contribution of the mannose-specific EII to GAS pathogenesis is 
restricted to the skin.
A ∆  mutant exhibits increased lesion severity compared to MGAS5005
 To determine if the route of glucose metabolism affects overall GAS pathogenesis, 
we in ected MGAS5005, ∆nagC, and ∆ptsI subcutaneously in CD-1 female mice and 
measured lesion size, severity, and total CFUs per mg of spleen for all three strains as 
indicated in chapter 3. As observed previously by our group (Gera et al., 014), ∆ptsI 
exhibited larger lesions as compared to MGAS5005  however, ∆nagC mice showed 
lesions comparable in size to wild type at 48 h post infection (Fig 7.6A). Still, the lesions 
associated with ∆nagC infection were more severe than those of MGAS5005, and more 
similar to those of ∆ptsI-infected mice (Fig 7.6BC). These results correlate with the 
hemolytic profile of all three strains, where ∆ptsI shows early and robust hemolysis, while 
∆nagC was early but not as robust as ∆ptsI (Fig 7.5B). All three strains showed similar 
CFUs mg of spleen at 48 h from all mice tested, suggesting that dissemination from the 
local site of infection was similar (Fig 7.6D). This was somewhat unexpected as ∆ptsI 
did not survive in whole human blood and may indicate a human-specific phenotype. 
It also suggests that the PTS and nagC help control hemolytic activity at the local site 
of skin infections, but this does not translate to greater dissemination (Fig 7.6E). In 
conclusion, glucose metabolism through the PTS is important for survival in whole human 
blood. However, impaired glucose utilization in general leads to the early production of 

































































































































Figure 7.6. Contribution of glucose pathway mutants in GAS pathogenesis in a 
murine subcutaneous infection model.  MGAS5005, ∆ptsI, and ∆nagC were in ected 
subcutaneously into CD-1 mice (See Chapter 3). Lesion size (A) and severity (B) shown for 
MGAS5005-infected (black), ∆pts infected (red), and ∆ C-infected (blue) mice at 48 
hours post infection. (C) epresentative images of lesions associated with infection from 
each strain was taken at 48 hpi. (D). CFUs mg spleen were graphed to assess diseemination. 
(E) Survival of mice associated with each infection that were not sacrificed for spleen CFU 
counts were monitored for survival over  days. 
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Discussion
 In this chapter, we generated mutants in predicted glucose utilization pathways and 
compared the contribution of the non-PTS pathway (nagC) to the PTS pathway for overall 
glucose metabolism. e found that elimination of the alternate glucose metabolic pathway 
led to a more drastic reduction in growth on glucose as the sole carbon source as compared to 
effects of eliminating the PTS. Interestingly, we discovered that deletion of the glucokinase 
nagC also lead to decreased growth in PTS sugars, likely resulting from the decreased 
expression of ptsI in this background. Altering metabolic pathways for glucose metabolism 
affected the activity of SLS, as both ∆nagC and ∆glcU showed an early hemolytic profile 
during growth. Although the route of glucose metabolism did not affect the onset of early 
hemolysis, it did affect survival in human blood as the ∆ptsI mutant is unable to survive 
whereas the ∆nagC mutant did. Early onset of hemolysis translated to an increased lesion 
severity, but not increased lesion size, at the site of infection when mice were infected
with ∆nagC. However, there was no observable dissemination defect (spleen) nor was 
there a significant reduction of lethality with ∆nagC. We established that there are at least 
two metabolic routes for glucose metabolism that are interconnected and influence the 
expression of the toxin SLS. 
 In GAS, there are two main routes hypothesized for glucose utilization: (1) 
PTS and (2) a non-PTS transporter. Elimination of both nagC and ptsI ablated glucose 
metabolism in S. aureus (Vitko et al., 2016), so it is unlikely that GAS does have any 
additional alternative glucose metabolic pathways. Both the glucokinase (∆nagC) and PTS 
(∆ptsI) mutants were grown in different concentrations of glucose over 48 h to monitor 
which pathway was more important in the overall metabolism of glucose and found that 
disruption of the non-PTS glucose pathway (∆nagC) lead to a greater loss of growth in all 
concentrations of glucose as compared to ∆ptsI. This suggests that the non-PTS glucose 
metabolic pathway is the preferred route of glucose metabolism at most concentrations, 
we identified a non-PTS glucose transporter gene (glcU) in GAS based on homologous to 
the S. aureus transporter important in glucose metabolism (Vitko et al., 2016). Inactivation 
of glcU lead to very modest growth defect in all glucose concentrations tested. Coupled 
with the fact that a ∆glcU∆ptsI double mutant was still able to grow on glucose (data not 
shown), this strongly indicates the presence of a third glucose transporter(s) that has yet 
to be identified.  Ideally, a ∆nagC∆ptsI double mutant would allow us to confirm this as 
was used for S. aureus (Vitko et al., 016). However, S. aureus has a much more robust 
metabolic network compared to GAS, and therefore substrates to grow the double mutant 
are more readily identifiable. e have yet to find a carbon source that would facilitate 
growth of a GAS ∆ptsI∆nagC double mutant.
 Unexpectedly, ∆nagC also had trouble growing on the PTS sugars mannose, 
fructose, sucrose, and maltose, likely due to its reduction of the expression of ptsI. The 
mechanism of this repression is unknown, but it is possible that the intracellular PEP pool 
is low in a ∆nagC mutant, leading to lowered PTS activity. educed PEP level may also fail 
to stimulate ade uate induction of ptsI  however, the regulators involved are not known. 
Since growth defects of the ∆nagC mutant in PTS sugars disappeared when C media (low 
glucose-high peptide) was used in place of CDM (no carbon source), it is possible that 
growing ∆nagC in low glucose allows for the generation of enough PEP to stimulate PTS 
expression and allow for growth on PTS sugars. As CDM has no additional carbon source, 
the levels of PEP would remain low in this condition. Oddly, ∆nagC was able to grow in 
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lactose and trehalose, even though in the utilization assay they are unable to utilize these 
sugars. One limitation of the utilization assay is that the readout for positive utilization is 
a drop in pH based on a pH indicator dye. In GAS, this is largely due to the generation of 
lactic acid at the end of the fermentation of a sugar. In ∆nagC, it is possible that there is a 
shift in the metabolic network, where fermentation of lactose and trehalose may now lead 
to a different end metabolite, causing the utilization assay to present a false negative.   
 Invasive GAS (iGAS) uses the bloodstream to disseminate from the local 
site of infection to other sterile sites in the body, leading to life-threatening systemic 
infection. Since human blood is glucose rich, we interrogated if the route of glucose 
metabolism affected survival of GAS in whole human blood. Surprisingly, the non-
PTS transporter mutant (∆nagC) was able to survive, while the PTS mutant (∆ptsI) was 
not, strongly suggesting that glucose being transported through the PTS is important 
for GAS survival during bacteremia. One caveat is that that ∆ptsI mutant not only 
affects the glucose transport, but also impacts the metabolism of many carbon sources. 
Therefore, it is certainly possible that ∆ptsI has more far reaching perturbations outside 
of glucose transport that are re uired for survival in blood. This assertion is further 
strengthened by the fact that ∆ptsI would also not be able to phosphorylate P D-
containing virulence regulators, which can have a multitude of different conse uences. 
 Deletion of the glucokinase gene nagC lead to an increase in lesion severity in a 
subcutaneous murine infection model as compared to infection with wild type MGAS5005. 
This was expected, as ∆nagC exhibits early hemolysis, but at lower level than that of the 
∆ptsI. One explanation could be that there are fewer bacteria in the lesion, as ∆nagC may not 
be able to grow inside the skin as well as ∆ptsI. It could also be the conse uence of having a 
lower magnitude of hemolysis early in growth as compared to ∆ptsI. This suggests not only 
that lesion severity correlates with production of SLS, as was shown previously (Gera et al., 
014), but that the regulation of PTS-mediated SLS activity is indirectly affected by ∆nagC.
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 Dissemination of MGAS5005, ∆ptsI, and ∆nagC, based on CFU mg spleen in 
infected mice after  days, was uite similar (Fig. 7.6D). This was unexpected for ∆ptsI, 
as in whole human blood, it does not survive nearly as well as MGAS5005 or ∆nagC (Fig 
7.5C). A phenotype in human blood and not in mice can indicate a human-specific trait, 
which may not be surprising as our PTS fructose-metabolic operon mutants (∆fruBAC) also 
showed a human-specific role in survival in whole human blood (Chapter 6). Since that 
operon is part of the larger PTS network, this may explain the overall human-specificity 
seen with ∆ptsI. Survival, lesion size, and dissemination of mice infected with MGAS5005 
and ∆nagC were similar.
 Overall, this suggests that the importance of the route of glucose metabolism 
varies with the host and specific environment in GAS pathogenesis. Forcing glucose 
to be metabolized in one route versus the other impacts the ability of GAS to survive. 
This can be due to (1) efficiency of glucose metabolism and ( ) expression of other 
important pathogenic networks. Forcing glucose to be metabolized through the PTS 
may be inefficient, and therefore may affect survival in a glucose rich environment. 
However, this cannot be the case as ∆nagC has similar survival in blood as the wild 
type. The more likely scenario is that forcing glucose through the PTS changes glucose 
from a preferred sugar to a PTS-inducing sugar that can affect the phosphorylation of 
P Ds on PC s, thereby changing their activity. This would not be the case in the ∆ptsI 
mutant, where PTS phosphorylation of P Ds cannot occur, and would again change 
the activity of PC s. GAS may use the affinity of both systems for glucose transport, 
coupled with the ability to phosphorylate PC s in response to inducing sugars to 
regulate virulence programs in different environments. This process would be disrupted 
in a ∆nagC mutant, but to a higher degree in ∆ptsI and would lose regulation completely. 
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Chapter 8: Conclusions and Future Directions
 In this dissertation, we aimed to determine the root cause of the early SLS-mediated 
hemolytic activity that was observed in MGAS5005.∆ptsI. We had originally hypothesized 
that this was the result of the lack of transport of a particular PTS carbon source, as a ∆ptsI 
mutant has no PTS transport function. To tackle the question of which carbon source was 
primarily responsible, we insertionally inactivated each of the individual EIICs, as these 
are the carbohydrate transporters that provide sugar-specificity to the PTS (Chapter 4). 
Establishing an EIIC mutant library in MGAS5005 allowed us to not only metabolically 
characterize each one, but allows for screening of each EIIC mutant in host niches to 
determine if a transporter or a carbohydrate they specifically affect are important for GAS 
pathogenesis. We put this to the test by screening the library in survival in whole human 
blood, and discovered two EIIC mutants that have reduced survival compared to the 
parental strain MGAS5005. One of the EIICs discovered (FruA) did not have a reduction 
of survival in whole human blood in another M1T1 strain 5448 (Chapter 6). Differences 
in phenotypes between EII subunits in MGAS5005 and 5448 was also found with the 
mannose-specific EII, where the relative influence on metabolism and hemolysis varied 
between the two strains (Chapter 5). e additionally screened the EII library for early 
hemolytic activity, and found seven EIIC mutants that exhibit early hemolysis (Chapter 4). 
However, there was no sugar in common whose metabolism was affected by all the EIIs. 
We did observe that hemolysis occurs at low nutrient concentrations, so we investigated 
the nature of glucose metabolism in MGAS5005 by making mutants in the non-PTS 
and PTS glucose metabolic pathway (Chapter ). The deletion of both ∆ptsI and the 
glucokinase (∆nagC) affected glucose metabolism, although the glucokinase had a much 
larger influence. Interestingly, these two mutants had different phenotypes when grown in 
whole human blood, where ∆nagC survived better than ∆ptsI, even though both strains 
show early hemolytic activity (Chapter ). Unexpectedly, the ∆nagC mutant also had a
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growth defect on several PTS sugars, the result of lowered expression of ptsI. Finally, 
∆nagC had more severe lesions than MGAS5005 when GAS was injected subcutaneously, 
although the lesions were similar sizes which is not the case for ∆ptsI (Chapter ). 
This dissertation established a useful tool to screen for the importance of carbohydrate 
metabolic pathways in different infection environments, established the redundancy 
of many of these pathways, showed differences in the roles of identical proteins in 
different backgrounds, established the glucose metabolic pathway in MGAS5005, 
and allowed us to more clearly hypothesize the trigger for SLS-mediated hemolysis.
Different roles of EIICs in GAS physiology between two M1T1s
 e discovered that although the mannose-specific (manLMN) and the fructose-
specific (fruA) EIIs have the 100  same se uences in both MGAS5005 and 5448, their 
specific roles in metabolism and virulence are somewhat different. The differences 
observed in the mannose-specific EII roles between the two M1T1 strains is much larger 
than that of fruA, although this may be the result of the fact that the mannose-specific 
EII has a greater role in virulence and certainly in PTS carbohydrate metabolism, hence 
the greater possibility for variation. The greatest difference between the mannose-specific 
EII subunits between the two strains was seen with metabolism, where the MGAS5005 
version had a much larger positive influence than the 5448 version. Other than SNPs, 
one of the main differences between these two strains is the presence (or absence) of a 
functional CovS. Since the CovRS regulon includes many metabolic genes, it’s possible 
that an intact CovS in 5448 limits the role of the mannose-specific EII in 5448 since there 
is still another layer of regulation. However, in MGAS5005 which is covS-, deletion of the 
mannose-specific EII has a more drastic effect in an already altered metabolic background. 
To test this hypothesis, we would create the mannose-specific EII subunit mutants in both 
the animal passaged 5448 strain 5448AP (covS-), and a 5448.∆covS knockout mutant and
139
characterize  the influence on GAS PTS carbohydrate metabolism.  This would elucidate 
if the reason for the differences we observed is due to an intact CovRS system. Secondly, 
we would extend this out to all of the EIICs, by making the annotated EIIC mutant library 
in both 5448 and 5448AP as well, and comparing the influence of each of the remaining 
EIIs on PTS carbohydrate metabolism in all three strains (MGAS5005, 5448, 5448AP). If 
CovS plays a role in shaping the role of each EIIC, we would expect the influence of each 
EII to be similar in MGAS5005 and 5448AP as compared to 5448. This idea is further 
strengthened by the fact that CovS seems to play a role in the influence of the PTS on the 
expression of hasA (capsule production and speB) (Gera, 014). 
Both EIIC mutants that are impaired for their survival in whole human blood have 
altered fructose metabolism
 Survival in whole human blood is a necessary step for an invasive infection to spread 
from the localized site of infection to other sterile sites. Since these types of infections are 
often the most dangerous, it is of great interest to identify genes important for GAS survival 
in this environment. Screening the EIIC mutant library for survival in whole human blood 
identified both the ∆b-glucoside-specific EII and the fructose-specific EII as important for 
survival. Both of these EIIs contribute to efficient fructose metabolism, as their respective 
mutants have defects in growth on fructose as the sole carbon source. Although fructose is 
present in blood, it is at much lower concentrations than glucose (Chapter ). However, fruA 
is upregualted in the presence of heme stress (Sachla et al., 014), so it is possible that fructose 
metabolism may play an important role in combating both the immune response, as seen with 
fruB and fruR’s role in evading neutrophil killing, as well as metal stress. Interestingly, fruA 
was only important for survival in blood in MGAS5005, not 5448. To ascertain if this is the 
case for the ∆b-glucoside-specific EII as well, we would make a 5448 version of this mutant. 
Addtionally, we would characterize its metabolic operon, as it is predicted to be transcribed 
with a P D containing antiterminator (licT) and a beta-glucosidase (bglA). e would
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also characterize the EIIC mutant metabolically and in a Lancefield bactericidal assay 
to determine if there are differences between the two strains. To further elucidate 
the impact that fructose metabolism has on survival in whole human blood, we would 
perform a TNse  essentiality screen, similar to the transposon mutagenesis screen 
carried out by Le Breton et. al ( 015), to identify genes that are re uired for optimal 
fitness for surviving in blood. This could either strengthen the hypothesis that fructose 
metabolism plays an important role in this environment, or could identify other 
pathways whose efficiency is affected by fructose, or its downstream metabolites.
Routes of glucose metabolism in GAS 
 e made mutants in the two glucose metabolic pathways predicted in GAS (∆nagC 
 ∆ptsI) and assessed their ability to grow in glucose. Deletion of nagC lead to a more 
drastic reduction in growth, suggesting that it is the preferred route of glucose metabolism. 
Although the  ptsHI operon is not in the CcpA regulon, it does have a cre site, and therefore 
may be catabolite repressed. This would fit our model that the PTS is a less preferred 
glucose transport system.  The lack of growth of ∆nagC on PTS sugars was surprising. 
However, the fact that ptsI expression was lower in a ∆nagC mutant coupled with the fact 
that a slow growing ∆nagC mutant strain may have less PEP, could explain why growth on 
PTS sugars was impaired when they are the sole carbon source, but not in a media where 
there is low glucose. The levels of glucose metabolic intermediates and PEP in both of 
these backgrounds would be investigated via mass spectrometry to see if there are drastic 
alterations that may explain the phenotypes observed. This would also lend insight into 
how these two pathways may interact with each other, as metabolites are often cofactors 
for GAS gene regulation. 
 There is a third unidentified glucose transport mechanism present in GAS, as a 
∆ptsI∆glcU mutant is still able to grow in glucose, although at a lower rate. To identify a 
third potential transport mechanism, we would carry out a screen using MGAS5005 and
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grow it in CDM  DG as a carbon source. DG is a glucose analog that is not metabolizable 
in GAS, therefore prevents growth, and usually kills GAS cells. DG is transported through 
similar mechanisms as glucose, therefore, the hypothesis is that suppressors would appear 
that prevent transport of DG in MGAS5005 to allow the cell to survive. This strain should 
then be a glucose transport-null strain. However, to allow for growth in CDM  DG, we 
would need to introduce another carbon source to facilitate growth, as using DG as the 
sole carbon source would prevent any cell from surviving, even if a suppressor mutation 
occurs. ather, we would change the ratio of DG to the alternate carbon source in CDM 
to allow for baseline growth, but still select for suppressors. A second method would be 
to make a conditional mutant of ∆nagC using ∆ptsI as the background strain. This should 
get rid of both glucose-metabolic pathways, therefore rendering this strain as glucose-null. 
However, deletion of ptsI would eliminate growth on multiple other carbon sources as well, 
so no inferences can be made about solely glucose metabolism in this mutant, and therefore 
may not be useful.  
Occurrence of hemolysis in Group A Streptococcus M1T1 MGAS5005
 We observed that deletion of the PTS leads to the early activity of SLS, occurring 
during exponential phase rather than in late-log phase during growth. Seven EIIC mutants 
displayed early hemolysis as well, although none to the level of a ∆ptsI mutant (Chapter 
4). This suggests that all the EIICs identified contribute to the overall early hemolytic 
phenotype observed in ∆ptsI, a notion also backed by the fact that ∆Mannose has severe 
lesions similar to ∆ptsI in a murine skin infection model, but does not display the increased 
lesion size (Chapter 5). e did observe that all these EIICs identified fall into the CcpA 
regulon (Deb oy et al., 016). This suggests that perhaps the early hemolytic phenotype 
observed is not the result of the lack of PTS carbohydrate metabolism, but rather the 
disruption of efficient glucose metabolism. This is further strengthen by the fact that ∆ccpA
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also displays SLS-mediated hemolysis in exponential phase of growth. Additionally, 
we demonstrate that in MGAS5005, hemolysis only occurs in low nutrient conditions, 
regardless of the media used. ∆nagC and ∆glcU also display an extent of early hemolysis, 
and ∆nagC displays severe lesions similar to ∆pts  in a murine skin infection model. 
Similarly to ∆Mannose, these lesions are similar in size to MGAS5005 and not to ∆ptsI. 
 As a result of all of the data we have collected in this dissertation, we propose the 
following model for the induction of SLS-mediated hemolysis, and how each perturbation 
results in the observed early hemolytic activity. 
 MGAS5005 high vs low glucose (Fig 8.1). Glucose can enter the cell both through 
the PTS and non-PTS transport systems. When a high amount of glucose is present in the 
environment (Fig 8.1A), we hypothesize that glucose is transported primarily through the 
non-PTS glucose transporters (Blue section), as these enzymes are active in early exponential 
phase of growth (unpublished). Transport may still occur through the PTS, however, this 
is unlikely as ptsI is actively expressed during late log-phase of growth (unpublished). 
The rapid uptake of glucose would lead to a buildup of fructose-1,6-bisphosphate, a 
known trigger for Hpr  to phosphorylate HPr on its Serine-46 residue) (Deutscher, 008). 
HPr-Ser~P would then be a cofactor for CcpA to repress SLS-mediated hemolysis by 
preventing expression of the sag operon (Deb oy et al., 016). The exact mechanism 
for this is currently unknown, in that even though the sag operon is included in the CcpA 
regulon (Deb oy et al., 016) and binding of CcpA to the sag operon promoter occurs 
in vitro ( inkel  McIver, 008), it does not occur in vivo ( ietzman  Caparon, 010). 
Therefore, CcpA-mediated repression of the sag operon is likely indirect. Additionally, 
since glucose would primarily be transported by the non-PTS metabolic pathway, EIIs 
would likely remain phosphorylated, which could present the opportunity to phosphorylate 
Mga on it s P D  domain (Hondorp et al., 01 ). However, when glucose levels become 





















































Figure 8.1 Regulation of SLS-mediated hemolysis in MGAS5005 in both high (A) 
and low (B) glucose. Dotted lines represent protien interactions. Solid lines depict either 
metabolic reactions or influence on regulation of SLS. the grey portion of the cell represents 
glycolysis. The blue and green portions of the cell deptict the non-PTS and PTS glucose 
metabolic pathways respectively. The orange portion of the cell represents the the effect 
of the metabolic pathways on the regulation of SLS through the actions of CcpA and Mga. 
P represent phosophates.  represents the alternate set of unidentified transporters for 
glucose.  H~P represents the histidine that is phosphorylated, and S~P represents the serine 
that is phosphorylated. (1) and ( ) depict the P Ds 1 and  respectively present on Mga. 
Bold lines and dotted lines represent likely preferred routes of metabolism and the proteins 
that participate in them. 
was shown to be a high affinity glucose transporter in other bacteria (Fleming  Camilli, 
016). Also, expression of many EIIs begin to occur in late-log phase, which correlates 
with low glucose levels. As glucose levels lower and PTS activity ramps up (Fig 8.1B), 
HPr-Ser~P can either be phosphorylated by EI, or the phosphate on the serine can be 
cleaved by HprK. This leads to the derepression of the sag operon, as CcpA is no longer 
interacting with HPr. As the phosphorelay continues to shuttle phosphates to the EIIBs 
which phosphorylate the incoming sugar, Mga can no longer be phosphorylated on its 
P D , leading to further activation of the sag operon. This is thought to occur as Mga 
was shown to activate sag expression in low glucose conditions ( aldes, 016), although 
direct regulation has not been shown. This leads to robust SLS-mediated hemolysis in 
low-glucose conditions, as we observed in this dissertation. This system would rely on 
multiple inputs, so we will discuss below what we think occurs when we start to eliminate 
components that
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components that mediate SLS activity.
 ∆ptsI (Fig 8.2). ∆ptsI has robust SLS-mediated hemolysis even in high glucose 
conditions. Based on our model, elimination of the PTS would force glucose to only be 
metabolized by the non-PTS glucose pathway. Factoring in our growth data with ∆ptsI, the 
buildup of fructose-1,6-bisphoshate may not be as high, as glucose is forced into only one 
pathway which allows for adequate but not optimal growth. HprK may not phosphoryalte
Figure 8.2  Effect of the loss of ptsI on SLS-mediated hemolysis. EI is removed from the 
model, representing a ∆ptsI mutant.
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Figure 8.3 Effect of the loss of an EII on SLS-mediated hemolysis. The same color 
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EIIs fall into this category, encompassing the metabolism of most of the PTS carbohydrates. 
However, interaction between EIIs and Mga have not been tested in GAS. In this case, 
using Phos-tag gels to determine the phosphorylation state of Mga in each mutant, and 
using PC  to determine the influence each EII has on Mga activity (assay Mga regulon 
expression), would indicate the extent to which each EII affects Mga activity. e could 
then build on this model to determine which EIIs have a greater influence on Mga activity, 
and if this translates to an increase in magnitude of SLS-mediated hemolysis.
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HPr on its serine residue in this situation. This suggests that CcpA again would not 
efficiently be able to mediated repression of sag operon. Lack of CCR in a PTS mutant 
is also shown with the expression of speB (catabolite repressed), which is higher in ∆ptsI 
than MGAS5005 (Gera, 014). Finally, since Mga is phosphorylated on its P Ds by the 
PTS, and Mga activates sag expression in low glucose environments (where Mga is not 
phosphorylated), a ∆ptsI mutant would lock Mga in a non-phosphorylated state which 
permanently activates sag expression. This would explain the robust SLS-mediated 
hemolysis that was observed early in growth for the ∆ptsI mutant, and the subsequent 
massive tissue destruction observed in the murine subcutaneous infection model.
  ( ig . ). Predicting the impact of each EII that contributes to SLS activity is 
complicated, as each EII has a varied influence on PTS carbohydrate metabolism. The seven 
EIIC mutants that exbihit early hemolysis could be the result of the fact that these EIIs may 
be the interacting partners for Mga that phosphorylate its P D . In this case, an EIIC mutant 
would prevent phosphorylation of P D , and Mga would remain unphosphorylated. This 
would then induce SLS-mediated hemolysis. However, since CcpA is still intact, CCR is 
still possible as glucose levels are still high when these mutants are grown in THY. However, 
it is unknown how both CcpA and Mga regulate SLS expression, therefore it is unknown 
if an unphosphoryalted Mga could outcompete CcpA when exerting its influence on SLS 
expression. This would suggest that the seven EIIs, whose mutantions lead to early hemolysis, 
can provide a signal to the cell through Mga, which is feasible as all three mannose-family
Figure 8.4 Effect of the loss of nagC on SLS-mediated hemolysis. NagC is removed 
from the model, to simulate the conditions in ∆nagC. 
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Figure 8.5 Effect of the loss of p on SLS-mediated hemolysis. CcpA is removed form 
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 ∆  (Fig 8.4). Glucose in ∆nagC is forced through the PTS, meaning that PTS 
enzymes in our model would be dephosphorylated, because these phosphates will be shuttled 
onto glucose. This would mean that the PTS would not pass its phosphate to any P Ds, and 
in our case Mga, which would mean that Mga would be unphosphorylated and activate the 
expression of SLS. Additionally, Hpr would be predominately phosphorylated on its histidine 
residue, and not its serine residue, which would mean that Hpr-Ser~P would be present in 
very low quantities. Therefore, it would not be present in high enough levels to be used as a 
cofactor by CcpA to represses SLS expression. This would lead to the early activity of SLS 
observed in ∆nagC. However, unlike ∆ptsI, Mga is not locked into a unphosphorylated 
state, which could explain why the early hemolytic activity is not as robust as with ∆ptsI. 
 ∆ p  (Fig 8.5). ∆ccpA also exhibits early hemolytic acitivty ( inkel  McIver, 
008). This scenario is fairly straightforward, as not having CcpA to repress SLS activity 
leads to the increased expression of SLS as compared to the wildtype. Deletion of ccpA 
also increases the expression of many PTS enzymes. If this increased expression leads to 
the increased PTS activity, then Mga may not be phosphorylated on its P Ds, since these 
phosphates are shuttled to incoming sugars. This leads to early and sustained hemolysis, as 
observed previously ( inkel  McIver, 008). 
Future experiments to validate the model
 As this is a model based on the data currently available, there are still gaps in our 
knowledge of SLS regulation. Many of the hypotheses generated from the model rest on 
the fact that the differences in Mga regulation of the sag operon (directly or indirectly), are 
contingent on the fact that a phosphorylated Mga will not activate expression. I propose 
using the different phosphomimetic and phosphoablative forms of Mga in MGAS5005 to 
simulate the different phosphorylation conditions possible for Mga. In these strains, sag 
expression and SLS activity would be measured to determine in which simulated conditions 
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lead to SLS activity. Additionally, Phos-tag gels on ∆ptsI, ∆nagC, and ∆ccpA to assay the 
phosphorylation state of Mga would be carried out, again to determine if Mga is indeed 
unphosphorylated in each of these mutants as hypothesized in the model.  
 To identify other potential triggers for SLS-mediated hemolysis, we would carry 
out a screen to identify other mutants (regulators or carbon metabolic genes) that also 
exhibit early hemolytic activity. To do this, we would screen the master Tnseq transposon 
mutant library (Le Breton et al., 015) to look for mutants that displayed early hemolytic 
activity. When hemolysis occurs, RBCs burst and the cell contents seep into the medium 
fairly evenly. By using the well scanning mode on the Omega FLOUstar microplate 
reader, we can measure when hemolysis occurs in a high throughput fashion by screening 
individual mutants per well to assess if hemolysis begins earlier than WT. This would 
then be confirmed using a traditional hemolysis assay, and using AP-PC  and se uencing 
would identify the gene that was inactivated. 
 On the other side, we would also screen for potential substrates that may trigger 
SLS-mediated hemolysis. Because sag expression is under CCR, and CCR is both CcpA-
dependent and independent, it is possible that other carbohydrates may trigger SLS activity. 
To interrogate this possibility, we would grow GAS transformed with a plasmid expressing 
GFP under the sag promoter in the Biolog panel of carbon sources (190 different ones) in 
the Omega FLOUstar microplate reader, and measure the induction of GFP. This would 
allow us to determine if there are other carbon sources that can elicit CCR, and if groups 
of carbon sources lead to quicker induction of sag expression as compared to others, 
potentially establishing a hierarchy of preferred and non-preferred carbon sources.
Significance
 In this dissertation, we have established that early hemolytic activity is not the 
result of the lack of access of a PTS sugar, but rather the the potential premature relief of 
CCR based on the underappreciated signaling roles of the PTS. In addition, we have also
determined that gene annotations do not always define function, and that identical proteins 
may have different roles in different backgrounds. This highlights that although meta-
genomic analyses play an important role in learning about human pathogens, it is still 
important to characterize potentially important genes at the molecular level in more than 
one strain. This also suggests that inferences made of a protein’s function may not be easily 
extendable to other strains even if their respective gene se uences are identical. Finally, we 
have established an annotated EII mutant library that can now be used in further screens 
to determine the role of carbohydrate transport, metabolism, and signaling in different 
pathogenic scenarios. 
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Appendix : Media Compositions
Todd Hewitt Broth (rich media)
1) 30g Todd-Hewitt (TH) broth:
20g  peptone





2) 2g Yeast extract
3) 1L H2O
C-media (low glucose, high peptide)
0.5% (w/v) Protease peptone 3






*Media compositions as adapted from Gera et al., 2013
C emic ll 	 efi ed	 edi 	 C 	c r o 	free	medi
 0.0200 g/L      Adenine Sulfate, 2H2O
 0.1000 g/L      DL-Alanine
 0.1000 g/L      L-Arginine, FB
 0.1000 g/L      L-Asparagine, Anhydrous
 0.1000 g/L      L-Aspartic Acid
 0.0002 g/L      Biotin
 0.0005 g/L      Calcium Chloride, Anhydrous
 0.0020 g/L      D-Calcium Pantothenate
 0.0001 g/L      Cyanobalamin
 0.0652 g/L      L-Cystine, 3HCl
 0.0008 g/L      Folic Acid
 0.1000 g/L      L-Glutamic Acid
 0.2000 g/L      L-Glutamine
 0.1000 g/L      Glycine
 0.2000 g/L      Guanine, HCl, H2O
 0.1000 g/L      L-Histidine, FB
 0.1000 g/L      Hydroxy L-Proline
 0.1000 g/L      L-Isoleucine
 0.1000 g/L      L-Leucine
 0.1249 g/L      L-Lysine, HCl
 0.3419 g/L      Magnesium Sulfate, Anhydrous
 0.1000 g/L      L-Methionine
 0.0010 g/L      Niacinamide
 0.0025 g/L      b-NAD, 3 H2O
 0.0002 g/L      Para-Aminobenzoic Acid
153
154
 0.1000 g/L      L-Phenylalanine
 0.2000 g/L      Potassium Phosphate, Dibasic, Anhydrous
 1.0000 g/L      Potassium Phosphate, Monobasic, Anhydrous
 0.1000 g/L      L-Proline
 0.0010 g/L      Pyridoxal, HCl
 0.0010 g/L      Pyridoxamine, 2HCl
 0.00 0 g L      iboflavin
 0.1000 g/L      L-Serine
 2.7126 g/L      Sodium Acetate, Anhydrous
 7.3500 g/L      Sodium Phosphate, Dibasic, Anhydrous
 3.1950 g/L      Sodium Phosphate, Monobasic, H2O, ACS
 0.0010 g/L      Thiamine, HCl
 0.2000 g/L      L-Threonine
 0.1000 g/L      L-Tryptophan
 0.1442 g/L      L-Tyrosine, 2Na, 2H2O
 0.0200 g/L      Uracil
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